Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas, 2021: Tables

All Tables
Table 1a. Stage of disease at time of diagnosis of HIV infection during 2021 among persons aged ≥13 years, by selected characteristics—47 states and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)
Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)
Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)
Stage unknownb
Total No. No. % No. % No. % No. % No. %
Gender
Male 26,654 1,927 7.2 6,404 24.0 8,564 32.1 5,689 21.3 4,070 15.3
Female 6,069 361 5.9 1,796 29.6 1,651 27.2 1,283 21.1 978 16.1
Transgender womanc 785 69 8.8 256 32.6 271 34.5 94 12.0 95 12.1
Transgender manc 55 11 20.0 23 41.8 17 30.9 2 3.6 2 3.6
Additional gender identityd 43 3 7.0 9 20.9 18 41.9 6 14.0 7 16.3
Age at diagnosis (yr)
13–24 6,561 648 9.9 1,765 26.9 2,483 37.8 649 9.9 1,016 15.5
25–34 12,337 944 7.7 3,332 27.0 4,042 32.8 2,100 17.0 1,919 15.6
35–44 7,087 437 6.2 1,752 24.7 1,999 28.2 1,806 25.5 1,093 15.4
45–54 4,153 187 4.5 911 21.9 1,140 27.5 1,335 32.1 580 14.0
≥55 3,468 155 4.5 728 21.0 857 24.7 1,184 34.1 544 15.7
Race/ethnicity
American Indian/Alaska Native 220 19 8.6 49 22.3 70 31.8 42 19.1 40 18.2
Asian 699 44 6.3 140 20.0 254 36.3 182 26.0 79 11.3
Black/African American 13,650 872 6.4 3,328 24.4 4,330 31.7 2,688 19.7 2,432 17.8
Hispanic/Latinoe 9,416 740 7.9 2,342 24.9 3,120 33.1 2,088 22.2 1,126 12.0
Native Hawaiian/other Pacific Islander 74 3 4.1 23 31.1 19 25.7 18 24.3 11 14.9
White 8,580 619 7.2 2,372 27.6 2,415 28.1 1,846 21.5 1,328 15.5
Multiracial 967 74 7.7 234 24.2 313 32.4 210 21.7 136 14.1
Transmission categoryf
Male-to-male sexual contactg 22,659 1,725 7.6 5,621 24.8 7,479 33.0 4,530 20.0 3,306 14.6
Injection drug useh 2,326 134 5.8 582 25.0 610 26.2 508 21.8 492 21.1
 Male 1,311 75 5.7 284 21.7 355 27.1 307 23.5 290 22.1
 Female 1,015 60 5.9 298 29.4 255 25.1 201 19.8 201 19.8
Male-to-male sexual contactg and injection drug useh 1,301 106 8.2 379 29.1 383 29.4 209 16.1 224 17.3
Heterosexual contacti 7,244 401 5.5 1,888 26.1 2,030 28.0 1,807 24.9 1,118 15.4
 Male 2,178 92 4.2 380 17.4 629 28.9 733 33.7 345 15.8
 Female 5,065 309 6.1 1,508 29.8 1,402 27.7 1,074 21.2 773 15.3
Otherj 76 5 6.5 19 25.3 19 24.9 20 26.9 12 16.5
 Male 27 2 5.6 5 19.2 6 24.1 9 33.1 5 18.0
 Female 49 3 6.9 14 28.6 12 25.3 11 23.5 8 15.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 27,010 2,011 7.4 6,815 25.2 8,570 31.7 5,517 20.4 4,097 15.2
Metropolitan areas (pop. 50,000–499,999) 4,224 247 5.8 1,098 26.0 1,293 30.6 945 22.4 641 15.2
Nonmetropolitan areas (pop. <50,000) 2,254 107 4.7 551 24.4 621 27.6 593 26.3 382 16.9
Total 33,606 2,371 7.1 8,488 25.3 10,521 31.3 7,074 21.0 5,152 15.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact)
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 1b. Stage of disease at time of diagnosis of HIV infection during 2021 among persons aged ≥13 years, by area of residence—47 states and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)
Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)
Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)
Stage unknownb
Total No. No. % No. % No. % No. % No. %
Alabama 625 19 3.0 179 28.6 181 29.0 115 18.4 131 21.0
Alaska 30 6 20.0 4 13.3 9 30.0 10 33.3 1 3.3
Arizona 781 60 7.7 224 28.7 243 31.1 146 18.7 108 13.8
Arkansas 338 6 1.8 88 26.0 84 24.9 82 24.3 78 23.1
California 4,399 332 7.5 1,144 26.0 1,437 32.7 906 20.6 580 13.2
Colorado 406 88 21.7 107 26.4 103 25.4 72 17.7 36 8.9
Connecticut 233 23 9.9 62 26.6 76 32.6 48 20.6 24 10.3
Delaware 81 8 9.9 16 19.8 20 24.7 25 30.9 12 14.8
District of Columbia 195 14 7.2 49 25.1 58 29.7 37 19.0 37 19.0
Florida 4,072 194 4.8 1,116 27.4 1,332 32.7 847 20.8 583 14.3
Georgia 2,371 84 3.5 592 25.0 782 33.0 543 22.9 370 15.6
Hawaii 65 4 6.2 20 30.8 17 26.2 15 23.1 9 13.8
Illinois 1,195 99 8.3 290 24.3 352 29.5 212 17.7 242 20.3
Indiana 528 13 2.5 150 28.4 156 29.5 106 20.1 103 19.5
Iowa 124 5 4.0 37 29.8 41 33.1 31 25.0 10 8.1
Kansas 154 3 1.9 49 31.8 55 35.7 41 26.6 6 3.9
Kentucky 390 42 10.8 93 23.8 114 29.2 71 18.2 70 17.9
Louisiana 899 107 11.9 193 21.5 284 31.6 206 22.9 109 12.1
Maine 31 0 0.0 7 22.6 7 22.6 14 45.2 3 9.7
Maryland 749 74 9.9 199 26.6 222 29.6 183 24.4 71 9.5
Massachusetts 440 23 5.2 133 30.2 145 33.0 103 23.4 36 8.2
Michigan 633 64 10.1 165 26.1 193 30.5 121 19.1 90 14.2
Minnesota 297 27 9.1 64 21.5 94 31.6 66 22.2 46 15.5
Mississippi 419 11 2.6 73 17.4 85 20.3 87 20.8 163 38.9
Missouri 549 21 3.8 121 22.0 150 27.3 99 18.0 158 28.8
Montana 22 3 13.6 6 27.3 6 27.3 5 22.7 2 9.1
Nebraska 105 4 3.8 22 21.0 33 31.4 23 21.9 23 21.9
Nevada 501 27 5.4 139 27.7 169 33.7 120 24.0 46 9.2
New Hampshire 32 2 6.3 11 34.4 9 28.1 9 28.1 1 3.1
New Mexico 149 8 5.4 45 30.2 54 36.2 20 13.4 22 14.8
New York 2,116 216 10.2 523 24.7 702 33.2 479 22.6 196 9.3
North Carolina 1,390 120 8.6 281 20.2 402 28.9 265 19.1 322 23.2
North Dakota 37 0 0.0 15 40.5 10 27.0 10 27.0 2 5.4
Ohio 909 39 4.3 260 28.6 273 30.0 206 22.7 131 14.4
Oklahoma 387 16 4.1 72 18.6 115 29.7 69 17.8 115 29.7
Oregon 202 25 12.4 50 24.8 57 28.2 43 21.3 27 13.4
Rhode Island 68 2 2.9 20 29.4 19 27.9 17 25.0 10 14.7
South Carolina 652 30 4.6 161 24.7 218 33.4 168 25.8 75 11.5
South Dakota 31 1 3.2 11 35.5 5 16.1 9 29.0 5 16.1
Tennessee 831 28 3.4 214 25.8 258 31.0 140 16.8 191 23.0
Texas 4,363 376 8.6 1,021 23.4 1,390 31.9 912 20.9 664 15.2
Utah 133 23 17.3 24 18.0 45 33.8 26 19.5 15 11.3
Vermont 12 1 8.3 4 33.3 1 8.3 5 41.7 1 8.3
Virginia 792 62 7.8 197 24.9 231 29.2 180 22.7 122 15.4
Washington 461 32 6.9 140 30.4 158 34.3 94 20.4 37 8.0
West Virginia 149 11 7.4 26 17.4 34 22.8 31 20.8 47 31.5
Wisconsin 253 18 7.1 67 26.5 92 36.4 55 21.7 21 8.3
Wyoming 7 0 0.0 4 57.1 0 0.0 2 28.6 1 14.3
Region of residencec
Northeast (excluding NJ & PA) 2,932 267 9.1 760 25.9 959 32.7 675 23.0 271 9.2
Midwest 4,815 294 6.1 1,251 26.0 1,454 30.2 979 20.3 837 17.4
South 18,703 1,202 6.4 4,570 24.4 5,810 31.1 3,961 21.2 3,160 16.9
West (excluding ID) 7,156 608 8.5 1,907 26.6 2,298 32.1 1,459 20.4 884 12.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. New Jersey and Pennsylvania recently enacted laws to require laboratories to report all CD4 and VL test results, but a full calendar year of reporting laboratory results to CDC is required before data are included in care analyses.

a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c Data should be interpreted with caution as areas with incomplete reporting to CDC are not included.

Table 1c. Stage of disease at time of diagnosis of HIV infection during 2021 among persons aged ≥13 years, by race/ethnicity and selected characteristics—47 states and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)
Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)
Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)
Stage unknownb
Total No. No. % No. % No. % No. % No. %
American Indian/Alaska Native
Gender
Male 164 14 8.5 35 21.3 53 32.3 33 20.1 29 17.7
Female 46 4 8.7 12 26.1 14 30.4 7 15.2 9 19.6
Transgender womanc 10 1 10.0 2 20.0 3 30.0 2 20.0 2 20.0
Transgender manc 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Additional gender identityd 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 30 3 10.0 7 23.3 8 26.7 3 10.0 9 30.0
   25-34 73 7 9.6 12 16.4 29 39.7 15 20.5 10 13.7
   35-44 40 3 7.5 17 42.5 7 17.5 7 17.5 6 15.0
   45-54 18 1 5.6 1 5.6 9 50.0 5 27.8 2 11.1
≥55 13 1 7.7 0 0.0 3 23.1 5 38.5 4 30.8
Transmission categorye
Male-to-male sexual contactf 139 13 9.4 27 19.5 46 33.3 28 20.0 25 17.8
Injection drug useg 10 0 0.0 2 21.4 4 44.9 1 11.2 2 19.4
Male-to-male sexual contactf and injection drug useg 16 0 0.0 6 37.6 3 19.7 3 19.7 3 20.4
Heterosexual contacth 10 1 12.2 2 20.4 2 23.5 3 31.6 1 12.2
Otheri 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 96 8 8.3 17 17.7 34 35.4 16 16.7 21 21.9
Metropolitan areas (pop. 50,000-499,999) 33 4 12.1 11 33.3 8 24.2 6 18.2 4 12.1
Nonmetropolitan areas (pop. <50,000) 45 3 6.7 9 20.0 14 31.1 13 28.9 6 13.3
Subtotal 174 15 8.6 37 21.3 56 32.2 35 20.1 31 17.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 3 1 33.3 1 33.3 0 0.0 0 0.0 1 33.3
   25-34 17 2 11.8 5 29.4 4 23.5 2 11.8 4 23.5
   35-44 9 0 0.0 3 33.3 4 44.4 2 22.2 0 0.0
   45-54 14 1 7.1 2 14.3 4 28.6 3 21.4 4 28.6
≥55 3 0 0.0 1 33.3 2 66.7 0 0.0 0 0.0
Transmission categorye
Injection drug useg 17 4 23.3 6 33.7 4 23.8 2 8.7 2 10.5
   Heterosexual contacth 29 0 0.0 6 21.5 10 34.4 6 19.1 7 25.0
Otheri 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 25 2 8.0 8 32.0 7 28.0 2 8.0 6 24.0
Metropolitan areas (pop. 50,000-499,999) 9 1 11.1 1 11.1 2 22.2 3 33.3 2 22.2
Nonmetropolitan areas (pop. <50,000) 12 1 8.3 3 25.0 5 41.7 2 16.7 1 8.3
Subtotal 46 4 8.7 12 26.1 14 30.4 7 15.2 9 19.6
Total 220 19 8.6 49 22.3 70 31.8 42 19.1 40 18.2
Asian
Gender
Male 594 39 6.6 116 19.5 223 37.5 150 25.3 66 11.1
Female 86 3 3.5 20 23.3 21 24.4 29 33.7 13 15.1
Transgender womanc 17 2 11.8 4 23.5 8 47.1 3 17.6 0 0.0
Transgender manc 2 0 0.0 0 0.0 2 100 0 0.0 0 0.0
Additional gender identityd 0 0 0.0 0 0.0 0 0 0 0.0 0 0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 105 7 6.7 22 21.0 51 48.6 11 10.5 14 13.3
   25-34 240 23 9.6 54 22.5 91 37.9 43 17.9 29 12.1
   35-44 135 7 5.2 30 22.2 52 38.5 34 25.2 12 8.9
   45-54 82 1 1.2 11 13.4 25 30.5 38 46.3 7 8.5
≥55 49 3 6.1 3 6.1 12 24.5 27 55.1 4 8.2
Transmission categorye
Male-to-male sexual contactf 545 37 6.8 109 20.0 215 39.3 124 22.7 61 11.1
Injection drug useg 13 0 0.0 2 18.0 4 27.1 7 49.6 1 4.5
Male-to-male sexual contactf and injection drug useg 16 2 12.8 4 25.0 6 35.9 3 17.9 1 8.3
   Heterosexual contacth 36 2 4.7 5 12.4 7 19.9 20 54.1 3 8.8
Otheri 1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 556 38 6.8 113 20.3 207 37.2 139 25.0 59 10.6
Metropolitan areas (pop. 50,000-499,999) 44 2 4.5 6 13.6 20 45.5 11 25.0 5 11.4
Nonmetropolitan areas (pop. <50,000) 9 1 11.1 1 11.1 3 33.3 3 33.3 1 11.1
Subtotal 611 41 6.7 120 19.6 231 37.8 153 25.0 66 10.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 9 0 0.0 2 22.2 4 44.4 2 22.2 1 11.1
   25-34 21 1 4.8 8 38.1 8 38.1 4 19.0 0 0.0
   35-44 31 2 6.5 5 16.1 6 19.4 10 32.3 8 25.8
   45-54 12 0 0.0 3 25.0 3 25.0 4 33.3 2 16.7
≥55 15 0 0.0 2 13.3 2 13.3 9 60.0 2 13.3
Transmission categorye
Injection drug useg 6 0 1.7 2 25.4 2 39.0 2 27.1 0 6.8
   Heterosexual contacth 80 3 3.5 17 21.6 21 25.8 27 33.5 13 15.6
Otheri 2 0 4.8 1 57.1 0 4.8 1 28.6 0 4.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 70 2 2.9 15 21.4 19 27.1 22 31.4 12 17.1
Metropolitan areas (pop. 50,000-499,999) 14 1 7.1 4 28.6 4 28.6 5 35.7 0 0.0
Nonmetropolitan areas (pop. <50,000) 4 0 0.0 1 25.0 0 0.0 2 50.0 1 25.0
Subtotal 88 3 3.4 20 22.7 23 26.1 29 33.0 13 14.8
Total 699 44 6.3 140 20.0 254 36.3 182 26.0 79 11.3
Black/African American
Gender
Male 9,985 660 6.6 2,251 22.5 3,253 32.6 1,944 19.5 1,877 18.8
Female 3,274 175 5.3 958 29.3 935 28.6 699 21.4 507 15.5
Transgender womanc 363 33 9.1 110 30.3 133 36.6 43 11.8 44 12.1
Transgender manc 17 4 23.5 8 47.1 4 23.5 0 0.0 1 5.9
Additional gender identityd 11 0 0.0 1 9.1 5 45.5 2 18.2 3 27.3
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 3,059 291 9.5 770 25.2 1,171 38.3 282 9.2 545 17.8
   25-34 4,035 275 6.8 953 23.6 1,374 34.1 725 18.0 708 17.5
   35-44 1,605 62 3.9 350 21.8 429 26.7 425 26.5 339 21.1
   45-54 801 28 3.5 137 17.1 227 28.3 257 32.1 152 19.0
≥55 858 37 4.3 152 17.7 189 22.0 300 35.0 180 21.0
Transmission categorye
Male-to-male sexual contactf 8,451 605 7.2 2,015 23.8 2,848 33.7 1,452 17.2 1,531 18.1
Injection drug useg 336 19 5.6 59 17.4 85 25.2 86 25.6 88 26.2
Male-to-male sexual contactf and injection drug useg 226 15 6.5 61 26.9 65 28.9 31 13.9 54 23.8
   Heterosexual contacth 1,333 55 4.1 226 16.9 388 29.1 416 31.2 249 18.6
Otheri 13 0 0.0 2 15.1 4 31.7 4 29.4 3 20.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 8,497 591 7.0 1,933 22.7 2,826 33.3 1,592 18.7 1,555 18.3
Metropolitan areas (pop. 50,000-499,999) 1,206 75 6.2 292 24.2 374 31.0 233 19.3 232 19.2
Nonmetropolitan areas (pop. <50,000) 619 27 4.4 131 21.2 176 28.4 158 25.5 127 20.5
Subtotal 10,358 693 6.7 2,362 22.8 3,390 32.7 1,989 19.2 1,924 18.6
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 452 36 8.0 139 30.8 148 32.7 47 10.4 82 18.1
   25-34 885 60 6.8 285 32.2 269 30.4 126 14.2 145 16.4
   35-44 811 40 4.9 217 26.8 230 28.4 207 25.5 117 14.4
   45-54 601 28 4.7 155 25.8 159 26.5 179 29.8 80 13.3
≥55 543 15 2.8 170 31.3 134 24.7 140 25.8 84 15.5
Transmission categorye
Injection drug useg 276 9 3.3 77 28.0 76 27.4 65 23.4 50 17.9
   Heterosexual contacth 2,983 167 5.6 881 29.5 856 28.7 626 21.0 452 15.2
Otheri 33 3 8.3 7 22.3 8 25.7 8 24.5 6 19.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 2,676 154 5.8 799 29.9 753 28.1 555 20.7 415 15.5
Metropolitan areas (pop. 50,000-499,999) 410 15 3.7 118 28.8 128 31.2 98 23.9 51 12.4
Nonmetropolitan areas (pop. <50,000) 193 9 4.7 47 24.4 56 29.0 45 23.3 36 18.7
Subtotal 3,292 179 5.4 966 29.3 940 28.6 699 21.2 508 15.4
Total 13,650 872 6.4 3,328 24.4 4,330 31.7 2,688 19.7 2,432 17.8
Hispanic/Latinoj
Gender
Male 8,101 656 8.1 1,928 23.8 2,722 33.6 1,833 22.6 962 11.9
Female 1,041 63 6.1 316 30.4 305 29.3 221 21.2 136 13.1
Transgender womanc 246 19 7.7 89 36.2 83 33.7 29 11.8 26 10.6
Transgender manc 14 2 14.3 5 35.7 4 28.6 2 14.3 1 7.1
Additional gender identityd 14 0 0.0 4 28.6 6 42.9 3 21.4 1 7.1
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 1,602 183 11.4 412 25.7 650 40.6 182 11.4 175 10.9
   25-34 3,479 288 8.3 893 25.7 1,230 35.4 613 17.6 455 13.1
   35-44 1,867 134 7.2 435 23.3 562 30.1 548 29.4 188 10.1
   45-54 894 42 4.7 196 21.9 235 26.3 324 36.2 97 10.9
≥55 518 28 5.4 85 16.4 134 25.9 197 38.0 74 14.3
Transmission categorye
Male-to-male sexual contactf 7,340 613 8.4 1,819 24.8 2,509 34.2 1,544 21.0 855 11.7
Injection drug useg 282 19 6.7 56 19.8 69 24.6 89 31.6 49 17.3
Male-to-male sexual contactf and injection drug useg 314 27 8.5 83 26.4 101 32.1 63 20.2 40 12.8
   Heterosexual contacth 418 16 3.9 62 14.9 130 31.2 165 39.6 44 10.5
Otheri 6 0 0.0 2 26.2 2 24.6 2 35.4 1 10.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 7,343 615 8.4 1,779 24.2 2,475 33.7 1,607 21.9 867 11.8
Metropolitan areas (pop. 50,000-499,999) 694 44 6.3 162 23.3 234 33.7 171 24.6 83 12.0
Nonmetropolitan areas (pop. <50,000) 290 11 3.8 75 25.9 92 31.7 80 27.6 32 11.0
Subtotal 8,360 675 8.1 2,021 24.2 2,811 33.6 1,864 22.3 989 11.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 140 14 10.0 61 43.6 31 22.1 15 10.7 19 13.6
   25-34 301 21 7.0 97 32.2 98 32.6 47 15.6 38 12.6
   35-44 274 20 7.3 83 30.3 81 29.6 53 19.3 37 13.5
   45-54 198 6 3.0 44 22.2 65 32.8 56 28.3 27 13.6
≥55 143 4 2.8 36 25.2 34 23.8 53 37.1 16 11.2
Transmission categorye
Injection drug useg 151 12 8.2 39 25.8 43 28.5 32 21.4 24 16.0
Heterosexual contacth 899 52 5.8 279 31.0 265 29.4 191 21.2 112 12.5
Otheri 6 0 0.0 3 54.4 1 19.3 1 14.0 1 8.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 915 59 6.4 279 30.5 265 29.0 188 20.5 124 13.6
Metropolitan areas (pop. 50,000-499,999) 106 5 4.7 32 30.2 34 32.1 26 24.5 9 8.5
Nonmetropolitan areas (pop. <50,000) 33 1 3.0 10 30.3 9 27.3 9 27.3 4 12.1
Subtotal 1,056 65 6.2 321 30.4 309 29.3 224 21.2 137 13.0
Total 9,416 740 7.9 2,342 24.9 3,120 33.1 2,088 22.2 1,126 12.0
Native Hawaiian/other Pacific Islander
Gender
Male 60 3 5.0 18 30.0 16 26.7 15 25.0 8 13.3
Female 8 0 0.0 4 50.0 1 12.5 1 12.5 2 25.0
Transgender womanc 6 0 0.0 1 16.7 2 33.3 2 33.3 1 16.7
Transgender manc 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Additional gender identityd 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 10 1 10.0 2 20.0 5 50.0 1 10.0 1 10.0
   25-34 26 2 7.7 10 38.5 6 23.1 3 11.5 5 19.2
   35-44 17 0 0.0 2 11.8 5 29.4 8 47.1 2 11.8
   45-54 7 0 0.0 2 28.6 2 28.6 3 42.9 0 0.0
≥55 6 0 0.0 3 50.0 0 0.0 2 33.3 1 16.7
Transmission categorye
Male-to-male sexual contactf 59 3 5.1 18 30.5 16 27.1 14 23.9 8 13.3
Injection drug useg 1 0 0.0 0 0.0 0 0.0 1 85.7 0 0.0
Male-to-male sexual contactf and injection drug useg 4 0 0.0 1 31.4 1 28.6 0 11.4 1 28.6
   Heterosexual contacth 3 0 0.0 0 0.0 1 40.0 1 56.0 0 0.0
Otheri 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 56 2 3.6 18 32.1 15 26.8 14 25.0 7 12.5
Metropolitan areas (pop. 50,000-499,999) 4 1 25.0 1 25.0 1 25.0 1 25.0 0 0.0
Nonmetropolitan areas (pop. <50,000) 6 0 0.0 0 0.0 2 33.3 2 33.3 2 33.3
Subtotal 66 3 4.5 19 28.8 18 27.3 17 25.8 9 13.6
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
   25-34 2 0 0.0 1 50.0 0 0.0 0 0.0 1 50.0
   35-44 4 0 0.0 2 50.0 1 25.0 0 0.0 1 25.0
   45-54 2 0 0.0 1 50.0 0 0.0 1 50.0 0 0.0
≥55 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Transmission categorye
Injection drug useg 3 0 0.0 1 39.4 1 30.3 1 30.3 0 0.0
   Heterosexual contacth 5 0 0.0 3 57.4 0 0.0 0 0.0 2 42.6
Otheri 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 7 0 0.0 3 42.9 1 14.3 1 14.3 2 28.6
Metropolitan areas (pop. 50,000-499,999) 1 0 0.0 1 100.0 0 0.0 0 0.0 0 0.0
Nonmetropolitan areas (pop. <50,000) 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Subtotal 8 0 0.0 4 50.0 1 12.5 1 12.5 2 25.0
Total 74 3 4.1 23 31.1 19 25.7 18 24.3 11 14.9
White
Gender
Male 6,999 497 7.1 1,885 26.9 2,040 29.1 1,554 22.2 1,023 14.6
Female 1,435 104 7.2 436 30.4 329 22.9 282 19.7 284 19.8
Transgender womanc 112 11 9.8 38 33.9 34 30.4 10 8.9 19 17.0
Transgender manc 19 4 21.1 9 47.4 6 31.6 0 0.0 0 0.0
Additional gender identityd 15 3 20.0 4 26.7 6 40.0 0 0.0 2 13.3
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 769 76 9.9 233 30.3 276 35.9 71 9.2 113 14.7
   25-34 2,493 203 8.1 778 31.2 728 29.2 397 15.9 387 15.5
   35-44 1,697 114 6.7 445 26.2 483 28.5 390 23.0 265 15.6
   45-54 1,136 63 5.5 263 23.2 314 27.6 345 30.4 151 13.3
≥55 1,029 55 5.3 207 20.1 279 27.1 361 35.1 127 12.3
Transmission categorye
Male-to-male sexual contactf 5,478 399 7.3 1,490 27.2 1,611 29.4 1,230 22.5 749 13.7
Injection drug useg 631 35 5.6 155 24.6 185 29.3 117 18.5 139 22.0
Male-to-male sexual contactf and injection drug useg 675 60 8.9 205 30.3 194 28.7 102 15.1 115 17.0
   Heterosexual contacth 333 16 4.8 75 22.5 90 27.0 113 33.9 39 11.8
Otheri 6 1 13.1 1 21.3 1 9.8 2 36.1 1 19.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 5,074 402 7.9 1,394 27.5 1,486 29.3 1,056 20.8 736 14.5
Metropolitan areas (pop. 50,000-499,999) 1,234 71 5.8 322 26.1 376 30.5 285 23.1 180 14.6
Nonmetropolitan areas (pop. <50,000) 796 38 4.8 203 25.5 212 26.6 221 27.8 122 15.3
Subtotal 7,124 511 7.2 1,926 27.0 2,080 29.2 1,564 22.0 1,043 14.6
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 148 11 7.4 58 39.2 43 29.1 10 6.8 26 17.6
   25-34 408 35 8.6 137 33.6 88 21.6 56 13.7 92 22.5
   35-44 407 39 9.6 118 29.0 87 21.4 76 18.7 87 21.4
   45-54 278 13 4.7 80 28.8 66 23.7 80 28.8 39 14.0
≥55 215 10 4.7 53 24.7 51 23.7 60 27.9 41 19.1
Transmission categorye
Injection drug useg 529 30 5.7 161 30.5 123 23.2 93 17.6 122 23.0
   Heterosexual contacth 919 77 8.4 283 30.7 210 22.9 187 20.3 163 17.7
Otheri 8 0 0.0 2 30.3 2 30.3 2 26.3 1 9.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 955 81 8.5 278 29.1 232 24.3 173 18.1 191 20.0
Metropolitan areas (pop. 50,000-499,999) 315 14 4.4 112 35.6 66 21.0 69 21.9 54 17.1
Nonmetropolitan areas (pop. <50,000) 179 13 7.3 53 29.6 36 20.1 40 22.3 37 20.7
Subtotal 1,456 108 7.4 446 30.6 335 23.0 282 19.4 285 19.6
Total 8,580 619 7.2 2,372 27.6 2,415 28.1 1,846 21.5 1,328 15.5
Multiracial
Gender
Male 751 58 7.7 171 22.8 257 34.2 160 21.3 105 14.0
Female 179 12 6.7 50 27.9 46 25.7 44 24.6 27 15.1
Transgender womanc 31 3 9.7 12 38.7 8 25.8 5 16.1 3 9.7
Transgender manc 3 1 33.3 1 33.3 1 33.3 0 0.0 0 0.0
Additional gender identityd 3 0 0.0 0 0.0 1 33.3 1 33.3 1 33.3
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 208 23 11.1 47 22.6 89 42.8 25 12.0 24 11.5
   25-34 303 22 7.3 82 27.1 99 32.7 61 20.1 39 12.9
   35-44 140 12 8.6 31 22.1 41 29.3 32 22.9 24 17.1
   45-54 79 2 2.5 10 12.7 25 31.6 29 36.7 13 16.5
≥55 54 2 3.7 13 24.1 12 22.2 19 35.2 8 14.8
Transmission categorye
Male-to-male sexual contactf 647 55 8.5 143 22.1 235 36.2 138 21.3 77 12.0
Injection drug useg 38 1 3.1 10 26.1 9 22.5 7 17.8 12 30.5
Male-to-male sexual contactf and injection drug useg 52 2 4.6 20 37.5 13 25.6 6 12.1 11 20.2
   Heterosexual contacth 45 3 5.5 10 22.9 10 20.9 15 32.4 8 18.3
Otheri 1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 603 48 8.0 140 23.2 217 36.0 121 20.1 77 12.8
Metropolitan areas (pop. 50,000-499,999) 123 11 8.9 29 23.6 34 27.6 29 23.6 20 16.3
Nonmetropolitan areas (pop. <50,000) 53 2 3.8 13 24.5 14 26.4 13 24.5 11 20.8
Subtotal 784 61 7.8 183 23.3 266 33.9 166 21.2 108 13.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
   13-24 26 2 7.7 11 42.3 7 26.9 0 0.0 6 23.1
   25-34 54 5 9.3 17 31.5 18 33.3 8 14.8 6 11.1
   35-44 50 4 8.0 14 28.0 11 22.0 14 28.0 7 14.0
   45-54 31 2 6.5 6 19.4 6 19.4 11 35.5 6 19.4
≥55 22 0 0.0 3 13.6 5 22.7 11 50.0 3 13.6
Transmission categorye
Injection drug useg 33 4 11.7 12 37.8 6 19.4 6 19.4 4 11.7
   Heterosexual contacth 150 9 6.1 39 25.8 40 26.9 38 25.1 24 16.1
Otheri 1 0 0.0 0 0.0 1 55.6 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 137 9 6.6 39 28.5 33 24.1 31 22.6 25 18.2
Metropolitan areas (pop. 50,000-499,999) 31 3 9.7 7 22.6 12 38.7 8 25.8 1 3.2
Nonmetropolitan areas (pop. <50,000) 15 1 6.7 5 33.3 2 13.3 5 33.3 2 13.3
Subtotal 183 13 7.1 51 27.9 47 25.7 44 24.0 28 15.3
Total 967 74 7.7 234 24.2 313 32.4 210 21.7 136 14.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
j Hispanic/Latino persons can be of any race.

TTable 1d. Stage of disease at time of diagnosis of HIV infection during 2021 among males, based on assigned sex at birth, aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age at diagnosis—47 states and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)
Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)
Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)
Stage unknownb
Total No. No. % No. % No. % No. % No. %
American Indian/Alaska Native
13–24 29 3 10.5 7 23.1 8 26.9 3 10.1 8 29.4
25–34 58 6 10.1 8 13.5 23 40.6 13 21.9 8 13.9
35–44 32 3 9.5 13 40.0 7 22.2 5 17.1 4 11.1
45–54 11 1 7.2 0 0.0 6 55.0 3 23.4 2 14.4
≥55 10 1 5.1 0 0.0 2 20.2 4 42.4 3 32.3
Subtotal 139 13 9.4 27 19.5 46 33.3 28 20.0 25 17.8
Asian
13–24 101 7 6.9 21 20.8 50 49.6 9 8.8 14 13.9
25–34 224 22 9.8 47 21.1 86 38.5 40 17.7 29 12.9
35–44 115 5 4.4 29 25.0 46 40.2 25 22.1 10 8.3
45–54 71 1 1.1 11 14.9 24 34.5 30 41.7 6 7.8
≥55 35 2 6.8 2 5.4 8 22.4 20 57.2 3 8.2
Subtotal 545 37 6.8 109 20.0 215 39.3 124 22.7 61 11.1
Black/African American
13–24 2,888 279 9.7 733 25.4 1,105 38.3 265 9.2 506 17.5
25–34 3,525 246 7.0 847 24.0 1,207 34.2 625 17.7 599 17.0
35–44 1,143 43 3.8 266 23.2 317 27.7 281 24.6 237 20.7
45–54 488 16 3.2 90 18.5 136 28.0 146 30.0 99 20.3
≥55 407 21 5.0 79 19.4 83 20.4 135 33.1 90 22.0
Subtotal 8,451 605 7.2 2,015 23.8 2,848 33.7 1,452 17.2 1,531 18.1
Hispanic/Latinoc
13–24 1,496 174 11.6 384 25.6 611 40.8 165 11.0 162 10.8
25–34 3,134 259 8.3 819 26.1 1,105 35.3 549 17.5 402 12.8
35–44 1,602 122 7.6 384 24.0 492 30.7 445 27.8 159 9.9
45–54 729 38 5.2 166 22.8 199 27.3 247 33.8 79 10.9
≥55 379 21 5.5 65 17.3 102 26.9 138 36.5 53 13.9
Subtotal 7,340 613 8.4 1,819 24.8 2,509 34.2 1,544 21.0 855 11.7
Native Hawaiian/other Pacific Islander
13–24 8 1 12.5 2 25.0 4 50.0 1 12.5 0 0.0
25–34 24 2 8.4 9 37.8 5 21.0 3 11.8 5 21.0
35–44 16 0 0.0 2 12.3 5 30.1 7 45.4 2 12.3
45–54 7 0 0.0 2 28.4 2 29.9 3 41.8 0 0.0
≥55 4 0 0.0 3 78.9 0 0.0 0 0.0 1 21.1
Subtotal 59 3 5.1 18 30.5 16 27.1 14 23.9 8 13.3
White
13–24 669 67 10.0 206 30.7 245 36.5 59 8.9 92 13.8
25–34 1,921 155 8.1 597 31.1 580 30.2 321 16.7 268 13.9
35–44 1,199 88 7.3 318 26.5 317 26.5 302 25.2 174 14.5
45–54 863 48 5.6 201 23.3 241 27.9 256 29.7 117 13.6
≥55 827 41 4.9 169 20.4 228 27.6 291 35.2 98 11.8
Subtotal 5,478 399 7.3 1,490 27.2 1,611 29.4 1,230 22.5 749 13.7
Multiracial
13–24 194 21 10.6 42 21.6 86 44.4 25 12.8 21 10.6
25–34 250 21 8.3 59 23.6 87 34.9 55 22.1 28 11.1
35–44 106 10 9.4 22 21.1 34 32.4 24 23.0 15 14.2
45–54 60 2 3.3 8 14.0 19 32.1 23 37.6 8 13.0
≥55 38 2 4.2 11 30.0 8 20.3 11 29.2 6 16.3
Subtotal 647 55 8.5 143 22.1 235 36.2 138 21.3 77 12.0
All
13–24 5,384 552 10.2 1,394 25.9 2,109 39.2 527 9.8 803 14.9
25–34 9,135 711 7.8 2,387 26.1 3,094 33.9 1,605 17.6 1,339 14.7
35–44 4,212 270 6.4 1,033 24.5 1,218 28.9 1,091 25.9 600 14.2
45–54 2,228 106 4.7 478 21.5 627 28.2 707 31.7 310 13.9
≥55 1,699 86 5.1 329 19.4 431 25.3 600 35.3 253 14.9
Total 22,659 1,725 7.6 5,621 24.8 7,479 33.0 4,530 20.0 3,306 14.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Persons whose transmission category is classified as male-to-male sexual contact are presented based on assigned sex at birth and include transgender and additional gender identity persons.

a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c Hispanic/Latino persons can be of any race..

Table 1e. Stage of disease at time of diagnosis of HIV infection during 2021 among transgender and additional gender identity persons aged ≥13 years, by selected characteristics—47 states and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)
Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)
Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)
Stage unknownb
Total No. No. % No. % No. % No. % No. %
Transgender womanc
Age at diagnosis (yr)
13-24 280 27 9.6 97 34.6 103 36.8 17 6.1 36 12.9
25-34 323 32 9.9 107 33.1 104 32.2 44 13.6 36 11.1
35-44 125 7 5.6 35 28.0 43 34.4 24 19.2 16 12.8
45-54 36 2 5.6 10 27.8 16 44.4 5 13.9 3 8.3
≥55 21 1 4.8 7 33.3 5 23.8 4 19.0 4 19.0
Race/ethnicity
American Indian/Alaska Native 10 1 10.0 2 20.0 3 30.0 2 20.0 2 20.0
Asian 17 2 11.8 4 23.5 8 47.1 3 17.6 0 0.0
Black/African American 363 33 9.1 110 30.3 133 36.6 43 11.8 44 12.1
Hispanic/Latinod 246 19 7.7 89 36.2 83 33.7 29 11.8 26 10.6
Native Hawaiian/other Pacific Islander 6 0 0.0 1 16.7 2 33.3 2 33.3 1 16.7
White 112 11 9.8 38 33.9 34 30.4 10 8.9 19 17.0
Multiple races 31 3 9.7 12 38.7 8 25.8 5 16.1 3 9.7
Exposure categorye
Sexual contactf 692 61 8.8 229 33.1 245 35.4 82 11.8 75 10.8
Injection drug useg 3 0 0.0 0 0.0 1 33.3 0 0.0 2 66.7
Sexual contactf & injection drug useg 54 8 14.8 14 25.9 14 25.9 6 11.1 12 22.2
Otherh 36 0 0.0 13 36.1 11 30.6 6 16.7 6 16.7
Subtotal 785 69 8.8 256 32.6 271 34.5 94 12.0 95 12.1
Transgender manc
Age at diagnosis (yr)
13-24 14 1 7.1 3 21.4 7 50.0 2 14.3 1 7.1
25-34 30 6 20.0 15 50.0 8 26.7 0 0.0 1 3.3
35-44 8 3 37.5 4 50.0 1 12.5 0 0.0 0 0.0
45-54 1 0 0.0 1 100 0 0.0 0 0.0 0 0.0
≥55 2 1 50.0 0 0.0 1 50.0 0 0.0 0 0.0
Race/ethnicity
American Indian/Alaska Native 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Asian 2 0 0.0 0 0.0 2 100 0 0.0 0 0.0
Black/African American 17 4 23.5 8 47.1 4 23.5 0 0.0 1 5.9
Hispanic/Latinod 14 2 14.3 5 35.7 4 28.6 2 14.3 1 7.1
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
White 19 4 21.1 9 47.4 6 31.6 0 0.0 0 0.0
Multiple races 3 1 33.3 1 33.3 1 33.3 0 0.0 0 0.0
Exposure categorye
Sexual contactf 46 8 17.4 21 45.7 14 30.4 2 4.3 1 2.2
Injection drug useg 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Sexual contactf & injection drug useg 1 0 0.0 1 100 0 0.0 0 0.0 0 0.0
Otherh 8 3 37.5 1 12.5 3 37.5 0 0.0 1 12.5
Subtotal 55 11 20.0 23 41.8 17 30.9 2 3.6 2 3.6
Additional gender identityi
Age at diagnosis (yr)
13-24 25 3 12.0 4 16.0 9 36.0 5 20.0 4 16.0
25-34 11 0 0.0 3 27.3 7 63.6 0 0.0 1 9.1
35-44 3 0 0.0 0 0.0 1 33.3 0 0.0 2 66.7
45-54 4 0 0.0 2 50.0 1 25.0 1 25.0 0 0.0
≥55 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Race/ethnicity
American Indian/Alaska Native 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Asian 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Black/African American 11 0 0.0 1 9.1 5 45.5 2 18.2 3 27.3
Hispanic/Latinod 14 0 0.0 4 28.6 6 42.9 3 21.4 1 7.1
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
White 15 3 20.0 4 26.7 6 40.0 0 0.0 2 13.3
Multiple races 3 0 0.0 0 0.0 1 33.3 1 33.3 1 33.3
Exposure categorye
Sexual contactf 37 3 8.1 8 21.6 15 40.5 5 13.5 6 16.2
Injection drug useg 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Sexual contactf & injection drug useg 5 0 0.0 0 0.0 3 60.0 1 20.0 1 20.0
Otherh 1 0 0.0 1 100 0 0.0 0 0.0 0 0.0
Subtotal 43 3 7.0 9 20.9 18 41.9 6 14.0 7 16.3
Total 883 83 9.4 288 32.6 306 34.7 102 11.6 104 11.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Stage of disease at time of diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Hispanic/Latino persons can be of any race.
e Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
f For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
i Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 2a. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among persons aged ≥13 years, by selected characteristics—47 states and the District of Columbia
Linkage to Care Viral Suppression
≤1 month
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
Gender
Male 26,654 21,833 81.9 4,821 18.1 18,413 69.1
Female 6,069 4,961 81.7 1,108 18.3 4,126 68.0
Transgender womana 785 654 83.3 131 16.7 557 71.0
Transgender mana 55 51 92.7 4 7.3 50 90.9
Additional gender identityb 43 36 83.7 7 16.3 29 67.4
Age at diagnosis (yr)
13–24 6,561 5,263 80.2 1,298 19.8 4,589 69.9
25–34 12,337 10,074 81.7 2,263 18.3 8,546 69.3
35–44 7,087 5,824 82.2 1,263 17.8 4,847 68.4
45–54 4,153 3,462 83.4 691 16.6 2,880 69.3
≥55 3,468 2,912 84.0 556 16.0 2,313 66.7
Race/ethnicity
American Indian/Alaska Native 220 182 82.7 38 17.3 144 65.5
Asian 699 608 87.0 91 13.0 542 77.5
Black/African American 13,650 10,889 79.8 2,761 20.2 9,022 66.1
Hispanic/Latinoc 9,416 7,958 84.5 1,458 15.5 6,897 73.2
Native Hawaiian/other Pacific Islander 74 59 79.7 15 20.3 51 68.9
White 8,580 7,048 82.1 1,532 17.9 5,854 68.2
Multiracial 967 791 81.8 176 18.2 665 68.8
Transmission categoryd
Male-to-male sexual contacte 22,659 18,717 82.6 3,942 17.4 16,124 71.2
Injection drug usef 2,326 1,757 75.5 569 24.5 1,217 52.3
 Male 1,311 975 74.3 337 25.7 671 51.2
 Female 1,015 783 77.1 232 22.9 546 53.8
Male-to-male sexual contacte and injection drug usef 1,301 1,026 78.8 276 21.2 811 62.3
Heterosexual contactg 7,244 5,972 82.4 1,272 17.6 4,967 68.6
 Male 2,178 1,779 81.7 399 18.3 1,370 62.9
 Female 5,065 4,192 82.8 873 17.2 3,597 71.0
Otherh 76 63 83.7 12 16.3 55 73.0
 Male 27 23 87.2 3 12.8 19 72.2
 Female 49 40 81.8 9 18.2 36 73.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 27,010 22,266 82.4 4,744 17.6 18,755 69.4
Metropolitan areas (pop. 50,000-499,999) 4,224 3,395 80.4 829 19.6 2,831 67.0
Nonmetropolitan areas (pop. <50,000) 2,254 1,787 79.3 467 20.7 1,507 66.9
Total 33,606 27,535 81.9 6,071 18.1 23,175 69.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 2b. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among persons aged ≥13 years, by area of residence—47 states and the District of Columbia
Linkage to Care Viral Suppression
≤1 month
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
Alabama 625 502 80.3 123 19.7 427 68.3
Alaska 30 28 93.3 2 6.7 27 90.0
Arizona 781 661 84.6 120 15.4 557 71.3
Arkansas 338 261 77.2 77 22.8 200 59.2
California 4,399 3,628 82.5 771 17.5 2,984 67.8
Colorado 406 343 84.5 63 15.5 318 78.3
Connecticut 233 204 87.6 29 12.4 174 74.7
Delaware 81 68 84.0 13 16.0 58 71.6
District of Columbia 195 154 79.0 41 21.0 126 64.6
Florida 4,072 3,366 82.7 706 17.3 2,828 69.4
Georgia 2,371 1,934 81.6 437 18.4 1,585 66.8
Hawaii 65 55 84.6 10 15.4 45 69.2
Illinois 1,195 1,022 85.5 173 14.5 845 70.7
Indiana 528 401 75.9 127 24.1 373 70.6
Iowa 124 106 85.5 18 14.5 106 85.5
Kansas 154 139 90.3 15 9.7 127 82.5
Kentucky 390 289 74.1 101 25.9 202 51.8
Louisiana 899 725 80.6 174 19.4 615 68.4
Maine 31 27 87.1 4 12.9 26 83.9
Maryland 749 650 86.8 99 13.2 511 68.2
Massachusetts 440 403 91.6 37 8.4 357 81.1
Michigan 633 547 86.4 86 13.6 478 75.5
Minnesota 297 254 85.5 43 14.5 216 72.7
Mississippi 419 299 71.4 120 28.6 249 59.4
Missouri 549 427 77.8 122 22.2 388 70.7
Montana 22 21 95.5 1 4.5 18 81.8
Nebraska 105 88 83.8 17 16.2 75 71.4
Nevada 501 439 87.6 62 12.4 384 76.6
New Hampshire 32 32 100 0 0.0 25 78.1
New Mexico 149 127 85.2 22 14.8 106 71.1
New York 2,116 1,814 85.7 302 14.3 1,624 76.7
North Carolina 1,390 1,115 80.2 275 19.8 986 70.9
North Dakota 37 31 83.8 6 16.2 26 70.3
Ohio 909 757 83.3 152 16.7 623 68.5
Oklahoma 387 303 78.3 84 21.7 254 65.6
Oregon 202 159 78.7 43 21.3 142 70.3
Rhode Island 68 58 85.3 10 14.7 50 73.5
South Carolina 652 557 85.4 95 14.6 494 75.8
South Dakota 31 25 80.6 6 19.4 17 54.8
Tennessee 831 583 70.2 248 29.8 530 63.8
Texas 4,363 3,431 78.6 932 21.4 2,723 62.4
Utah 133 111 83.5 22 16.5 100 75.2
Vermont 12 12 100 0 0.0 10 83.3
Virginia 792 633 79.9 159 20.1 557 70.3
Washington 461 407 88.3 54 11.7 352 76.4
West Virginia 149 107 71.8 42 28.2 48 32.2
Wisconsin 253 226 89.3 27 10.7 204 80.6
Wyoming 7 6 85.7 1 14.3 5 71.4
Region of residencea
Northeast (excluding NJ and PA) 2,932 2,550 87.0 382 13.0 2,266 77.3
Midwest 4,815 4,023 83.6 792 16.4 3,478 72.2
South 18,703 14,977 80.1 3,726 19.9 12,393 66.3
West (excluding ID) 7,156 5,985 83.6 1,171 16.4 5,038 70.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. New Jersey and Pennsylvania recently enacted laws to require laboratories to report all CD4 and viral load test results, but a full calendar year of reporting laboratory results to CDC is required before data are included in care analyses.

a Data should be interpreted with caution as areas with incomplete reporting to CDC are included.

Table 2c. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among persons aged ≥13 years, by race/ethnicity and selected characteristics—47 states and the District of Columbia
Linkage to Care Viral Suppression
≤1 month
Total diagnoses ≥ CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
American Indian/Alaska Native
Gender
Male 164 138 84.1 26 15.9 108 65.9
Female 46 35 76.1 11 23.9 29 63.0
Transgender womana 10 9 90.0 1 10.0 7 70.0
Transgender mana 0 0 0.0 0 0.0 0 0.0
Additional gender identityb 0 0 0.0 0 0.0 0 0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 30 23 76.7 7 23.3 22 73.3
25-34 73 61 83.6 12 16.4 46 63.0
35-44 40 35 87.5 5 12.5 28 70.0
45-54 18 18 100 0 0.0 12 66.7
≥55 13 10 76.9 3 23.1 7 53.8
Transmission categoryc
Male-to-male sexual contactd 139 115 83.1 24 16.9 97 69.7
Injection drug usee 10 9 95.9 0 0.0 4 41.8
Male-to-male sexual contactd and injection drug usee 16 14 89.2 2 10.8 10 62.4
Heterosexual contactf 10 8 85.7 1 14.3 4 44.9
Otherg 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 96 78 81.3 18 18.8 65 67.7
Metropolitan areas (pop. 50,000-499,999) 33 29 87.9 4 12.1 24 72.7
Nonmetropolitan areas (pop. <50,000) 45 40 88.9 5 11.1 26 57.8
Subtotal 174 147 84.5 27 15.5 115 66.1
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 3 1 33.3 2 66.7 2 66.7
25-34 17 13 76.5 4 23.5 10 58.8
35-44 9 8 88.9 1 11.1 6 66.7
45-54 14 10 71.4 4 28.6 8 57.1
≥55 3 3 100 0 0.0 3 100
Transmission categoryc
Injection drug usee 17 14 80.2 3 19.8 11 65.1
Heterosexual contactf 29 21 73.6 8 26.4 18 61.8
Otherg 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 25 19 76.0 6 24.0 14 56.0
Metropolitan areas (pop. 50,000-499,999) 9 7 77.8 2 22.2 6 66.7
Nonmetropolitan areas (pop. <50,000) 12 9 75.0 3 25.0 9 75.0
Subtotal 46 35 76.1 11 23.9 29 63.0
Total 220 182 82.7 38 17.3 144 65.5
Asian
Gender
Male 594 516 86.9 78 13.1 465 78.3
Female 86 75 87.2 11 12.8 61 70.9
Transgender womana 17 15 88.2 2 11.8 14 82.4
Transgender mana 2 2 100 0 0.0 2 100
Additional gender identityb 0 0 0.0 0 0.0 0 0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 105 87 82.9 18 17.1 81 77.1
25-34 240 208 86.7 32 13.3 195 81.3
35-44 135 119 88.1 16 11.9 113 83.7
45-54 82 74 90.2 8 9.8 59 72.0
≥55 49 43 87.8 6 12.2 31 63.3
Transmission categoryc
Male-to-male sexual contactd 545 473 86.7 73 13.3 430 78.9
Injection drug usee 13 12 87.2 2 12.8 10 76.7
Male-to-male sexual contactd and injection drug usee 16 14 92.9 1 7.1 11 69.9
Heterosexual contactf 36 32 87.6 5 12.4 27 74.9
Otherg 1 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 556 482 86.7 74 13.3 438 78.8
Metropolitan areas (pop. 50,000-499,999) 44 40 90.9 4 9.1 35 79.5
Nonmetropolitan areas (pop. <50,000) 9 8 88.9 1 11.1 5 55.6
Subtotal 611 531 86.9 80 13.1 479 78.4
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 9 9 100 0 0.0 9 100
25-34 21 20 95.2 1 4.8 18 85.7
35-44 31 26 83.9 5 16.1 23 74.2
45-54 12 10 83.3 2 16.7 4 33.3
≥55 15 12 80.0 3 20.0 9 60.0
Transmission categoryc
Injection drug usee 6 6 96.6 0 0.0 4 59.3
Heterosexual contactf 80 69 86.6 11 13.4 57 71.9
Otherg 2 2 95.2 0 0.0 2 95.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 70 60 85.7 10 14.3 48 68.6
Metropolitan areas (pop. 50,000-499,999) 14 14 100 0 0.0 13 92.9
Nonmetropolitan areas (pop. <50,000) 4 3 75.0 1 25.0 2 50.0
Subtotal 88 77 87.5 11 12.5 63 71.6
Total 699 608 87.0 91 13.0 542 77.5
Black/African American
Gender
Male 9,985 7,858 78.7 2,127 21.3 6,478 64.9
Female 3,274 2,710 82.8 564 17.2 2,275 69.5
Transgender womana 363 297 81.8 66 18.2 246 67.8
Transgender mana 17 15 88.2 2 11.8 16 94.1
Additional gender identityb 11 9 81.8 2 18.2 7 63.6
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 3,059 2,387 78.0 672 22.0 2,050 67.0
25-34 4,035 3,214 79.7 821 20.3 2,651 65.7
35-44 1,605 1,242 77.4 363 22.6 984 61.3
45-54 801 640 79.9 161 20.1 514 64.2
≥55 858 680 79.3 178 20.7 531 61.9
Transmission categoryc
Male-to-male sexual contactd 8,451 6,690 79.2 1,761 20.8 5,637 66.7
Injection drug usee 336 246 73.4 89 26.6 174 51.9
Male-to-male sexual contactd and injection drug usee 226 162 71.8 64 28.2 120 53.0
Heterosexual contactf 1,333 1,054 79.1 279 20.9 790 59.2
Otherg 13 11 84.1 2 15.9 10 78.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 8,497 6,746 79.4 1,751 20.6 5,541 65.2
Metropolitan areas (pop. 50,000-499,999) 1,206 927 76.9 279 23.1 776 64.3
Nonmetropolitan areas (pop. <50,000) 619 465 75.1 154 24.9 391 63.2
Subtotal 10,358 8,163 78.8 2,195 21.2 6,730 65.0
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 452 364 80.5 88 19.5 314 69.5
25-34 885 733 82.8 152 17.2 617 69.7
35-44 811 675 83.2 136 16.8 559 68.9
45-54 601 501 83.4 100 16.6 441 73.4
≥55 543 453 83.4 90 16.6 361 66.5
Transmission categoryc
Injection drug usee 276 222 80.5 54 19.5 170 61.6
Heterosexual contactf 2,983 2,477 83.0 506 17.0 2,098 70.3
Otherg 33 26 80.1 7 19.9 24 72.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 2,676 2,224 83.1 452 16.9 1,872 70.0
Metropolitan areas (pop. 50,000-499,999) 410 346 84.4 64 15.6 281 68.5
Nonmetropolitan areas (pop. <50,000) 193 148 76.7 45 23.3 132 68.4
Subtotal 3,292 2,726 82.8 566 17.2 2,292 69.6
Total 13,650 10,889 79.8 2,761 20.2 9,022 66.1
Hispanic/Latinoh
Gender
Male 8,101 6,859 84.7 1,242 15.3 5,925 73.1
Female 1,041 861 82.7 180 17.3 760 73.0
Transgender womana 246 212 86.2 34 13.8 189 76.8
Transgender mana 14 13 92.9 1 7.1 13 92.9
Additional gender identityb 14 13 92.9 1 7.1 10 71.4
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 1,602 1,342 83.8 260 16.2 1,178 73.5
25-34 3,479 2,915 83.8 564 16.2 2,572 73.9
35-44 1,867 1,627 87.1 240 12.9 1,390 74.5
45-54 894 760 85.0 134 15.0 643 71.9
≥55 518 439 84.7 79 15.3 340 65.6
Transmission categoryc
Male-to-male sexual contactd 7,340 6,233 84.9 1,106 15.1 5,467 74.5
Injection drug usee 282 221 78.6 60 21.4 155 55.1
Male-to-male sexual contactd and injection drug usee 314 265 84.5 49 15.5 208 66.3
Heterosexual contactf 418 357 85.4 61 14.6 289 69.2
Otherg 6 6 93.8 0 0.0 4 53.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 7,343 6,244 85.0 1,099 15.0 5,422 73.8
Metropolitan areas (pop. 50,000-499,999) 694 565 81.4 129 18.6 481 69.3
Nonmetropolitan areas (pop. <50,000) 290 246 84.8 44 15.2 193 66.6
Subtotal 8,360 7,083 84.7 1,277 15.3 6,123 73.2
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 140 117 83.6 23 16.4 108 77.1
25-34 301 249 82.7 52 17.3 227 75.4
35-44 274 229 83.6 45 16.4 201 73.4
45-54 198 165 83.3 33 16.7 134 67.7
≥55 143 115 80.4 28 19.6 104 72.7
Transmission categoryc
Injection drug usee 151 124 82.5 26 17.5 88 58.4
Heterosexual contactf 899 745 82.8 154 17.2 681 75.8
Otherg 6 6 96.5 0 0.0 5 80.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 915 758 82.8 157 17.2 674 73.7
Metropolitan areas (pop. 50,000-499,999) 106 89 84.0 17 16.0 77 72.6
Nonmetropolitan areas (pop. <50,000) 33 26 78.8 7 21.2 21 63.6
Subtotal 1,056 875 82.9 181 17.1 774 73.3
Total 9,416 7,958 84.5 1,458 15.5 6,897 73.2
Native Hawaiian/other Pacific Islander
Gender
Male 60 48 80.0 12 20.0 42 70.0
Female 8 6 75.0 2 25.0 5 62.5
Transgender womana 6 5 83.3 1 16.7 4 66.7
Transgender mana 0 0 0.0 0 0.0 0 0.0
Additional gender identityb 0 0 0.0 0 0.0 0 0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 10 9 90.0 1 10.0 8 80.0
25-34 26 18 69.2 8 30.8 17 65.4
35-44 17 14 82.4 3 17.6 11 64.7
45-54 7 6 85.7 1 14.3 6 85.7
≥55 6 6 100 0 0.0 4 66.7
Transmission categoryc
Male-to-male sexual contactd 59 48 81.4 11 18.6 41 70.1
Injection drug usee 1 1 100 0 0.0 1 92.9
Male-to-male sexual contactd and injection drug usee 4 1 40.0 2 60.0 1 34.3
Heterosexual contactf 3 3 100 0 0.0 2 96.0
Otherg 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 56 46 82.1 10 17.9 39 69.6
Metropolitan areas (pop. 50,000-499,999) 4 2 50.0 2 50.0 2 50.0
Nonmetropolitan areas (pop. <50,000) 6 5 83.3 1 16.7 5 83.3
Subtotal 66 53 80.3 13 19.7 46 69.7
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 0 0 0.0 0 0.0 0 0.0
25-34 2 1 50.0 1 50.0 1 50.0
35-44 4 3 75.0 1 25.0 3 75.0
45-54 2 2 100 0 0.0 1 50.0
≥55 0 0 0.0 0 0.0 0 0.0
Transmission categoryc
Injection drug usee 3 3 100 0 0.0 2 69.7
Heterosexual contactf 5 3 57.4 2 42.6 3 57.4
Otherg 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 7 5 71.4 2 28.6 4 57.1
Metropolitan areas (pop. 50,000-499,999) 1 1 100 0 0.0 1 100
Nonmetropolitan areas (pop. <50,000) 0 0 0.0 0 0.0 0 0.0
Subtotal 8 6 75.0 2 25.0 5 62.5
Total 74 59 79.7 15 20.3 51 68.9
White
Gender
Male 6,999 5,800 82.9 1,199 17.1 4,876 69.7
Female 1,435 1,130 78.7 305 21.3 875 61.0
Transgender womana 112 88 78.6 24 21.4 77 68.8
Transgender mana 19 18 94.7 1 5.3 16 84.2
Additional gender identityb 15 12 80.0 3 20.0 10 66.7
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 769 617 80.2 152 19.8 552 71.8
25-34 2,493 2,029 81.4 464 18.6 1,711 68.6
35-44 1,697 1,381 81.4 316 18.6 1,158 68.2
45-54 1,136 962 84.7 174 15.3 807 71.0
≥55 1,029 910 88.4 119 11.6 734 71.3
Transmission categoryc
Male-to-male sexual contactd 5,478 4,616 84.2 863 15.8 3,986 72.8
Injection drug usee 631 458 72.5 173 27.5 308 48.8
Male-to-male sexual contactd and injection drug usee 675 529 78.4 146 21.6 432 64.0
Heterosexual contactf 333 291 87.4 42 12.6 230 69.2
Otherg 6 5 90.2 1 9.8 5 82.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 5,074 4,244 83.6 830 16.4 3,541 69.8
Metropolitan areas (pop. 50,000-499,999) 1,234 994 80.6 240 19.4 842 68.2
Nonmetropolitan areas (pop. <50,000) 796 648 81.4 148 18.6 565 71.0
Subtotal 7,124 5,899 82.8 1,225 17.2 4,962 69.7
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 148 121 81.8 27 18.2 95 64.2
25-34 408 314 77.0 94 23.0 238 58.3
35-44 407 311 76.4 96 23.6 243 59.7
45-54 278 226 81.3 52 18.7 177 63.7
≥55 215 177 82.3 38 17.7 139 64.7
Transmission categoryc
Injection drug usee 529 388 73.3 141 26.7 252 47.7
Heterosexual contactf 919 755 82.2 164 17.8 634 69.0
Otherg 8 6 76.3 2 23.7 5 68.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 955 752 78.7 203 21.3 579 60.6
Metropolitan areas (pop. 50,000-499,999) 315 253 80.3 62 19.7 191 60.6
Nonmetropolitan areas (pop. <50,000) 179 139 77.7 40 22.3 117 65.4
Subtotal 1,456 1,149 78.9 307 21.1 892 61.3
Total 8,580 7,048 82.1 1,532 17.9 5,854 68.2
Multiracial
Gender
Male 751 614 81.8 137 18.2 519 69.1
Female 179 144 80.4 35 19.6 121 67.6
Transgender womana 31 28 90.3 3 9.7 20 64.5
Transgender mana 3 3 100 0 0.0 3 100
Additional gender identityb 3 2 66.7 1 33.3 2 66.7
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 208 167 80.3 41 19.7 152 73.1
25-34 303 254 83.8 49 16.2 203 67.0
35-44 140 112 80.0 28 20.0 97 69.3
45-54 79 66 83.5 13 16.5 54 68.4
≥55 54 45 83.3 9 16.7 35 64.8
Transmission categoryc
Male-to-male sexual contactd 647 543 83.8 105 16.2 467 72.1
Injection drug usee 38 27 69.5 12 30.5 18 46.5
Male-to-male sexual contactd and injection drug usee 52 40 76.2 12 23.8 29 56.2
Heterosexual contactf 45 35 76.2 11 23.8 27 58.6
Otherg 1 1 75.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 603 499 82.8 104 17.2 426 70.6
Metropolitan areas (pop. 50,000-499,999) 123 101 82.1 22 17.9 81 65.9
Nonmetropolitan areas (pop. <50,000) 53 39 73.6 14 26.4 30 56.6
Subtotal 784 644 82.1 140 17.9 541 69.0
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 26 19 73.1 7 26.9 18 69.2
25-34 54 45 83.3 9 16.7 40 74.1
35-44 50 42 84.0 8 16.0 31 62.0
45-54 31 22 71.0 9 29.0 20 64.5
≥55 22 19 86.4 3 13.6 15 68.2
Transmission categoryc
Injection drug usee 33 25 77.8 7 22.2 19 57.8
Heterosexual contactf 150 121 80.9 29 19.1 105 69.9
Otherg 1 1 66.7 0 0.0 1 66.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 137 109 79.6 28 20.4 92 67.2
Metropolitan areas (pop. 50,000-499,999) 31 27 87.1 4 12.9 21 67.7
Nonmetropolitan areas (pop. <50,000) 15 11 73.3 4 26.7 11 73.3
Subtotal 183 147 80.3 36 19.7 124 67.8
Total 967 791 81.8 176 18.2 665 68.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
d Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
h Hispanic/Latino persons can be of any race.

Table 2d. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among males, based on assigned sex at birth, aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age at diagnosis—47 states and the District of Columbia
Linkage to Care Viral Suppression
≤1 month
Total diagnoses ≥ CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
American Indian/Alaska Native
13–24 29 22 77.6 6 22.4 22 75.2
25-34 58 47 80.9 11 19.1 38 65.8
35-44 32 28 88.9 4 11.1 24 77.1
45-54 11 11 100 0 0.0 7 64.9
≥55 10 7 73.7 3 26.3 6 58.6
Subtotal 139 115 83.1 24 16.9 97 69.7
Asian
13–24 101 84 83.2 17 16.8 77 76.2
25-34 224 193 86.3 31 13.7 181 81.1
35-44 115 102 89.1 13 10.9 98 85.3
45-54 71 63 89.3 8 10.7 52 73.3
≥55 35 31 86.4 5 13.6 23 63.7
Subtotal 545 473 86.7 73 13.3 430 78.9
Black/African American
13–24 2,888 2,264 78.4 624 21.6 1,962 68.0
25-34 3,525 2,831 80.3 694 19.7 2,372 67.3
35-44 1,143 888 77.7 255 22.3 726 63.5
45-54 488 386 79.1 102 20.9 316 64.9
≥55 407 321 78.9 86 21.1 260 64.0
Subtotal 8,451 6,690 79.2 1,761 20.8 5,637 66.7
Hispanic/Latinoa
13–24 1,496 1,253 83.7 243 16.3 1,108 74.0
25-34 3,134 2,639 84.2 495 15.8 2,365 75.5
35-44 1,602 1,398 87.2 204 12.8 1,204 75.1
45-54 729 619 84.9 110 15.1 535 73.3
≥55 379 325 85.8 54 14.2 255 67.4
Subtotal 7,340 6,233 84.9 1,106 15.1 5,467 74.5
Native Hawaiian/other Pacific Islander
13–24 8 8 100 0 0.0 7 87.5
25-34 24 17 70.6 7 29.4 16 66.4
35-44 16 13 81.6 3 18.4 11 65.0
45-54 7 6 86.6 1 13.4 6 85.1
≥55 4 4 100 0 0.0 2 52.6
Subtotal 59 48 81.4 11 18.6 41 70.1
White
13–24 669 545 81.4 124 18.6 492 73.5
25-34 1,921 1,608 83.7 314 16.3 1,394 72.5
35-44 1,199 997 83.2 202 16.8 861 71.9
45-54 863 728 84.4 135 15.6 629 72.9
≥55 827 738 89.3 88 10.7 610 73.8
Subtotal 5,478 4,616 84.2 863 15.8 3,986 72.8
Multiracial
13–24 194 159 81.8 35 18.2 144 74.2
25-34 250 215 86.0 35 14.0 177 71.1
35-44 106 87 82.0 19 18.0 79 74.5
45-54 60 52 86.0 8 14.0 43 72.5
≥55 38 31 81.1 7 18.9 23 61.3
Subtotal 647 543 83.8 105 16.2 467 72.1
All
13–24 5,384 4,334 80.5 1,050 19.5 3,811 70.8
25-34 9,135 7,549 82.6 1,586 17.4 6,543 71.6
35-44 4,212 3,513 83.4 699 16.6 3,003 71.3
45-54 2,228 1,865 83.7 364 16.3 1,588 71.3
≥55 1,699 1,457 85.7 243 14.3 1,179 69.4
Total 22,659 18,717 82.6 3,942 17.4 16,124 71.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Persons whose transmission category is classified as male-to-male sexual contact are presented based on assigned sex at birth and include transgender and additional gender identity persons. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Hispanic/Latino persons can be of any race.

Table 2e. Linkage to HIV medical care within 1 month and viral suppression within 6 months of HIV diagnosis during 2021 among transgender and additional gender identity persons aged ≥13 years, by selected characteristics—47 states and the District of Columbia
Linkage to Care Viral Suppression
≤1 month
Total diagnoses ≥ CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
Transgender womana
Age at diagnosis (yr)
13-24 280 225 80.4 55 19.6 193 68.9
25-34 323 272 84.2 51 15.8 228 70.6
35-44 125 106 84.8 19 15.2 95 76.0
45-54 36 32 88.9 4 11.1 26 72.2
≥55 21 19 90.5 2 9.5 15 71.4
Race/ethnicity
American Indian/Alaska Native 10 9 90.0 1 10.0 7 70.0
Asian 17 15 88.2 2 11.8 14 82.4
Black/African American 363 297 81.8 66 18.2 246 67.8
Hispanic/Latinob 246 212 86.2 34 13.8 189 76.8
Native Hawaiian/other Pacific Islander 6 5 83.3 1 16.7 4 66.7
White 112 88 78.6 24 21.4 77 68.8
Multiple races 31 28 90.3 3 9.7 20 64.5
Exposure categoryc
Sexual contactd 692 582 84.1 110 15.9 508 73.4
Injection drug usee 3 1 33.3 2 66.7 0 0.0
Sexual contactd & injection drug usee 54 41 75.9 13 24.1 28 51.9
   Otherf 36 30 83.3 6 16.7 21 58.3
Subtotal 785 654 83.3 131 16.7 557 71.0
Transgender mana
Age at diagnosis (yr)
13-24 14 13 92.9 1 7.1 12 85.7
25-34 30 28 93.3 2 6.7 28 93.3
35-44 8 8 100 0 0.0 8 100
45-54 1 1 100 0 0.0 1 100
≥55 2 1 50.0 1 50.0 1 50.0
Race/ethnicity
American Indian/Alaska Native 0 0 0.0 0 0.0 0 0.0
Asian 2 2 100 0 0.0 2 100
Black/African American 17 15 88.2 2 11.8 16 94.1
Hispanic/Latinob 14 13 92.9 1 7.1 13 92.9
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0
White 19 18 94.7 1 5.3 16 84.2
Multiple races 3 3 100 0 0.0 3 100
Exposure categoryc
Sexual contactd 46 44 95.7 2 4.3 44 95.7
Injection drug usee 0 0 0.0 0 0.0 0 0.0
Sexual contactd & injection drug usee 1 1 100 0 0.0 1 100
Otherf 8 6 75.0 2 25.0 5 62.5
Subtotal 55 51 92.7 4 7.3 50 90.9
Additional gender identityg
Age at diagnosis (yr)
13-24 25 21 84.0 4 16.0 17 68.0
25-34 11 10 90.9 1 9.1 7 63.6
35-44 3 1 33.3 2 66.7 1 33.3
45-54 4 4 100 0 0.0 4 100
≥55 0 0 0.0 0 0.0 0 0.0
Race/ethnicity
American Indian/Alaska Native 0 0 0.0 0 0.0 0 0.0
Asian 0 0 0.0 0 0.0 0 0.0
Black/African American 11 9 81.8 2 18.2 7 63.6
Hispanic/Latinob 14 13 92.9 1 7.1 10 71.4
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0
White 15 12 80.0 3 20.0 10 66.7
Multiple races 3 2 66.7 1 33.3 2 66.7
Exposure categoryc
Sexual contactd 37 32 86.5 5 13.5 27 73.0
Injection drug usee 0 0 0.0 0 0.0 0 0.0
Sexual contactd & injection drug usee 5 4 80.0 1 20.0 2 40.0
Otherf 1 0 0.0 1 100 0 0.0
Subtotal 43 36 83.7 7 16.3 8729 67.4
Total 883 741 83.9 142 16.1 636 72.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after diagnosis of HIV infection. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2021. Data are based on residence at time of diagnosis of HIV infection. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Hispanic/Latino persons can be of any race.
c Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
f Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
g Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 3a. Receipt of HIV medical care and viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia
Persons alive at year-end 2021 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
Gender
Male 733,871 553,173 75.4 395,057 53.8 486,719 66.3
Female 217,656 162,841 74.8 116,999 53.8 140,231 64.4
Transgender womanc 11,674 9,627 82.5 7,058 60.5 7,757 66.4
Transgender manc 499 438 87.8 298 59.7 370 74.1
Additional gender identityd 302 261 86.4 213 70.5 223 73.8
Age at year-end 2020 (yr)
13–24 27,140 21,599 79.6 15,013 55.3 17,677 65.1
25–34 152,935 117,976 77.1 79,208 51.8 97,532 63.8
35–44 183,689 137,728 75.0 94,672 51.5 117,369 63.9
45–54 233,009 175,697 75.4 125,588 53.9 154,813 66.4
≥55 367,229 273,340 74.4 205,144 55.9 247,909 67.5
Race/ethnicity
American Indian/Alaska Native 2,992 2,254 75.3 1,569 52.4 1,908 63.8
Asiane 15,188 11,321 74.5 8,327 54.8 10,614 69.9
Black/African American 386,688 283,784 73.4 200,781 51.9 238,353 61.6
Hispanic/Latinof 227,387 164,738 72.4 123,552 54.3 146,163 64.3
Native Hawaiian/other Pacific Islander 855 622 72.7 424 49.6 542 63.4
White 280,199 220,753 78.8 154,168 55.0 200,892 71.7
Multiracial 50,067 42,824 85.5 30,769 61.5 36,786 73.5
Transmission categoryg
Male-to-male sexual contacth 561,493 433,734 77.2 308,936 55.0 385,254 68.6
Injection drug usei 96,246 63,798 66.3 45,988 47.8 53,923 56.0
 Male 54,849 33,996 62.0 24,719 45.1 28,778 52.5
 Female 41,397 29,802 72.0 21,269 51.4 25,145 60.7
Male-to-male sexual contacth and injection drug usei 53,043 41,363 78.0 29,568 55.7 34,514 65.1
Heterosexual contactj 239,228 177,248 74.1 127,973 53.5 153,516 64.2
 Male 69,386 48,979 70.6 35,713 51.5 42,133 60.7
 Female 169,842 128,269 75.5 92,260 54.3 111,383 65.6
Otherk 13,992 10,198 72.9 7,160 51.2 8,094 57.8
 Male 7,039 4,960 70.5 3,364 47.8 3,996 56.8
 Female 6,953 5,239 75.3 3,796 54.6 4,099 58.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 792,024 597,277 75.4 428,524 54.1 522,654 66.0
Metropolitan areas (pop. 50,000–499,999) 94,410 72,773 77.1 51,794 54.9 63,423 67.2
Nonmetropolitan areas (pop. <50,000) 56,132 42,356 75.5 30,416 54.2 37,105 66.1
Totall 964,002 726,340 75.3 519,625 53.9 635,300 65.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Performed ≥3 months apart during 2021.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Includes Asian/Pacific Islander legacy cases (see Technical Notes).
f Hispanic/Latino persons can be of any race.
g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
i Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
l Includes 626 persons of unknown race/ethnicity.

Table 3a. Receipt of HIV medical care and viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia
Persons alive at year-end 2021 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
Alabama 13,774 9,898 71.9 6,336 46.0 8,146 59.1
Alaska 718 631 87.9 411 57.2 572 79.7
Arizona 17,490 12,733 72.8 9,464 54.1 10,955 62.6
Arkansas 5,900 3,953 67.0 2,691 45.6 3,097 52.5
California 131,709 98,344 74.7 69,411 52.7 87,675 66.6
Colorado 13,022 8,584 65.9 5,449 41.8 7,890 60.6
Connecticut 10,406 8,270 79.5 5,877 56.5 7,484 71.9
Delaware 3,439 2,822 82.1 1,924 55.9 2,525 73.4
District of Columbia 13,401 8,798 65.7 5,699 42.5 7,418 55.4
Florida 113,218 87,864 77.6 70,379 62.2 77,793 68.7
Georgia 57,083 41,473 72.7 31,048 54.4 35,470 62.1
Hawaii 2,323 2,007 86.4 1,450 62.4 1,839 79.2
Illinois 34,556 26,373 76.3 16,789 48.6 21,881 63.3
Indiana 11,821 9,376 79.3 6,371 53.9 8,322 70.4
Iowa 2,923 2,576 88.1 1,844 63.1 2,389 81.7
Kansas 3,340 2,749 82.3 2,112 63.2 2,523 75.5
Kentucky 7,759 6,236 80.4 4,265 55.0 5,062 65.2
Louisiana 20,700 16,273 78.6 12,330 59.6 14,263 68.9
Maine 1,650 1,360 82.4 950 57.6 1,279 77.5
Maryland 32,719 23,559 72.0 15,589 47.6 20,214 61.8
Massachusetts 20,672 15,742 76.2 10,192 49.3 14,483 70.1
Michigan 16,652 13,486 81.0 8,702 52.3 11,987 72.0
Minnesota 8,915 6,531 73.3 3,464 38.9 5,962 66.9
Mississippic 9,474 6,727 71.0 4,524 47.8 5,646 59.6
Missouri 12,570 9,697 77.1 6,772 53.9 8,403 66.8
Montana 698 614 88.0 430 61.6 564 80.8
Nebraska 2,274 1,751 77.0 1,057 46.5 1,541 67.8
Nevada 10,921 8,033 73.6 5,566 51.0 6,971 63.8
New Hampshire 1,333 1,076 80.7 700 52.5 1,006 75.5
New Mexico 3,873 2,957 76.3 1,812 46.8 2,183 56.4
New York 122,351 89,211 72.9 70,433 57.6 79,119 64.7
North Carolina 32,933 25,496 77.4 17,097 51.9 22,383 68.0
North Dakota 506 402 79.4 262 51.8 317 62.6
Ohio 23,181 17,368 74.9 10,995 47.4 15,307 66.0
Oklahoma 6,585 4,720 71.7 3,548 53.9 4,046 61.4
Oregon 7,268 6,237 85.8 3,451 47.5 5,616 77.3
Rhode Island 2,647 1,969 74.4 893 33.7 1,809 68.3
South Carolina 17,474 14,315 81.9 11,139 63.7 12,679 72.6
South Dakota 687 606 88.2 394 57.4 380 55.3
Tennessee 17,938 14,133 78.8 10,326 57.6 12,005 66.9
Texas 96,292 72,212 75.0 51,418 53.4 60,494 62.8
Utah 3,317 2,518 75.9 1,610 48.5 2,338 70.5
Vermont 712 561 78.8 354 49.7 531 74.6
Virginia 23,635 16,959 71.8 11,574 49.0 15,378 65.1
Washington 14,141 12,012 84.9 7,711 54.5 11,121 78.6
West Virginiac 2,056 1,417 68.9 838 40.8 1,118 54.4
Wisconsin 6,579 5,409 82.2 3,765 57.2 4,869 74.0
Wyoming 367 302 82.3 209 56.9 247 67.3
Region of residenced
Northeast (excluding NJ & PA) 159,771 118,189 74.0 89,399 56.0 105,711 66.2
Midwest 124,004 96,324 77.7 62,527 50.4 83,881 67.6
South 474,380 356,855 75.2 260,725 55.0 307,737 64.9
West (excluding ID) 205,847 154,972 75.3 106,974 52.0 137,971 67.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. New Jersey and Pennsylvania recently enacted laws to require laboratories to report all CD4 and VL test results, but a full calendar year of reporting laboratory results to CDC is required before data are included in care analyses.

a Performed ≥3 months apart during 2021.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
c Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.
d Data should be interpreted with caution as areas with incomplete reporting to CDC are not included.

Table 3c. Receipt of HIV medical care and viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by race/ethnicity and selected characteristics—47 states and the District of Columbia
Persons alive at year-end 2021 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
American Indian/Alaska Native
Gender
Male 2,203 1,647 74.8 1,148 52.1 1,416 64.3
Female 731 559 76.5 389 53.2 453 62.0
Transgender womanc 53 44 83.0 29 54.7 35 66.0
Transgender manc 4 3 75.0 3 75.0 3 75.0
Additional Gender identityd 1 1 100 0 0.0 1 100
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 92 71 77.2 42 45.7 61 66.3
25-34 503 405 80.5 270 53.7 327 65.0
35-44 527 402 76.3 282 53.5 348 66.0
45-54 534 397 74.3 281 52.6 347 65.0
≥55 601 417 69.4 302 50.2 369 61.4
Transmission categorye
Male-to-male sexual contactf 1,614 1,231 76.3 859 53.2 1,078 66.8
Injection drug useg 212 144 68.1 97 46.0 113 53.3
Male-to-male sexual contactf and injection drug useg 275 203 73.8 145 52.8 168 61.0
   Heterosexual contacth 139 100 72.0 69 49.6 82 58.8
Otheri 17 14 81.8 7 38.8 12 68.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 1,225 877 71.6 624 50.9 771 62.9
Metropolitan areas (pop. 50,000-499,999) 389 325 83.5 232 59.6 271 69.7
Nonmetropolitan areas (pop. <50,000) 597 459 76.9 304 50.9 385 64.5
Subtotal 2,257 1,692 75.0 1,177 52.1 1,452 64.3
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 11 7 63.6 5 45.5 5 45.5
25-34 93 62 66.7 44 47.3 49 52.7
35-44 190 156 82.1 103 54.2 112 58.9
45-54 201 148 73.6 98 48.8 123 61.2
≥55 240 189 78.8 142 59.2 167 69.6
Transmission categorye
Injection drug useg 248 181 73.0 120 48.3 139 56.0
   Heterosexual contacth 470 372 79.2 268 57.1 311 66.2
Otheri 17 9 53.2 4 23.7 6 35.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 345 239 69.3 158 45.8 203 58.8
Metropolitan areas (pop. 50,000-499,999) 146 126 86.3 101 69.2 100 68.5
Nonmetropolitan areas (pop. <50,000) 226 183 81.0 127 56.2 144 63.7
Subtotal 735 562 76.5 392 53.3 456 62.0
Total 2,992 2,254 75.3 1,569 52.4 1,908 63.8
Asianj
Gender
Male 12,402 9,278 74.8 6,805 54.9 8,709 70.2
Female 2,577 1,870 72.6 1,394 54.1 1,741 67.6
Transgender womanc 195 162 83.1 120 61.5 154 79.0
Transgender manc 9 7 77.8 4 44.4 7 77.8
Additional Gender identityd 5 4 80.0 4 80.0 3 60.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 410 334 81.5 227 55.4 307 74.9
25-34 2,574 1,984 77.1 1,412 54.9 1,862 72.3
35-44 2,940 2,211 75.2 1,583 53.8 2,077 70.6
45-54 3,596 2,746 76.4 2,019 56.1 2,575 71.6
≥55 3,081 2,168 70.4 1,687 54.8 2,044 66.3
Transmission categorye
Male-to-male sexual contactf 10,714 8,104 75.6 5,922 55.3 7,617 71.1
Injection drug useg 415 258 62.3 191 46.0 241 58.1
Male-to-male sexual contactf and injection drug useg 406 300 73.9 208 51.3 277 68.2
   Heterosexual contacth 947 695 73.4 546 57.6 652 68.9
Otheri 120 86 71.8 61 50.9 78 64.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 11,520 8,668 75.2 6,393 55.5 8,156 70.8
Metropolitan areas (pop. 50,000-499,999) 695 516 74.2 363 52.2 474 68.2
Nonmetropolitan areas (pop. <50,000) 186 135 72.6 97 52.2 122 65.6
Subtotal 12,601 9,443 74.9 6,928 55.0 8,865 70.4
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 90 73 81.1 46 51.1 70 77.8
25-34 276 213 77.2 165 59.8 195 70.7
35-44 757 561 74.1 407 53.8 528 69.7
45-54 736 514 69.8 381 51.8 477 64.8
≥55 728 517 71.0 400 54.9 479 65.8
Transmission categorye
Injection drug useg 172 113 66.0 82 47.6 107 62.3
   Heterosexual contacth 2,294 1,676 73.1 1,253 54.7 1,557 67.9
Otheri 122 89 73.2 64 52.5 85 70.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 2,213 1,611 72.8 1,212 54.8 1,504 68.0
Metropolitan areas (pop. 50,000-499,999) 235 167 71.1 127 54.0 154 65.5
Nonmetropolitan areas (pop. <50,000) 75 58 77.3 38 50.7 51 68.0
Subtotal 2,587 1,878 72.6 1,399 54.1 1,749 67.6
Total 15,188 11,321 74.5 8,327 54.8 10,614 69.9
Black/African American
Gender
Male 253,694 184,743 72.8 129,892 51.2 154,389 60.9
Female 127,294 94,348 74.1 67,611 53.1 80,324 63.1
Transgender womanc 5,376 4,417 82.2 3,087 57.4 3,424 63.7
Transgender manc 203 179 88.2 114 56.2 138 68.0
Additional Gender identityd 121 97 80.2 77 63.6 78 64.5
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 11,858 9,379 79.1 6,354 53.6 7,517 63.4
25-34 59,288 45,006 75.9 29,707 50.1 35,646 60.1
35-44 48,584 36,386 74.9 24,807 51.1 29,810 61.4
45-54 52,037 38,257 73.5 27,490 52.8 32,632 62.7
≥55 87,410 60,219 68.9 44,688 51.1 52,278 59.8
Transmission categorye
Male-to-male sexual contactf 173,951 130,922 75.3 90,775 52.2 109,425 62.9
Injection drug useg 24,920 15,274 61.3 11,069 44.4 12,810 51.4
Male-to-male sexual contactf and injection drug useg 13,950 10,450 74.9 7,562 54.2 8,338 59.8
   Heterosexual contacth 43,066 30,348 70.5 22,086 51.3 25,611 59.5
Otheri 3,290 2,253 68.5 1,555 47.3 1,699 51.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 215,118 157,504 73.2 109,976 51.1 131,215 61.0
Metropolitan areas (pop. 50,000-499,999) 23,830 17,579 73.8 12,732 53.4 14,740 61.9
Nonmetropolitan areas (pop. <50,000) 14,181 10,467 73.8 7,937 56.0 8,839 62.3
Subtotal 259,177 189,247 73.0 133,046 51.3 157,883 60.9
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 3,270 2,511 76.8 1,836 56.1 1,879 57.5
25-34 14,204 10,408 73.3 6,951 48.9 8,021 56.5
35-44 26,435 19,126 72.4 13,065 49.4 15,721 59.5
45-54 35,772 26,725 74.7 19,004 53.1 22,990 64.3
≥55 47,830 35,767 74.8 26,879 56.2 31,859 66.6
Transmission categorye
Injection drug useg 19,231 13,623 70.8 9,768 50.8 11,534 60.0
Heterosexual contacth 104,386 78,028 74.7 55,873 53.5 66,764 64.0
Otheri 3,893 2,887 74.1 2,094 53.8 2,172 55.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 106,083 78,592 74.1 56,178 53.0 66,816 63.0
Metropolitan areas (pop. 50,000-499,999) 12,212 9,420 77.1 6,907 56.6 8,043 65.9
Nonmetropolitan areas (pop. <50,000) 6,388 4,722 73.9 3,481 54.5 4,080 63.9
Subtotal 127,511 94,537 74.1 67,735 53.1 80,470 63.1
Total 386,688 283,784 73.4 200,781 51.9 238,353 61.6
Hispanic/Latinok
Gender
Male 183,521 131,299 71.5 97,966 53.4 116,938 63.7
Female 39,790 30,121 75.7 22,992 57.8 26,469 66.5
Transgender womanc 3,884 3,149 81.1 2,464 63.4 2,609 67.2
Transgender manc 112 96 85.7 70 62.5 83 74.1
Additional Gender identityd 80 73 91.3 60 75.0 64 80.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 5,498 4,418 80.4 3,144 57.2 3,788 68.9
25-34 35,257 27,732 78.7 19,404 55.0 23,935 67.9
35-44 43,547 31,296 71.9 22,780 52.3 27,479 63.1
45-54 48,006 33,507 69.8 25,354 52.8 30,027 62.5
≥55 55,168 37,559 68.1 29,801 54.0 34,375 62.3
Transmission categorye
Male-to-male sexual contactf 143,970 106,515 74.0 79,380 55.1 95,745 66.5
Injection drug useg 15,510 8,566 55.2 6,574 42.4 7,326 47.2
Male-to-male sexual contactf and injection drug useg 12,456 9,295 74.6 6,896 55.4 7,679 61.6
   Heterosexual contacth 14,058 9,118 64.9 6,909 49.1 8,049 57.3
Otheri 1,482 1,018 68.7 724 48.9 806 54.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 165,997 120,863 72.8 90,822 54.7 107,615 64.8
Metropolitan areas (pop. 50,000-499,999) 12,290 8,374 68.1 5,992 48.8 7,379 60.0
Nonmetropolitan areas (pop. <50,000) 6,525 3,717 57.0 2,674 41.0 3,235 49.6
Subtotal 187,476 134,512 71.7 100,483 53.6 119,604 63.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 965 772 80.0 568 58.9 607 62.9
25-34 4,287 3,264 76.1 2,338 54.5 2,687 62.7
35-44 8,010 5,914 73.8 4,306 53.8 5,031 62.8
45-54 11,025 8,361 75.8 6,331 57.4 7,341 66.6
≥55 15,624 11,915 76.3 9,526 61.0 10,893 69.7
Transmission categorye
Injection drug useg 8,021 5,866 73.1 4,500 56.1 4,995 62.3
   Heterosexual contacth 30,418 23,209 76.3 17,709 58.2 20,674 68.0
Otheri 1,471 1,151 78.2 860 58.5 890 60.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 35,193 26,762 76.0 20,576 58.5 23,526 66.8
Metropolitan areas (pop. 50,000-499,999) 2,678 2,076 77.5 1,510 56.4 1,820 68.0
Nonmetropolitan areas (pop. <50,000) 1,343 958 71.3 713 53.1 832 62.0
Subtotal 39,911 30,226 75.7 23,069 57.8 26,559 66.5
Total 227,387 164,738 72.4 123,552 54.3 146,163 64.3
Native Hawaiian/other Pacific Islander
Gender
Male 686 505 73.6 342 49.9 439 64.0
Female 136 94 69.1 67 49.3 84 61.8
Transgender womanc 33 23 69.7 15 45.5 19 57.6
Transgender manc 0 0 0.0 0 0.0 0 0.0
Additional Gender identityd 0 0 0.0 0 0.0 0 0.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 28 19 67.9 9 32.1 16 57.1
25-34 168 124 73.8 74 44.0 107 63.7
35-44 197 136 69.0 89 45.2 115 58.4
45-54 151 118 78.1 82 54.3 106 70.2
≥55 175 131 74.9 103 58.9 114 65.1
Transmission categorye
Male-to-male sexual contactf 615 455 74.1 310 50.4 404 65.7
Injection drug useg 22 13 60.4 9 41.0 6 27.6
Male-to-male sexual contactf and injection drug useg 49 34 70.6 19 39.1 29 60.3
   Heterosexual contacth 30 21 70.7 17 58.2 15 51.9
Otheri 4 4 100 2 50.0 3 73.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 592 430 72.6 295 49.8 376 63.5
Metropolitan areas (pop. 50,000-499,999) 79 63 79.7 42 53.2 55 69.6
Nonmetropolitan areas (pop. <50,000) 34 27 79.4 16 47.1 21 61.8
Subtotal 719 528 73.4 357 49.7 458 63.7
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 4 3 75.0 2 50.0 2 50.0
25-34 19 14 73.7 7 36.8 12 63.2
35-44 33 23 69.7 17 51.5 21 63.6
45-54 30 20 66.7 15 50.0 18 60.0
≥55 50 34 68.0 26 52.0 31 62.0
Transmission categorye
Injection drug useg 23 14 62.2 11 47.4 14 61.3
   Heterosexual contacth 112 79 70.8 56 49.9 70 62.1
Otheri 1 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 96 65 67.7 47 49.0 57 59.4
Metropolitan areas (pop. 50,000-499,999) 22 17 77.3 11 50.0 15 68.2
Nonmetropolitan areas (pop. <50,000) 13 9 69.2 7 53.8 9 69.2
Subtotal 136 94 69.1 67 49.3 84 61.8
Total 855 622 72.7 424 49.6 542 63.4
White
Gender
Male 243,121 193,315 79.5 135,703 55.8 176,842 72.7
Female 35,681 26,251 73.6 17,603 49.3 23,012 64.5
Transgender womanc 1,212 1,021 84.2 742 61.2 886 73.1
Transgender manc 122 109 89.3 74 60.7 99 81.1
Additional Gender identityd 63 57 90.5 46 73.0 53 84.1
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 2,865 2,344 81.8 1,605 56.0 2,080 72.6
25-34 23,716 18,882 79.6 12,372 52.2 16,656 70.2
35-44 35,276 27,965 79.3 18,205 51.6 24,825 70.4
45-54 58,758 47,120 80.2 32,233 54.9 42,754 72.8
≥55 123,773 98,076 79.2 72,070 58.2 91,461 73.9
Transmission categorye
Male-to-male sexual contactf 201,273 161,582 80.3 113,955 56.6 149,247 74.2
Injection drug useg 11,488 7,855 68.4 5,357 46.6 6,704 58.4
Male-to-male sexual contactf and injection drug useg 21,626 17,367 80.3 12,013 55.5 14,979 69.3
   Heterosexual contacth 8,342 6,373 76.4 4,399 52.7 5,746 68.9
Otheri 1,659 1,210 73.0 761 45.9 1,100 66.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 188,320 149,089 79.2 105,170 55.8 136,883 72.7
Metropolitan areas (pop. 50,000-499,999) 30,651 25,111 81.9 17,517 57.1 22,637 73.9
Nonmetropolitan areas (pop. <50,000) 18,962 15,582 82.2 10,883 57.4 14,102 74.4
Subtotal 244,388 194,387 79.5 136,485 55.8 177,776 72.7
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 718 553 77.0 392 54.6 470 65.5
25-34 3,949 2,875 72.8 1,791 45.4 2,304 58.3
35-44 6,883 4,966 72.1 3,123 45.4 4,176 60.7
45-54 9,720 7,168 73.7 4,695 48.3 6,244 64.2
≥55 14,541 10,804 74.3 7,682 52.8 9,922 68.2
Transmission categorye
Injection drug useg 11,037 7,766 70.4 5,143 46.6 6,507 59.0
   Heterosexual contacth 23,786 17,885 75.2 12,046 50.6 15,973 67.2
Otheri 988 715 72.4 494 50.0 636 64.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 23,930 17,437 72.9 11,829 49.4 15,342 64.1
Metropolitan areas (pop. 50,000-499,999) 6,200 4,785 77.2 3,201 51.6 4,128 66.6
Nonmetropolitan areas (pop. <50,000) 4,450 3,347 75.2 2,180 49.0 2,947 66.2
Subtotal 35,811 26,366 73.6 17,683 49.4 23,116 64.5
Total 280,199 220,753 78.8 154,168 55.0 200,892 71.7
Multiracial
Gender
Male 37,789 32,347 85.6 23,171 61.3 27,949 74.0
Female 11,276 9,593 85.1 6,938 61.5 8,143 72.2
Transgender womanc 921 811 88.1 601 65.3 630 68.4
Transgender manc 49 44 89.8 33 67.3 40 81.6
Additional Gender identityd 32 29 90.6 26 81.3 24 75.0
Male sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 976 827 84.7 576 59.0 660 67.6
25-34 7,277 5,948 81.7 3,925 53.9 4,906 67.4
35-44 7,891 6,618 83.9 4,550 57.7 5,512 69.9
45-54 9,173 7,935 86.5 5,693 62.1 6,902 75.2
≥55 13,421 11,855 88.3 9,050 67.4 10,619 79.1
Transmission categorye
Male-to-male sexual contactf 29,045 24,894 85.7 17,713 61.0 21,708 74.7
Injection drug useg 2,218 1,882 84.8 1,419 64.0 1,575 71.0
Male-to-male sexual contactf and injection drug useg 4,241 3,711 87.5 2,723 64.2 3,042 71.7
   Heterosexual contacth 2,780 2,322 83.5 1,686 60.6 1,976 71.1
Otheri 455 374 82.2 253 55.6 297 65.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 31,949 27,417 85.8 19,639 61.5 23,618 73.9
Metropolitan areas (pop. 50,000-499,999) 3,664 3,133 85.5 2,275 62.1 2,695 73.6
Nonmetropolitan areas (pop. <50,000) 2,282 1,996 87.5 1,450 63.5 1,748 76.6
Subtotal 38,738 33,183 85.7 23,794 61.4 28,599 73.8
Female sex at birth, adult or adolescent
Age at diagnosis (yrs)
13-24 350 288 82.3 207 59.1 215 61.4
25-34 1,312 1,058 80.6 747 56.9 824 62.8
35-44 2,395 1,967 82.1 1,354 56.5 1,613 67.3
45-54 3,148 2,672 84.9 1,904 60.5 2,268 72.0
≥55 4,124 3,656 88.7 2,763 67.0 3,267 79.2
Transmission categorye
Injection drug useg 2,611 2,238 85.7 1,645 63.0 1,848 70.8
   Heterosexual contacth 8,270 7,016 84.8 5,051 61.1 6,031 72.9
Otheri 448 387 86.4 279 62.3 308 68.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 8,969 7,679 85.6 5,570 62.1 6,530 72.8
Metropolitan areas (pop. 50,000-499,999) 1,288 1,081 83.9 784 60.9 912 70.8
Nonmetropolitan areas (pop. <50,000) 832 696 83.7 509 61.2 590 70.9
Subtotal 11,329 9,641 85.1 6,975 61.6 8,187 72.3
Total 50,067 42,824 85.5 30,769 61.5 36,786 73.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Performed ≥3 months apart during 2021.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
c “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
j Includes Asian/Pacific Islander legacy cases (see Technical Notes).
k Hispanic/Latino persons can be of any race.

Table 3d. Receipt of HIV medical care and viral suppression during 2021 among males, based on assigned sex at birth, aged ≥13 years with infection attributed to male-to-male sexual contact, by race/ethnicity and age group—47 states and the District of Columbia
Males alive at year-end 2021 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
American Indian/Alaska Native
13–24 75 58 77.5 35 46.7 49 65.5
25-34 408 330 80.9 218 53.4 272 66.7
35-44 403 309 76.7 215 53.3 275 68.1
45-54 368 275 74.6 199 53.9 249 67.7
≥55 360 259 71.9 193 53.5 233 64.8
Subtotal 1,614 1,231 76.3 859 53.2 1,078 66.8
Asianc
13–24 340 277 81.4 183 53.8 256 75.3
25-34 2,412 1,862 77.2 1,328 55.1 1,751 72.6
35-44 2,573 1,936 75.2 1,392 54.1 1,816 70.6
45-54 2,976 2,290 76.9 1,671 56.1 2,146 72.1
≥55 2,412 1,740 72.1 1,349 55.9 1,648 68.3
Subtotal 10,714 8,104 75.6 5,922 55.3 7,617 71.1
Black/African American
13–24 9,983 8,013 80.3 5,429 54.4 6,479 64.9
25-34 52,325 40,119 76.7 26,454 50.6 31,976 61.1
35-44 38,284 29,114 76.0 19,756 51.6 24,016 62.7
45-54 32,854 24,573 74.8 17,577 53.5 21,235 64.6
≥55 40,504 29,103 71.9 21,558 53.2 25,720 63.5
Subtotal 173,951 130,922 75.3 90,775 52.2 109,425 62.9
Hispanic/Latinod
13–24 4,800 3,900 81.2 2,789 58.1 3,384 70.5
25-34 31,135 24,688 79.3 17,334 55.7 21,567 69.3
35-44 35,995 26,386 73.3 19,308 53.6 23,488 65.3
45-54 36,435 26,108 71.7 19,799 54.3 23,724 65.1
≥55 35,606 25,433 71.4 20,150 56.6 23,583 66.2
Subtotal 143,970 106,515 74.0 79,380 55.1 95,745 66.5
Native Hawaiian/other Pacific Islander
13–24 24 15 63.0 8 33.6 13 54.6
25-34 143 110 77.2 66 46.0 96 67.5
35-44 177 124 69.9 84 47.5 108 60.9
45-54 128 100 78.1 68 53.2 90 70.5
≥55 143 106 74.3 84 58.6 97 67.6
Subtotal 615 455 74.1 310 50.4 404 65.7
White
13–24 2,310 1,924 83.3 1,326 57.4 1,719 74.4
25-34 19,500 15,594 80.0 10,265 52.6 14,020 71.9
35-44 28,456 22,645 79.6 14,768 51.9 20,435 71.8
45-54 48,023 38,685 80.6 26,550 55.3 35,487 73.9
≥55 102,983 82,734 80.3 61,045 59.3 77,587 75.3
Subtotal 201,273 161,582 80.3 113,955 56.6 149,247 74.2
Multiracial
13–24 764 653 85.4 460 60.2 525 68.7
25-34 6,294 5,160 82.0 3,403 54.1 4,298 68.3
35-44 6,407 5,370 83.8 3,686 57.5 4,530 70.7
45-54 6,782 5,894 86.9 4,202 61.9 5,224 77.0
≥55 8,797 7,818 88.9 5,962 67.8 7,131 81.1
Subtotal 29,045 24,894 85.7 17,713 61.0 21,708 74.7
All races
13–24 18,297 14,840 81.1 10,229 55.9 12,423 67.9
25-34 112,216 87,863 78.3 59,068 52.6 73,979 65.9
35-44 112,306 85,885 76.5 59,210 52.7 74,668 66.5
45-54 127,623 97,931 76.7 70,072 54.9 88,162 69.1
≥55 191,051 147,215 77.1 110,357 57.8 136,021 71.2
Total 561,493 433,734 77.2 308,936 55.0 385,254 68.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for those diagnosed by year-end 2020, and age groups are based on age at year-end 2020. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Persons whose transmission category is classified as male-to-male sexual contact are presented based on assigned sex at birth and include transgender and additional gender identity persons. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Performed ≥3 months apart during 2021.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.

Table 3e. Receipt of HIV medical care and viral suppression during 2021 among transgender and additional gender identity persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia
Persons alive at year-end 2021 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
Transgender womanc
Age at year-end 2020 (yr)
13–24 790 654 82.8 432 54.7 472 59.7
25-34 4,197 3,435 81.8 2,393 57.0 2,641 62.9
35-44 3,093 2,515 81.3 1,881 60.8 2,033 65.7
45-54 2,150 1,797 83.6 1,383 64.3 1,531 71.2
≥55 1,444 1,226 84.9 969 67.1 1,080 74.8
Race/ethnicity
American Indian/Alaska Native 53 44 83.0 29 54.7 35 66.0
Asiand 195 162 83.1 120 61.5 154 79.0
Black/African American 5,376 4,417 82.2 3,087 57.4 3,424 63.7
Hispanic/Latinoe 3,884 3,149 81.1 2,464 63.4 2,609 67.2
Native Hawaiian/other Pacific Islander 33 23 69.7 15 45.5 19 57.6
White 1,212 1,021 84.2 742 61.2 886 73.1
Multiracial 921 811 88.1 601 65.3 630 68.4
Exposure categoryf
Sexual contactg 9,909 8,176 82.5 5,978 60.3 6,647 67.1
Injection drug useh 25 19 76.0 14 56.0 12 48.0
Sexual contactg and injection drug useh 1,531 1,300 84.9 975 63.7 996 65.1
   Otheri 209 132 63.2 91 43.5 102 48.8
Subtotal 11,674 9,627 82.5 7,058 60.5 7,757 66.4
Transgender manc
Age at year-end 2020 (yr)
13–24 42 37 88.1 31 73.8 32 76.2
25-34 161 142 88.2 94 58.4 119 73.9
35-44 127 111 87.4 79 62.2 100 78.7
45-54 96 82 85.4 55 57.3 69 71.9
≥55 73 66 90.4 39 53.4 50 68.5
Race/ethnicity
American Indian/Alaska Native 4 3 75.0 3 75.0 3 75.0
Asiand 9 7 77.8 4 44.4 7 77.8
Black/African American 203 179 88.2 114 56.2 138 68.0
Hispanic/Latinoe 112 96 85.7 70 62.5 83 74.1
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0
White 122 109 89.3 74 60.7 99 81.1
Multiracial 49 44 89.8 33 67.3 40 81.6
Exposure categoryf
Sexual contactg 375 330 88.0 223 59.5 288 76.8
Injection drug useh 10 8 80.0 5 50.0 6 60.0
Sexual contactg and injection drug useh 61 55 90.2 38 62.3 35 57.4
   Otheri 53 45 84.9 32 60.4 41 77.4
Subtotal 499 438 87.8 298 59.7 370 74.1
Additional gender identityj
Age at year-end 2020 (yr)
13–24 40 34 85.0 29 72.5 32 80.0
25-34 119 107 89.9 76 63.9 89 74.8
35-44 59 51 86.4 45 76.3 43 72.9
45-54 48 39 81.3 34 70.8 32 66.7
≥55 36 30 83.3 29 80.6 27 75.0
Race/ethnicity
American Indian/Alaska Native 1 1 100 0 0.0 1 100
Asiand 5 4 80.0 4 80.0 3 60.0
Black/African American 121 97 80.2 77 63.6 78 64.5
Hispanic/Latinoe 80 73 91.3 60 75.0 64 80.0
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0
White 63 57 90.5 46 73.0 53 84.1
Multiracial 32 29 90.6 26 81.3 24 75.0
Exposure categoryf
Sexual contactg 265 230 86.8 185 69.8 196 74.0
Injection drug useh 1 1 100 1 100 1 100
Sexual contactg and injection drug useh 25 23 92.0 20 80.0 19 76.0
   Otheri 11 7 63.6 7 63.6 7 63.6
Subtotal 302 261 86.4 213 70.5 223 73.8
Total 12,475 10,326 82.8 7,569 60.7 8,350 66.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Performed ≥3 months apart during 2021.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
g For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
j Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 4a. HIV viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia
VL <200 copies/mL
Persons alive at year-end 2021 Persons with ≥1 CD4 or VL tests Persons with ≥1 VL tests Among persons alive at year-end 2021 Among persons with ≥1 CD4 or VL tests Among persons with ≥1 VL tests
No. %a No. % No. % No. % % %
Gender
Male 733,871 76.1 553,173 75.4 531,938 72.5 486,719 66.3 88.0 91.5
Female 217,656 22.6 162,841 74.8 156,749 72.0 140,231 64.4 86.1 89.5
Transgender womanb 11,674 1.2 9,627 82.5 9,334 80.0 7,757 66.4 80.6 83.1
Transgender manb 499 0.1 438 87.8 417 83.6 370 74.1 84.5 88.7
Additional gender identityc 302 0.0 261 86.4 259 85.8 223 73.8 85.4 86.1
Age at year-end (yr)
13-24 27,140 2.8 21,599 79.6 20,925 77.1 17,677 65.1 81.8 84.5
25-34 152,935 15.9 117,976 77.1 113,823 74.4 97,532 63.8 82.7 85.7
35-44 183,689 19.1 137,728 75.0 132,453 72.1 117,369 63.9 85.2 88.6
45-54 233,009 24.2 175,697 75.4 169,154 72.6 154,813 66.4 88.1 91.5
≥55 367,229 38.1 273,340 74.4 262,342 71.4 247,909 67.5 90.7 94.5
Race/ethnicity
American Indian/Alaska Native 2,992 0.3 2,254 75.3 2,171 72.6 1,908 63.8 84.6 87.9
Asiand 15,188 1.6 11,321 74.5 10,924 71.9 10,614 69.9 93.8 97.2
Black/African American 386,688 40.1 283,784 73.4 272,495 70.5 238,353 61.6 84.0 87.5
Hispanic/Latinoe 227,387 23.6 164,738 72.4 159,325 70.1 146,163 64.3 88.7 91.7
Native Hawaiian/Other Pacific Islander 855 0.1 622 72.7 591 69.1 542 63.4 87.1 91.7
White 280,199 29.1 220,753 78.8 211,960 75.6 200,892 71.7 91.0 94.8
Multiracial 50,067 5.2 42,824 85.5 41,189 82.3 36,786 73.5 85.9 89.3
Transmission categoryf
Male-to-male sexual contactg 561,493 58.2 433,734 77.2 417,648 74.4 385,253 68.6 88.8 92.2
Injection drug useh 96,246 10.0 63,798 66.3 61,096 63.5 53,923 56.0 84.5 88.3
   Male 54,849 5.7 33,996 62.0 32,460 59.2 28,778 52.5 84.7 88.7
   Female 41,397 4.3 29,802 72.0 28,636 69.2 25,145 60.7 84.4 87.8
Male-to-male sexual contactg and injection drug useh 53,043 5.5 41,363 78.0 39,633 74.7 34,514 65.1 83.4 87.1
Heterosexual contacti 239,228 24.8 177,248 74.1 170,438 71.2 153,516 64.2 86.6 90.1
   Male 69,386 7.2 48,979 70.6 46,955 67.7 42,133 60.7 86.0 89.7
   Female 169,842 17.6 128,269 75.5 123,483 72.7 111,383 65.6 86.8 90.2
Otherj 13,992 1.5 10,198 72.9 9,882 70.6 8,094 57.8 79.4 81.9
   Male 7,039 0.7 4,960 70.5 4,805 68.3 3,996 56.8 80.6 83.2
   Female 6,953 0.7 5,239 75.3 5,077 73.0 4,098 58.9 78.2 80.7
Population area of residence
Metropolitan statistical areas (pop. >=500,000) 792,024 82.2 597,277 75.4 575,011 72.6 522,654 66.0 87.5 90.9
Metropolitan areas (pop. 50,000-499,999) 94,410 9.8 72,773 77.1 69,769 73.9 63,423 67.2 87.2 90.9
Nonmetropolitan areas (pop. <50,000) 56,132 5.8 42,356 75.5 40,645 72.4 37,105 66.1 87.6 91.3
Totalk 964,002 100 726,340 75.3 698,697 72.5 635,300 65.9 87.5 90.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Represents percentage of the total number for the column.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Includes 626 persons of unknown race/ethnicity. .

Table 4b. HIV viral suppression during 2021 among persons aged ≥13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by area of residence—47 states and the District of Columbia
VL <200 copies/mL
Persons alive at year-end 2021 Persons with ≥1 CD4 or VL tests Persons with ≥1 VL tests Among persons alive at year-end 2021 Among persons with ≥1 CD4 or VL tests Among persons with ≥1 VL tests
No. No. % No. % No. % % %
Alabama 13,774 9,898 71.9 9,180 66.6 8,146 59.1 82.3 88.7
Alaska 718 631 87.9 614 85.5 572 79.7 90.6 93.2
Arizona 17,490 12,733 72.8 11,875 67.9 10,955 62.6 86.0 92.3
Arkansas 5,900 3,953 67.0 3,502 59.4 3,097 52.5 78.3 88.4
California 131,709 98,344 74.7 94,179 71.5 87,675 66.6 89.2 93.1
Colorado 13,022 8,584 65.9 8,291 63.7 7,890 60.6 91.9 95.2
Connecticut 10,406 8,270 79.5 8,022 77.1 7,484 71.9 90.5 93.3
Delaware 3,439 2,822 82.1 2,772 80.6 2,525 73.4 89.5 91.1
District of Columbia 13,401 8,798 65.7 8,302 62.0 7,418 55.4 84.3 89.4
Florida 113,218 87,864 77.6 85,233 75.3 77,793 68.7 88.5 91.3
Georgia 57,083 41,473 72.7 40,137 70.3 35,470 62.1 85.5 88.4
Hawaii 2,323 2,007 86.4 1,973 84.9 1,839 79.2 91.6 93.2
Illinois 34,556 26,373 76.3 24,329 70.4 21,881 63.3 83.0 89.9
Indiana 11,821 9,376 79.3 9,125 77.2 8,322 70.4 88.8 91.2
Iowa 2,923 2,576 88.1 2,546 87.1 2,389 81.7 92.7 93.8
Kansas 3,340 2,749 82.3 2,716 81.3 2,523 75.5 91.8 92.9
Kentucky 7,759 6,236 80.4 5,558 71.6 5,062 65.2 81.2 91.1
Louisiana 20,700 16,273 78.6 16,063 77.6 14,263 68.9 87.6 88.8
Maine 1,650 1,360 82.4 1,336 81.0 1,279 77.5 94.0 95.7
Maryland 32,719 23,559 72.0 22,366 68.4 20,214 61.8 85.8 90.4
Massachusetts 20,672 15,742 76.2 15,203 73.5 14,483 70.1 92.0 95.3
Michigan 16,652 13,486 81.0 13,125 78.8 11,987 72.0 88.9 91.3
Minnesota 8,915 6,531 73.3 6,378 71.5 5,962 66.9 91.3 93.5
Mississippia 9,474 6,727 71.0 6,406 67.6 5,646 59.6 83.9 88.1
Missouri 12,570 9,697 77.1 9,260 73.7 8,403 66.8 86.7 90.7
Montana 698 614 88.0 599 85.8 564 80.8 91.9 94.2
Nebraska 2,274 1,751 77.0 1,641 72.2 1,541 67.8 88.0 93.9
Nevada 10,921 8,033 73.6 7,593 69.5 6,971 63.8 86.8 91.8
New Hampshire 1,333 1,076 80.7 1,047 78.5 1,006 75.5 93.5 96.1
New Mexico 3,873 2,957 76.3 2,407 62.1 2,183 56.4 73.8 90.7
New York 122,351 89,211 72.9 88,096 72.0 79,119 64.7 88.7 89.8
North Carolina 32,933 25,496 77.4 24,833 75.4 22,383 68.0 87.8 90.1
North Dakota 506 402 79.4 352 69.6 317 62.6 78.9 90.1
Ohio 23,181 17,368 74.9 16,871 72.8 15,307 66.0 88.1 90.7
Oklahoma 6,585 4,720 71.7 4,520 68.6 4,046 61.4 85.7 89.5
Oregon 7,268 6,237 85.8 5,943 81.8 5,616 77.3 90.0 94.5
Rhode Island 2,647 1,969 74.4 1,889 71.4 1,809 68.3 91.9 95.8
South Carolina 17,474 14,315 81.9 13,875 79.4 12,679 72.6 88.6 91.4
South Dakota 687 606 88.2 433 63.0 380 55.3 62.7 87.8
Tennessee 17,938 14,133 78.8 13,624 76.0 12,005 66.9 84.9 88.1
Texas 96,292 72,212 75.0 68,304 70.9 60,494 62.8 83.8 88.6
Utah 3,317 2,518 75.9 2,480 74.8 2,338 70.5 92.9 94.3
Vermont 712 561 78.8 556 78.1 531 74.6 94.7 95.5
Virginia 23,635 16,959 71.8 16,653 70.5 15,378 65.1 90.7 92.3
Washington 14,141 12,012 84.9 11,761 83.2 11,121 78.6 92.6 94.6
West Virginiaa 2,056 1,417 68.9 1,256 61.1 1,118 54.4 78.9 89.0
Wisconsin 6,579 5,409 82.2 5,207 79.1 4,869 74.0 90.0 93.5
Wyoming 367 302 82.3 266 72.5 247 67.3 81.8 92.9
Region of residenceb
Northeast (excluding NJ & PA) 159,771 118,189 74.0 116,149 72.7 105,711 66.2 89.4 91.0
Midwest 124,004 96,324 77.7 91,983 74.2 83,881 67.6 87.1 91.2
South 474,380 356,855 75.2 342,584 72.2 307,737 64.9 86.2 89.8
West (excluding ID) 205,847 154,972 75.3 147,981 71.9 137,971 67.0 89.0 93.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico. New Jersey and Pennsylvania recently enacted laws to require laboratories to report all CD4 and VL test results, but a full calendar year of reporting laboratory results to CDC is required before data are included in care analyses.

a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.
b Data should be interpreted with caution as areas with incomplete reporting to CDC are not included.

Table 5. Prevalence-based HIV care continuum for persons aged ≥13 years living with HIV infection (diagnosed or undiagnosed) at year-end 2021, by selected characteristics—United States
Persons with HIV infection alive at year-end 2021a Persons with diagnosed HIV infection alive at year-end 2021b Receipt of carec Retention in carec Viral suppressionc
Total No. No. % No. % No. % No %
Sex at birth
Male 946,500 819,141 87 618,451 65 441,517 47 543,090 57
Female 265,900 239,759 90 179,340 67 128,990 49 154,645 58
Age at year-end 2021 (yr)
13–24 41,900 23,671 56 18,842 45 13,090 31 15,410 37
25–34 217,100 157,035 72 121,074 56 81,344 37 100,188 46
35–44 238,300 202,019 85 151,514 64 104,040 44 129,090 54
45–54 263,000 243,001 92 183,223 70 130,978 50 161,353 61
≥55 452,000 433,174 96 322,281 71 242,144 54 292,392 65
Race/ethnicity
American Indian/Alaska Native 4,100 3,245 80 2,443 60 1,700 41 2,070 50
Asiand 18,600 16,455 89 12,259 66 9,017 48 11,502 62
Black/African American 487,500 425,519 87 312,331 64 220,844 45 262,120 54
Hispanic/Latinoe 297,200 252,342 85 182,696 61 137,022 46 162,256 55
Native Hawaiian/other Pacific Islander 1,200 948 81 689,196 57 470 39 601 50
White 342,000 304,871 89 240,238 70 167,679 49 218,593 64
Multiracial 61,200 54,864 90 46,909 77 33,741 55 40,325 66
Transmission categoryf
Male-to-male sexual contactg 716,900 615,019 86 474,795 66 338,260 47 421,903 59
Injection drug useh 121,900 112,395 92 74,518 61 53,725 44 62,941 52
   Male 70,400 64,530 92 40,009 57 29,103 41 33,878 48
   Female 51,600 47,864 93 34,462 67 24,602 48 29,053 56
Male-to-male sexual contactg and injection drug useh 62,900 57,559 92 44,896 71 32,060 51 37,471 60
Heterosexual contacti 306,700 270,255 88 200,259 65 144,586 47 173,504 57
   Male 94,100 79,991 85 56,474 60 41,195 44 48,555 52
   Female 212,600 190,265 90 143,650 68 103,314 49 124,814 59
Totalj 1,212,400 1,058,900 87 797,352 66 570,747 47 697,815 58

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; RSE, relative standard error [footnotes only].

a Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis (i.e., persons living with diagnosed or undiagnosed HIV infection). Estimates for year 2021 should be interpreted with caution due to adjustments made to the CD4+ T-lymphocyte (CD4)-based depletion model to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤ 1,000 to reflect model uncertainty. Estimates with a relative standard error 30%-50% are preceded by an asterisk (*) and should be interpreted with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and replaced by an ellipsis (…). Data previously published in the HIV Surveillance Supplemental Report 2023;28(No. 3). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
b Reported to National HIV Surveillance System. Data previously published in the HIV Surveillance Supplemental Report 2021;28(No. 3). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
c Estimates are the result of extrapolating data from the 48 jurisdictions with complete CD4 and viral load reporting by applying the percentage in the 48 jurisdictions (found in Tables 4a and 5a) to the total number of people living with diagnosed HIV in the United States. Estimates were calculated by sex at birth and are rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 6a. Stage 3 (AIDS) at time of diagnosis of HIV infection among persons aged ≥13 years, by year of diagnosis and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 pandemic) 2021
Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa
Total No. No. % Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Gender
Male 30,398 6,315 20.8 29,563 6,129 20.7 28,779 5,906 20.5 24,148 5,206 21.6 28,283 6,031 21.3
Female 7,229 1,598 22.1 7,008 1,532 21.9 6,873 1,415 20.6 5,387 1,236 22.9 6,522 1,385 21.2
Transgender womanb 651 84 12.9 661 85 12.9 692 94 13.6 676 82 12.1 811 96 11.8
Transgender manb 32 5 15.6 48 2 4.2 45 5 11.1 41 2 4.9 56 2 3.6
Additional gender identityc 18 3 16.7 19 1 5.3 32 0 0.0 23 4 17.4 44 6 13.6
Age at diagnosis (yr)
13–24 8,297 741 8.9 7,865 710 9.0 7,660 634 8.3 6,125 560 9.1 6,927 688 9.9
25–34 13,400 2,153 16.1 13,346 2,119 15.9 13,027 2,125 16.3 11,279 1,949 17.3 13,081 2,208 16.9
35–44 7,235 1,869 25.8 7,150 1,846 25.8 7,048 1,780 25.3 5,874 1,490 25.4 7,543 1,914 25.4
45–54 5,563 1,880 33.8 5,194 1,746 33.6 4,874 1,555 31.9 3,872 1,368 35.3 4,442 1,438 32.4
≥55 3,833 1,362 35.5 3,744 1,328 35.5 3,812 1,326 34.8 3,125 1,163 37.2 3,723 1,272 34.2
Race/ethnicity
American Indian/Alaska Native 193 41 21.2 170 28 16.5 193 26 13.5 189 42 22.2 223 43 19.3
Asian 911 231 25.4 844 224 26.5 722 175 24.2 610 168 27.5 737 188 25.5
Black/African American 16,107 3,227 20.0 15,593 3,077 19.7 15,296 2,956 19.3 12,643 2,528 20.0 14,522 2,882 19.8
Hispanic/Latinod 9,995 2,104 21.1 9,921 2,148 21.7 9,851 2,098 21.3 8,037 1,831 22.8 10,059 2,227 22.1
Native Hawaiian/other Pacific Islander 46 12 26.1 57 12 21.1 59 11 18.6 63 12 19.0 76 18 23.7
White 9,543 2,087 21.9 9,323 2,009 21.5 8,985 1,889 21.0 7,732 1,745 22.6 9,058 1,938 21.4
Multiracial 1,533 303 19.8 1,391 251 18.0 1,315 265 20.2 1,001 204 20.4 1,041 224 21.5
Transmission categorye
Male-to-male sexual contactf 25,345 4,813 19.0 24,464 4,717 19.3 23,870 4,491 18.8 20,460 4,102 20.0 23,855 4,753 19.9
Injection drug useg 2,400 563 23.5 2,493 555 22.3 2,545 551 21.6 2,064 462 22.4 2,490 543 21.8
   Male 1,291 348 26.9 1,376 326 23.7 1,362 340 25.0 1,170 276 23.6 1,415 330 23.3
   Female 1,109 215 19.4 1,117 229 20.5 1,182 210 17.8 895 186 20.8 1,075 213 19.9
Male-to-male sexual contactf and injection drug useg 1,517 223 14.7 1,531 222 14.5 1,581 261 16.5 1,185 193 16.3 1,373 215 15.7
Heterosexual contacth 8,988 2,385 26.5 8,731 2,235 25.6 8,339 2,093 25.1 6,500 1,753 27.0 7,916 1,986 25.1
   Male 2,882 1,009 35.0 2,839 943 33.2 2,643 893 33.8 2,006 709 35.4 2,460 825 33.5
   Female 6,106 1,377 22.5 5,892 1,292 21.9 5,695 1,200 21.1 4,494 1,044 23.2 5,456 1,161 21.3
Otheri 78 21 26.4 80 19 23.7 87 24 27.8 66 20 29.7 83 22 26.6
   Male 32 10 30.1 32 6 17.6 42 14 34.1 26 11 41.6 29 9 30.1
   Female 46 11 23.9 48 13 27.9 45 10 22.0 41 9 22.2 54 13 24.7
Region of residence
Northeast 5,988 1,286 21.5 5,552 1,257 22.6 5,317 1,161 21.8 4,241 948 22.4 4,988 1,107 22.2
Midwest 5,099 1,084 21.3 4,941 1,109 22.4 4,767 997 20.9 4,106 875 21.3 4,815 979 20.3
South 19,645 4,154 21.1 19,225 3,898 20.3 18,950 3,841 20.3 15,537 3,360 21.6 18,703 3,961 21.2
West 7,596 1,481 19.5 7,581 1,485 19.6 7,387 1,421 19.2 6,391 1,347 21.1 7,210 1,473 20.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 31,366 6,319 20.1 30,411 6,105 20.1 29,658 5,884 19.8 24,446 5,089 20.8 28,822 5,886 20.4
Metropolitan areas (pop. 50,000–499,999) 4,475 1,042 23.3 4,462 1,027 23.0 4,347 951 21.9 3,738 890 23.8 4,478 1,009 22.5
Nonmetropolitan areas (pop. <50,000) 2,249 596 26.5 2,318 604 26.1 2,280 569 25.0 1,940 525 27.1 2,290 605 26.4
Total 38,328 8,005 20.9 37,299 7,749 20.8 36,421 7,420 20.4 30,275 6,530 21.6 35,716 7,520 21.1

Abbreviations: pop, population; CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 6b. Stage 3 (AIDS) at time of diagnosis of HIV infection among persons aged ≥13 years, by year of diagnosis and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 pandemic) 2021
Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa
Total No. No. % Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Gender
Male 30,765 6,380 20.7 29,941 6,214 20.8 29,118 5,982 20.5 24,409 5,262 21.6 28,620 6,113 21.4
Female 7,323 1,622 22.1 7,089 1,549 21.9 6,956 1,442 20.7 5,433 1,248 23.0 6,604 1,404 21.3
Transgender womanb 653 84 12.9 665 86 12.9 694 94 13.5 679 83 12.2 812 96 11.8
Transgender manb 32 5 15.6 48 2 4.2 45 5 11.1 41 2 4.9 56 2 3.6
Additional gender identityc 18 3 16.7 19 1 5.3 32 0 0.0 23 4 17.4 44 6 13.6
Age at diagnosis (yr)
13–24 8,376 746 8.9 7,948 715 9.0 7,724 640 8.3 6,177 563 9.1 6,987 693 9.9
25–34 13,523 2,171 16.1 13,482 2,137 15.9 13,145 2,148 16.3 11,361 1,958 17.2 13,204 2,233 16.9
35–44 7,323 1,893 25.9 7,227 1,867 25.8 7,126 1,797 25.2 5,940 1,508 25.4 7,634 1,935 25.3
45–54 5,655 1,903 33.7 5,289 1,775 33.6 4,943 1,583 32.0 3,926 1,387 35.3 4,519 1,467 32.5
≥55 3,914 1,381 35.3 3,816 1,358 35.6 3,907 1,355 34.7 3,181 1,183 37.2 3,792 1,293 34.1
Race/ethnicity
American Indian/Alaska Native 193 41 21.2 170 28 16.5 193 26 13.5 189 42 22.2 223 43 19.3
Asian 914 233 25.5 848 224 26.4 729 178 24.4 610 168 27.5 738 188 25.5
Black/African American 16,112 3,228 20.0 15,605 3,080 19.7 15,304 2,959 19.3 12,650 2,528 20.0 14,528 2,883 19.8
Hispanic/Latinod 10,441 2,187 20.9 10,359 2,245 21.7 10,250 2,193 21.4 8,338 1,900 22.8 10,467 2,326 22.2
Native Hawaiian/other Pacific Islander 49 14 28.6 59 14 23.7 63 12 19.0 64 12 18.8 76 18 23.7
White 9,547 2,088 21.9 9,329 2,010 21.5 8,991 1,890 21.0 7,733 1,745 22.6 9,063 1,939 21.4
Multiracial 1,535 303 19.7 1,392 251 18.0 1,315 265 20.2 1,001 204 20.4 1,041 224 21.5
Transmission categorye
Male-to-male sexual contactf 25,587 4,851 19.0 24,742 4,766 19.3 24,110 4,533 18.8 20,660 4,130 20.0 24,107 4,810 20.0
Injection drug useg 2,444 569 23.3 2,521 563 22.3 2,572 561 21.8 2,087 470 22.5 2,512 550 21.9
 Male 1,325 354 26.7 1,401 335 23.9 1,385 348 25.2 1,189 284 23.9 1,436 337 23.5
 Female 1,118 215 19.3 1,120 229 20.4 1,188 213 17.9 898 186 20.7 1,077 213 19.8
Male-to-male sexual contactf and injection drug useg 1,529 224 14.7 1,542 228 14.8 1,594 265 16.7 1,190 194 16.3 1,375 215 15.7
Heterosexual contacth 9,153 2428 26.5 8,877 2,275 25.6 8,482 2,139 25.2 6,582 1,785 27.1 8,059 2,023 25.1
 Male 2,962 1,028 34.7 2,906 966 33.2 2,709 915 33.8 2,046 729 35.6 2,523 843 33.4
 Female 6,190 1,401 22.6 5,970 1,309 21.9 5,773 1,224 21.2 4,536 1,056 23.3 5,536 1,180 21.3
Otheri 79 21 26.2 80 19 23.7 87 24 27.7 66 20.0 29.6 83 22 26.6
Male 33 10 30.0 32 6 17.6 42 14 34.1 26 11 41.4 29 9 30.0
Female 46 11 23.5 48 13 27.9 45 10 21.9 41 9 22.1 54 13 24.7
Region of residence
Northeast 5,988 1,286 21.5 5,552 1,257 22.6 5,317 1,161 21.8 4,241 948 22.4 4,988 1,107 22.2
Midwest 5,099 1,084 21.3 4,941 1,109 22.4 4,767 997 20.9 4,106 875 21.3 4,815 979 20.3
South 19,645 4,154 21.1 19,225 3,898 20.3 18,950 3,841 20.3 15,537 3,36 21.6 18,703 3,961 21.2
West 7,596 1,481 19.5 7,581 1,485 19.6 7,387 1,421 19.2 6,391 1,347 21.1 7,210 1,473 20.4
U.S. dependent areas 463 89 19.2 463 103 22.2 424 103 24.3 310 69 22.3 420 101 24.0
Total 38,791 8,094 20.9 37,762 7,852 20.8 36,845 7,523 20.4 30,585 6,599 21.6 36,136 7,621 21.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 6c. Stage 3 (AIDS) at time of diagnosis of HIV infection among persons aged ≥13 years, by year of diagnosis and area of residence, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 pandemic) 2021
Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa
Total No. No. % Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Alabama 647 141 21.8 606 128 21.1 635 135 21.3 590 126 21.4 625 115 18.4
Alaska 29 7 24.1 23 4 17.4 27 2 7.4 29 3 10.3 30 10 33.3
Arizona 721 134 18.6 752 159 21.1 748 134 17.9 657 146 22.2 781 146 18.7
Arkansas 285 50 17.5 283 60 21.2 289 72 24.9 245 60 24.5 338 82 24.3
California 4,856 923 19.0 4,764 884 18.6 4,508 836 18.5 4,010 851 21.2 4,399 906 20.6
Colorado 433 78 18.0 400 95 23.8 463 85 18.4 327 69 21.1 406 72 17.7
Connecticut 274 65 23.7 258 64 24.8 213 60 28.2 171 42 24.6 233 48 20.6
Delaware 125 32 25.6 92 22 23.9 93 20 21.5 92 26 28.3 81 25 30.9
District of Columbia 315 40 12.7 278 43 15.5 248 36 14.5 194 41 21.1 195 37 19.0
Florida 4,546 973 21.4 4,352 928 21.3 4,150 910 21.9 3,230 707 21.9 4,072 847 20.8
Georgia 2,607 567 21.7 2,505 495 19.8 2,408 491 20.4 1,974 435 22.0 2,371 543 22.9
Hawaii 76 13 17.1 72 15 20.8 63 13 20.6 50 18 36.0 65 15 23.1
Idaho 45 11 24.4 36 14 38.9 34 14 41.2 35 13 37.1 54 14 25.9
Illinois 1,382 295 21.3 1,379 277 20.1 1,281 246 19.2 1,081 224 20.7 1,195 212 17.7
Indiana 514 126 24.5 514 127 24.7 484 100 20.7 430 104 24.2 528 106 20.1
Iowa 125 31 24.8 114 26 22.8 101 22 21.8 100 25 25.0 124 31 25.0
Kansas 119 25 21.0 155 40 25.8 132 26 19.7 140 35 25.0 154 41 26.6
Kentucky 368 88 23.9 377 76 20.2 326 68 20.9 300 63 21.0 390 71 18.2
Louisiana 987 226 22.9 954 182 19.1 879 183 20.8 718 159 22.1 899 206 22.9
Maine 29 11 37.9 31 10 32.3 30 11 36.7 16 8 50.0 31 14 45.2
Maryland 1,014 249 24.6 994 202 20.3 914 206 22.5 709 152 21.4 749 183 24.4
Massachusetts 600 123 20.5 645 150 23.3 537 112 20.9 430 99 23.0 440 103 23.4
Michigan 771 153 19.8 718 167 23.3 675 148 21.9 517 97 18.8 633 121 19.1
Minnesota 278 76 27.3 288 68 23.6 276 64 23.2 230 47 20.4 297 66 22.2
Mississippi 431 116 26.9 475 129 27.2 469 119 25.4 404 90 22.3 419 87 20.8
Missouri 505 84 16.6 449 96 21.4 488 88 18.0 369 68 18.4 549 99 18.0
Montana 29 6 20.7 24 5 20.8 25 5 20.0 14 5 35.7 22 5 22.7
Nebraska 87 13 14.9 77 25 32.5 80 21 26.3 73 18 24.7 105 23 21.9
Nevada 497 107 21.5 498 95 19.1 517 120 23.2 397 71 17.9 501 120 24.0
New Hampshire 32 5 15.6 38 10 26.3 31 5 16.1 32 8 25.0 32 9 28.1
New Jersey 1,110 239 21.5 1,015 234 23.1 1,084 234 21.6 799 175 21.9 1,143 228 19.9
New Mexico 148 30 20.3 155 37 23.9 176 29 16.5 129 24 18.6 149 20 13.4
New York 2,741 567 20.7 2,454 541 22.0 2,345 494 21.1 1,975 430 21.8 2,116 479 22.6
North Carolina 1,289 264 20.5 1,180 204 17.3 1,367 213 15.6 1,079 226 20.9 1,390 265 19.1
North Dakota 39 10 25.6 35 5 14.3 40 9 22.5 37 16 43.2 37 10 27.0
Ohio 980 212 21.6 977 225 23.0 965 213 22.1 882 189 21.4 909 206 22.7
Oklahoma 302 63 20.9 278 61 21.9 346 55 15.9 342 71 20.8 387 69 17.8
Oregon 203 49 24.1 227 51 22.5 198 49 24.7 179 28 15.6 202 43 21.3
Pennsylvania 1,097 243 22.2 1,018 218 21.4 994 229 23.0 753 175 23.2 913 204 22.3
Rhode Island 85 24 28.2 75 22 29.3 72 14 19.4 52 8 15.4 68 17 25.0
South Carolina 704 178 25.3 726 174 24.0 721 164 22.7 660 163 24.7 652 168 25.8
South Dakota 41 8 19.5 29 7 24.1 34 8 23.5 34 4 11.8 31 9 29.0
Tennessee 720 123 17.1 740 145 19.6 768 133 17.3 646 109 16.9 831 140 16.8
Texas 4,363 857 19.6 4,429 858 19.4 4,350 843 19.4 3,596 744 20.7 4,363 912 20.9
Utah 116 22 19.0 121 17 14.0 135 27 20.0 133 30 22.6 133 26 19.5
Vermont 20 9 45.0 18 8 44.4 11 2 18.2 13 3 23.1 12 5 41.7
Virginia 864 169 19.6 863 170 19.7 832 169 20.3 618 164 26.5 792 180 22.7
Washington 433 97 22.4 497 108 21.7 480 105 21.9 417 87 20.9 461 94 20.4
West Virginia 78 18 23.1 93 21 22.6 155 24 15.5 140 24 17.1 149 31 20.8
Wisconsin 258 51 19.8 206 46 22.3 211 52 24.6 213 48 22.5 253 55 21.7
Wyoming 10 4 40.0 12 1 8.3 13 2 15.4 14 2 14.3 7 2 28.6
Total 38,328 8,005 20.9 37,299 7,749 20.8 36,421 7,420 20.4 30,275 6,530 21.6 35,716 7,520 21.1
U.S. dependent areas
American Samoa 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Guam 6 4 66.7 7 3 42.9 11 3 27.3 1 0 0.0 0 0 0.0
Northern Mariana Islands 1 0 0.0 1 0 0.0 2 1 50.0 0 0 0.0 0 0 0.0
Puerto Rico 447 84 18.8 437 96 22.0 396 93 23.5 300 69 23.0 410 100 24.4
Republic of Palau 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
U.S. Virgin Islands 9 1 11.1 18 4 22.2 15 6 40.0 9 0 0.0 10 1 10.0
Subtotal 463 89 19.2 463 103 22.2 424 103 24.3 310 69 22.3 420 101 24.0
Total 38,791 8,094 20.9 37,762 7,852 20.8 36,845 7,523 20.4 30,585 6,599 21.6 36,136 7,621 21.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.

Table 6d. Stage 3 (AIDS) at time of diagnosis of HIV infection among persons aged ≥13 years, by race/ethnicity and area of residence, 2021—United States
Black/African American Hispanic/Latinoa White Otherb
Stage 3 (AIDS) at diagnosisc Stage 3 (AIDS) at diagnosisc Stage 3 (AIDS) at diagnosisc Stage 3 (AIDS) at diagnosisc
Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Alabama 380 65 17.1 26 6 23.1 189 38 20.1 30 6 20.0
Alaska 2 0 0.0 4 2 50.0 13 4 30.8 11 4 36.4
Arizona 125 23 18.4 355 66 18.6 244 46 18.9 57 11 19.3
Arkansas 150 36 24.0 28 7 25.0 138 34 24.6 22 5 22.7
California 754 133 17.6 2,285 505 22.1 1,005 190 18.9 355 78 22.0
Colorado 68 11 16.2 130 23 17.7 187 34 18.2 21 4 19.0
Connecticut 84 11 13.1 74 21 28.4 69 14 20.3 6 2 33.3
Delaware 44 15 34.1 12 3 25.0 21 7 33.3 4 0 0.0
District of Columbia 135 25 18.5 29 5 17.2 20 5 25.0 11 2 18.2
Florida 1,671 342 20.5 1,434 279 19.5 878 197 22.4 89 29 32.6
Georgia 1,690 374 22.1 245 66 26.9 345 80 23.2 91 23 25.3
Hawaii 6 0 0.0 11 1 9.1 18 2 11.1 30 12 40.0
Idaho 3 2 66.7 14 6 42.9 35 6 17.1 2 0 0.0
Illinois 531 84 15.8 311 58 18.6 270 51 18.9 83 19 22.9
Indiana 209 39 18.7 78 18 23.1 219 46 21.0 22 3 13.6
Iowa 29 9 31.0 20 5 25.0 63 14 22.2 12 3 25.0
Kansas 35 8 22.9 36 11 30.6 76 20 26.3 7 2 28.6
Kentucky 118 18 15.3 30 12 40.0 221 40 18.1 21 1 4.8
Louisiana 578 119 20.6 73 26 35.6 229 54 23.6 19 7 36.8
Maine 4 0 0.0 1 0 0.0 22 11 50.0 4 3 75.0
Maryland 529 125 23.6 102 32 31.4 87 16 18.4 31 10 32.3
Massachusetts 148 52 35.1 119 24 20.2 155 23 14.8 18 4 22.2
Michigan 343 62 18.1 45 11 24.4 217 42 19.4 28 6 21.4
Minnesota 124 30 24.2 43 14 32.6 103 14 13.6 27 8 29.6
Mississippi 309 67 21.7 13 0 0.0 93 17 18.3 4 3 75.0
Missouri 244 32 13.1 52 9 17.3 220 53 24.1 33 5 15.2
Montana 0 0 0.0 1 0 0 18 4 22.2 3 1 33.3
Nebraska 23 2 8.7 20 7 35.0 53 13 24.5 9 1 11.1
Nevada 149 31 20.8 182 40 22.0 131 40 30.5 39 9 23.1
New Hampshire 3 2 66.7 2 1 50.0 26 5 19.2 1 1 100
New Jersey 450 91 20.2 457 96 21.0 170 27 15.9 66 14 21.2
New Mexico 7 2 28.6 80 11 13.8 34 2 5.9 28 5 17.9
New York 827 166 20.1 773 178 23.0 341 92 27.0 175 43 24.6
North Carolina 804 145 18.0 214 45 21.0 296 65 22.0 76 10 13.2
North Dakota 12 4 33.3 3 1 33.3 17 4 23.5 5 1 20.0
Ohio 448 92 20.5 56 17 30.4 362 88 24.3 43 9 20.9
Oklahoma 109 18 16.5 70 12 17.1 144 30 20.8 64 9 14.1
Oregon 16 2 12.5 53 11 20.8 113 25 22.1 20 5 25.0
Pennsylvania 419 101 24.1 172 37 21.5 273 59 21.6 49 7 14.3
Rhode Island 13 4 30.8 24 4 16.7 29 9 31.0 2 0 0.0
South Carolina 361 86 23.8 74 21 28.4 157 41 26.1 60 20 33.3
South Dakota 4 1 25.0 2 0 0.0 13 4 30.8 12 4 33.3
Tennessee 444 60 13.5 87 21 24.1 275 52 18.9 25 7 28.0
Texas 1,467 264 18.0 1,880 428 22.8 788 167 21.2 228 53 23.2
Utah 9 1 11.1 55 13 23.6 59 9 15.3 10 3 30.0
Vermont 3 0 0.0 1 1 100 8 4 50.0 0 0 0.0
Virginia 440 94 21.4 95 27 28.4 213 51 23.9 44 8 18.2
Washington 96 18 18.8 121 26 21.5 185 41 22.2 59 9 15.3
West Virginia 13 3 23.1 6 2 33.3 124 24 19.4 6 2 33.3
Wisconsin 92 13 14.1 59 17 28.8 87 23 26.4 15 2 13.3
Wyoming 0 0 0.0 2 1 50.0 5 1 20.0 0 0 0.0
Total 14,522 2,882 19.8 10,059 2,227 22.1 9,058 1,938 21.4 2,077 473 22.8
Region of residence
Northeast 1,951 427 21.9 1,623 362 22.3 1093 244 22.3 321 74 23.1
Midwest 2,094 376 18.0 725 168 23.2 1,700 372 21.9 296 63 21.3
South 9,242 1,856 20.1 4,418 992 22.5 4,218 918 21.8 825 195 23.6
West 1,235 223 18.1 3,293 705 21.4 2,047 404 19.7 635 141 22.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on residence at time of diagnosis of HIV infection.

a Hispanic/Latino persons can be of any race.
b Includes American Indian/Alaska Native, Asian, Native Hawaiian/other Pacific Islander, and multiracial persons.
c Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.

Table 7a. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 pandemic) 2021
No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa
Gender
Male 12,239 16.1 12,102 15.5 12,307 15.4 14,208 17.5 14,663 17.7
Female 3,988 16.8 3,985 16.5 3,841 15.7 4,627 18.7 4,742 19.0
Transgender womanb 108 9.9 118 10.3 145 12.0 207 16.4 215 16.1
Transgender manb 5 12.3 5 11.1 5 10.1 10 18.9 2 3.5
Additional gender identityc 3 12.4 1 3.8 2 6.8 0 0.0 1 2.8
Age at death (yr)
13–24 152 0.3 3.5 130 0.3 3.1 135 0.3 3.4 153 0.3 4.1 109 0.2 3.0
25–34 1,047 2.3 6.5 1,034 2.3 6.2 1,100 2.4 6.4 1,258 2.8 7.2 1,360 3.0 7.7
35–44 1,833 4.5 9.5 1,774 4.3 9.1 1,795 4.3 9.1 2,074 4.8 10.4 2,247 5.2 11.0
45–54 4,469 10.6 14.6 4,183 10.1 14.1 3,648 8.9 12.8 3,858 9.4 14.2 3,783 9.3 14.6
≥55 8,842 9.5 29.1 9,090 9.6 27.4 9,622 10.0 26.7 11,709 12.0 30.1 12,124 12.3 29.3
Race/ethnicity
American Indian/Alaska Native 47 2.4 16.8 49 2.5 16.8 57 2.9 18.6 82 4.1 25.6 80 3.9 23.9
Asiand 88 0.6 6.4 83 0.5 5.7 100 0.6 6.5 103 0.6 6.5 125 0.7 7.5
Black/African American 7,193 21.6 17.6 6,981 20.7 16.7 7,008 20.6 16.4 8,327 24.2 19.2 8,402 24.2 19.1
Hispanic/Latinoe 2,693 6.0 11.8 2,838 6.2 12.0 2,770 5.9 11.3 3,452 7.1 13.8 3,498 7.1 13.5
Native Hawaiian/other Pacific Islander 9 1.9 12.0 13 2.7 16.2 14 2.8 16.5 11 2.2 12.3 14 2.7 14.5
White 5,234 3.1 17.6 5,150 3.0 17.0 5,256 3.1 17.2 5,754 3.3 18.6 6,025 3.5 19.3
Multiracial 1,077 23.7 19.0 1,097 23.3 19.2 1,091 22.4 19.0 1,322 26.1 23.0 1,478 28.2 25.9
Transmission categoryf
Male-to-male sexual contactg 7,010 12.6 6,888 12.0 7,184 12.1 8,237 13.6 8,672 13.9
Injection drug useh 3,527 29.3 3,504 29.3 3,403 28.7 3,922 33.4 3,801 32.7
   Male 2,154 30.8 2,169 31.3 2,087 30.4 2,427 35.8 2,335 34.9
   Female 1,373 27.3 1,335 26.6 1,316 26.3 1,494 30.1 1,466 29.7
Male-to-male sexual contactg and injection drug useh 1,383 23.3 1,453 24.4 1,395 23.4 1,665 28.0 1,687 28.5
Heterosexual contacti 4,242 16.3 4,194 15.9 4,157 15.4 5,021 18.5 5,262 19.1
   Male 1,694 21.6 1,600 20.1 1,688 20.8 1,961 24.1 2,071 25.2
   Female 2,548 14.1 2,594 14.0 2,470 13.1 3,060 16.1 3,191 16.5
Otherj 180 12.3 172 11.6 161 10.6 206 13.4 201 12.8
   Male 108 14.3 110 14.4 100 12.9 124 15.8 113 14.3
   Female 72 10.2 62 8.6 61 8.2 82 10.8 87 11.2
Region of residence
Northeast 3,693 7.7 15.7 3,522 7.4 14.9 3,653 7.6 15.3 4,522 9.2 19.0 4,324 8.8 18.1
Midwest 1,914 3.4 15.9 2,003 3.5 16.2 1,960 3.4 15.6 2,316 4.0 18.0 2,284 3.9 17.4
South 7,996 7.8 17.5 7,880 7.6 16.8 7,916 7.5 16.4 9,076 8.6 18.5 9,539 8.9 19.0
West 2,740 4.3 13.8 2,806 4.3 13.7 2,771 4.2 13.2 3,138 4.8 14.7 3,476 5.2 16.0
Totalk 16,343 6.0 16.2 16,211 5.9 15.7 16,300 5.9 15.4 19,052 6.8 17.8 19,623 7.0 18.0

Abbreviations: pop, population; PWDH, persons with diagnosed HIV infection; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm.

a Denominator was calculated as (No. PWDH at the end of [year X − 1]) + (No. new diagnoses during year X).
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Includes persons of unknown race/ethnicity.

Table 7b. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 pandemic) 2021
No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa
Gender
Male 12,540 16.2 12,392 15.7 12,583 15.6 14,482 17.6 14,942 17.8
Female 4,096 16.9 4,061 16.5 3,920 15.7 4,713 18.7 4,824 18.9
Transgender womanb 110 10.1 119 10.3 147 12.1 208 16.4 216 16.2
Transgender manb 5 12.3 5 11.0 5 10.1 10 18.8 2 3.5
Additional gender identityc 3 12.4 1 3.8 2 6.8 0 0.0 1 2.8
Age at death (yr)
13–24 154 0.3 3.5 134 0.3 3.2 137 0.3 3.4 155 0.3 4.1 110 0.2 3.0
25–34 1,068 2.3 6.6 1,054 2.3 6.2 1,118 2.4 6.4 1,266 2.7 7.2 1,373 3.0 7.7
35–44 1,883 4.6 9.6 1,822 4.4 9.2 1,851 4.4 9.2 2,128 4.9 10.5 2,290 5.2 11.0
45–54 4,598 10.8 14.7 4,272 10.2 14.1 3,757 9.1 13.0 3,939 9.5 14.3 3,854 9.4 14.7
≥55 9,051 9.6 29.1 9,296 9.7 27.4 9,794 10.0 26.6 11,925 12.1 30.1 12,358 12.4 29.3
Race/ethnicity
American Indian/Alaska Native 47 16.8 49 16.7 57 18.6 82 25.6 80 23.9
Asiand 88 6.4 83 5.7 100 6.5 104 6.5 125 7.4
Black/African American 7,198 17.6 6,981 16.7 7,009 16.4 8,330 19.2 8,405 19.1
Hispanic/Latinoe 3,098 12.7 3,200 12.7 3,119 12.0 3,807 14.3 3,857 14.0
Native Hawaiian/other Pacific Islander 9 11.5 16 19.2 16 18.1 11 11.8 14 14.0
White 5,235 17.6 5,151 17.0 5,258 17.2 5,756 18.6 6,025 19.3
Multiracial 1,077 19.0 1,098 19.2 1,094 19.0 1,322 23.0 1,478 25.8
Transmission categoryf
Male-to-male sexual contactg 7,081 12.6 6,967 12.0 7,257 12.1 8,319 13.6 8,730 13.9
Injection drug useh 3,694 29.6 3,658 29.5 3,555 28.9 4,055 33.3 3,937 32.7
   Male 2,286 31.1 2,290 31.5 2,209 30.7 2,534 35.7 2,451 35.0
   Female 1,409 27.4 1,368 26.7 1,345 26.4 1,521 30.0 1,486 29.6
Male-to-male sexual contactg and injection drug useh 1,408 23.4 1,475 24.4 1,420 23.5 1,695 28.1 1,714 28.6
Heterosexual contacti 4,387 16.5 4,297 15.9 4,260 15.5 5,134 18.4 5,402 19.2
   Male 1,768 21.8 1,663 20.2 1,744 20.9 2,015 24.0 2,149 25.4
   Female 2,620 14.2 2,635 14.0 2,517 13.1 3,119 16.0 3,253 16.5
Otherj 182 12.2 181 11.9 165 10.7 210 13.3 202 12.6
   Male 109 14.2 117 15.0 102 12.9 127 15.9 114 14.2
   Female 73 10.1 64 8.7 63 8.3 83 10.7 87 11.0
Region of residence
Northeast 3,693 7.7 15.7 3,522 7.4 14.9 3,653 7.6 15.3 4,522 9.2 19.0 4,324 8.8 18.1
Midwest 1,914 3.4 15.9 2,003 3.5 16.2 1,960 3.4 15.6 2,316 4.0 18.0 2,284 3.9 17.4
South 7,996 7.8 17.5 7,880 7.6 16.8 7,916 7.5 16.4 9,076 8.6 18.5 9,539 8.9 19.0
West 2,740 4.3 13.8 2,806 4.3 13.7 2,771 4.2 13.2 3,138 4.8 14.7 3,476 5.2 16.0
U.S. dependent areas 411 12.9 24.3 367 11.8 21.9 357 11.4 21.2 361 11.2 21.5 362 11.2 21.5
Totalk 16,754 6.1 16.3 16,578 6.0 15.8 16,657 6.0 15.5 19,413 6.9 17.8 19,985 7.1 18.0

Abbreviations: pop, population; PWDH, persons with diagnosed HIV infection; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm..

a Denominator was calculated as (No. PWDH at the end of [year X − 1]) + (No. new diagnoses during year X).
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Includes persons of unknown race/ethnicity.

Table 7c. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2017–2021—United States and 6 dependent areas
2017 2018 2019
No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH
Alabama 261 6.4 6.3 19.7 18.1 236 5.7 5.5 17.3 15.4 271 6.6 6.2 19.2 16.8
Alaska 7 1.2 1.2 9.7 8.6 9 1.5 1.4 12.7 9.4 12 2.0 2.0 16.4 13.4
Arizona 248 4.2 4.0 15.5 13.8 251 4.2 4.0 15.1 12.7 233 3.8 3.7 13.4 11.4
Arkansas 105 4.2 4.1 18.7 17.0 83 3.3 3.4 14.5 12.9 112 4.4 4.3 18.8 17.8
California 1,723 5.2 5.0 13.3 11.1 1,732 5.3 4.9 13.1 10.6 1,764 5.3 5.0 13.1 10.8
Colorado 133 2.8 2.7 10.9 8.5 142 3.0 2.9 11.2 8.5 131 2.7 2.6 10.1 8.6
Connecticut 199 6.5 5.4 18.9 15.1 182 5.9 5.0 17.1 11.7 204 6.7 5.5 18.9 12.8
Delaware 67 8.3 7.0 20.1 13.8 68 8.3 7.1 20.3 14.9 77 9.3 8.6 22.3 17.7
District of Columbia 234 39.1 41.3 16.3 13.3 203 33.6 36.8 14.3 11.5 203 33.5 35.6 14.3 11.0
Florida 2,045 11.4 10.2 18.4 15.0 1,941 10.6 9.4 17.2 13.7 1,996 10.8 9.3 17.3 13.7
Georgia 839 9.7 9.4 15.7 14.8 863 9.9 9.5 15.5 14.3 836 9.4 9.0 14.5 13.2
Hawaii 37 3.1 2.9 15.3 15.7 36 3.0 2.6 15.2 10.4 44 3.7 3.1 18.3 13.0
Idaho 20 1.4 1.4 17.7 13.9 16 1.1 1.1 13.6 9.7 11 0.7 0.7 8.8 6.3
Illinois 507 4.7 4.4 14.4 13.2 559 5.2 4.8 15.5 13.8 550 5.2 4.7 15.2 13.2
Indiana 210 3.8 3.7 18.8 16.9 195 3.5 3.4 16.9 15.0 165 2.9 2.8 14.1 11.9
Iowa 44 1.7 1.7 16.3 13.2 50 1.9 1.8 17.8 14.2 61 2.3 2.0 20.9 17.0
Kansas 47 2.0 1.9 15.4 14.3 51 2.1 2.0 16.3 14.8 57 2.4 2.3 17.8 15.5
Kentucky 139 3.7 3.5 19.6 16.9 136 3.6 3.5 18.5 16.2 109 2.9 2.7 14.3 12.8
Louisiana 411 10.6 10.5 20.0 18.7 429 11.1 10.8 20.4 18.3 380 9.8 9.7 17.7 16.0
Maine 34 2.9 2.3 21.4 15.0 20 1.7 1.5 12.3 8.4 41 3.5 2.9 24.5 18.0
Maryland 603 11.9 10.9 18.2 14.9 635 12.5 11.1 18.8 15.3 614 12.1 10.7 18.1 14.6
Massachusetts 305 5.2 4.6 14.8 11.6 305 5.1 4.6 14.6 10.9 300 5.0 4.5 14.2 10.8
Michigan 276 3.3 3.1 17.4 15.8 313 3.7 3.3 19.3 17.2 277 3.3 3.0 16.5 14.5
Minnesota 91 2.0 1.9 10.9 9.4 85 1.8 1.7 9.9 7.7 83 1.8 1.7 9.4 8.3
Mississippib 218 8.8 8.7 23.2 21.3 229 9.2 9.2 23.9 21.2 192 7.7 7.6 19.5 17.6
Missouri 213 4.2 4.0 17.1 14.6 234 4.6 4.3 18.3 15.6 231 4.5 4.2 17.8 16.2
Montana 15 1.7 1.7 24.1 21.3 13 1.5 1.4 20.2 16.5 13 1.4 1.4 19.4 15.2
Nebraska 33 2.1 2.0 15.4 14.5 31 2.0 1.8 14.2 12.9 33 2.1 2.1 14.7 11.6
Nevada 176 7.1 6.6 18.3 16.5 160 6.3 5.9 15.7 13.7 155 6.0 5.8 14.4 13.6
New Hampshire 21 1.8 1.6 17.6 13.8 18 1.5 1.4 14.3 15.5 18 1.5 1.4 13.7 8.8
New Jersey 646 8.6 7.5 18.5 14.0 635 8.5 7.3 18.1 13.7 626 8.3 7.0 17.6 12.6
New Mexico 62 3.6 3.3 17.9 13.6 76 4.3 4.3 20.7 16.3 57 3.2 3.0 14.9 11.5
New York 1,797 10.8 9.6 14.2 10.8 1,737 10.5 9.2 13.6 10.1 1,807 10.9 9.4 14.2 10.4
North Carolina 552 6.4 5.9 17.7 15.4 532 6.1 5.5 16.5 13.8 508 5.7 5.2 15.2 12.5
North Dakota 3 0.5 0.4 7.2 8.7 8 1.3 1.3 17.5 23.8 5 0.8 0.8 10.0 10.0
Ohio 380 3.9 3.7 17.2 15.7 373 3.8 3.6 16.5 14.2 399 4.0 3.8 17.0 15.1
Oklahoma 108 3.3 3.4 17.7 16.9 117 3.6 3.4 18.7 17.3 144 4.4 4.2 22.1 19.7
Oregon 116 3.3 3.0 16.7 12.6 106 3.0 2.7 14.9 12.6 129 3.6 3.3 17.5 13.5
Pennsylvania 645 5.9 5.3 18.1 14.6 573 5.2 4.7 15.8 12.6 603 5.5 4.9 16.3 12.8
Rhode Island 34 3.7 3.3 13.2 9.8 41 4.5 4.0 15.6 10.9 41 4.5 3.7 15.2 11.1
South Carolina 338 8.0 7.2 20.2 17.7 316 7.4 6.9 18.4 15.6 313 7.2 6.5 17.7 15.2
South Dakota 9 1.3 1.3 15.5 12.5 13 1.8 1.9 20.9 16.3 11 1.5 1.7 16.7 13.7
Tennessee 334 5.9 5.6 19.6 18.2 359 6.3 6.0 20.3 18.2 315 5.5 5.2 17.4 14.8
Texas 1,413 6.1 6.2 15.8 15.1 1,379 5.9 5.9 14.8 14.0 1,472 6.2 6.2 15.3 14.0
Utah 22 0.9 1.0 7.9 8.4 45 1.8 2.0 15.1 13.3 37 1.5 1.5 11.8 9.9
Vermont 12 2.2 1.9 17.4 11.6 11 2.0 1.5 15.6 9.4 13 2.4 2.1 18.1 11.5
Virginia 298 4.2 3.8 13.2 10.9 308 4.3 4.0 13.3 11.3 327 4.5 4.1 13.7 11.1
Washington 176 2.8 2.6 13.3 10.5 213 3.4 3.1 15.5 12.0 180 2.8 2.6 12.8 10.3
West Virginiab 31 2.0 1.8 16.9 13.9 46 3.0 2.7 23.6 20.5 47 3.1 2.8 22.9 18.0
Wisconsin 101 2.1 1.9 16.3 12.9 91 1.9 1.7 14.4 12.1 88 1.8 1.6 13.5 10.7
Wyoming 5 1.0 0.9 15.1 25.3 7 1.5 1.4 19.7 15.3 5 1.0 0.8 14.2 10.3
Subtotal 16,343 6.0 5.6 16.2 13.7 16,211 5.9 5.5 15.7 13.0 16,300 5.9 5.4 15.4 12.7
U.S. dependent area
American Samoa 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 2 5.5 6.6 666.7 365.5
Guamb 0 0.0 0.0 0.0 0.0 4 3.1 3.7 37.4 38.6 4 3.1 3.2 34.8 25.1
Northern Mariana Islands 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Puerto Rico 405 14.0 13.1 24.9 19.4 359 12.8 11.6 22.3 18.6 351 12.5 11.9 21.7 17.4
Republic of Palau 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
U.S. Virgin Islandsb 6 6.8 6.5 11.1 8.6 4 4.5 3.1 7.2 4.6 0 0.0 0.0 0.0 0.0
Subtotal 411 12.9 12.0 24.3 18.9 367 11.8 10.8 21.9 18.3 357 11.4 10.9 21.2 16.9
Total 16,754 6.1 5.7 16.3 13.8 16,578 6.0 5.5 15.8 13.1 16,657 6.0 5.5 15.5 12.8
Table 7c. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection, by year of death and area of residence, 2017–2021—United States and 6 dependent areas
2020 (COVID-19 pandemic) 2021
No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH
Alabama 288 6.8 6.4 20.0 17.9 331 7.8 7.1 22.4 18.9
Alaska 16 2.7 2.6 21.5 17.3 18 3.0 3.0 23.5 18.8
Arizona 286 4.7 4.5 16.0 13.2 339 5.5 5.1 18.3 14.9
Arkansas 109 4.3 4.1 17.9 16.5 124 4.9 4.7 19.5 16.9
California 1,982 6.0 5.5 14.5 11.5 2,149 6.5 6.0 15.5 12.0
Colorado 176 3.6 3.5 13.2 10.4 185 3.7 3.5 13.6 11.6
Connecticut 216 7.0 5.8 20.0 13.3 209 6.7 5.5 19.3 13.3
Delaware 75 8.9 7.7 21.4 19.1 75 8.8 6.9 20.9 14.2
District of Columbia 264 44.7 46.6 18.8 13.5 265 46.3 48.4 19.1 15.0
Florida 2,251 12.1 10.4 19.2 14.9 2,429 12.9 11.0 20.3 15.4
Georgia 919 10.3 9.8 15.6 14.1 967 10.7 10.0 16.0 14.0
Hawaii 39 3.2 2.8 16.2 16.4 48 3.9 3.3 19.7 12.7
Idaho 21 1.4 1.2 16.3 11.0 19 1.2 1.1 14.3 10.9
Illinois 709 6.6 5.9 19.5 16.6 609 5.7 5.2 16.8 13.8
Indiana 222 3.9 3.7 18.4 15.2 228 4.0 3.7 18.1 16.2
Iowa 63 2.4 2.3 21.1 17.2 44 1.6 1.4 14.2 11.1
Kansas 62 2.5 2.4 18.4 14.8 63 2.6 2.4 17.7 14.2
Kentucky 159 4.2 4.1 19.9 17.7 152 4.0 3.8 18.3 15.6
Louisiana 467 12.1 11.7 21.5 19.5 501 13.0 12.6 22.7 19.6
Maine 25 2.1 1.7 15.0 9.3 44 3.7 2.7 25.3 15.9
Maryland 657 12.7 11.3 19.3 15.5 692 13.3 11.8 20.3 15.5
Massachusetts 313 5.2 4.5 14.7 10.3 340 5.6 4.9 15.8 10.8
Michigan 350 4.1 3.7 20.4 17.4 295 3.5 3.1 16.8 14.2
Minnesota 96 2.0 1.7 10.6 9.1 107 2.2 2.1 11.5 9.6
Mississippib 244 9.9 9.2 24.6 21.4 197 8.0 7.7 19.6 16.6
Missouri 247 4.8 4.4 18.9 15.9 278 5.4 4.9 20.8 17.2
Montana 6 0.7 0.7 8.7 17.4 13 1.4 1.3 17.7 14.3
Nebraska 27 1.7 1.6 11.5 9.4 39 2.4 2.2 16.1 13.1
Nevada 179 6.8 6.3 16.1 13.6 207 7.8 7.3 17.8 14.5
New Hampshire 20 1.7 1.4 15.0 11.2 22 1.8 1.5 15.9 9.8
New Jersey 724 9.2 7.8 20.3 15.0 723 9.2 7.8 20.1 14.7
New Mexico 88 4.9 4.6 22.1 16.9 83 4.6 4.5 20.2 16.5
New York 2,443 14.3 12.2 19.2 14.0 2,211 13.1 11.1 17.4 12.3
North Carolina 657 7.4 6.6 19.2 16.1 654 7.3 6.6 18.7 15.2
North Dakota 8 1.2 1.2 15.2 14.1 6 0.9 0.8 11.0 10.9
Ohio 422 4.2 3.9 17.6 15.1 511 5.1 4.7 20.8 17.3
Oklahoma 156 4.8 4.5 23.1 19.9 147 4.4 4.4 20.7 17.5
Oregon 126 3.5 3.0 16.9 13.0 141 3.9 3.4 18.5 13.0
Pennsylvania 718 6.5 5.6 19.3 15.1 721 6.5 5.6 19.2 14.2
Rhode Island 50 5.3 4.6 18.4 12.5 42 4.4 3.7 15.2 10.0
South Carolina 375 8.6 7.7 20.7 16.6 411 9.3 8.2 22.2 17.9
South Dakota 6 0.8 0.9 8.6 6.5 15 2.0 2.1 20.4 15.5
Tennessee 441 7.6 7.1 23.5 21.0 439 7.5 7.1 22.9 19.4
Texas 1,565 6.5 6.5 15.8 14.2 1,748 7.2 7.1 17.1 15.2
Utah 30 1.1 1.3 9.1 7.3 43 1.6 1.8 12.3 9.8
Vermont 13 2.3 1.9 18.1 13.4 12 2.1 1.9 16.2 12.5
Virginia 398 5.5 5.0 16.4 13.4 351 4.8 4.3 14.2 11.3
Washington 182 2.8 2.6 12.6 10.7 228 3.5 3.2 15.4 11.9
West Virginiab 51 3.3 3.4 23.5 20.1 56 3.7 3.5 24.9 22.9
Wisconsin 104 2.1 1.9 15.5 11.7 89 1.8 1.6 12.9 10.5
Wyoming 7 1.4 1.3 19.3 15.0 3 0.6 0.7 7.9 6.2
Subtotal 19,052 6.8 6.2 17.8 14.4 19,623 7.0 6.3 18.0 14.2
U.S. dependent area
American Samoa 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Guamb 1 0.8 0.8 9.1 6.6 0 0.0 0.0 0.0 0.0
Northern Mariana Islands 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Puerto Rico 353 12.1 10.9 22.0 16.9 359 12.3 10.7 22.2 16.3
Republic of Palau 1 5.5 6.0 100 87.5 0 0.0 0.0 0.0 0.0
U.S. Virgin Islandsb 6 6.8 6.1 10.7 8.6 3 3.4 2.2 5.3 2.9
Subtotal 361 11.2 10.1 21.5 16.6 362 11.2 9.8 21.5 15.7
Total 19,413 6.9 6.2 17.8 14.4 19,985 7.1 6.4 18.0 14.2

Abbreviations: PWDH, persons with diagnosed HIV infection; pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm.

a Denominator was calculated as (No. PWDH at the end of [year X − 1]) + (No. new diagnoses during year X).
b Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Table 7d. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 pandemic) 2021
No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa
Gender
Male 9,655 24.0 9,448 23.3 9,449 23.1 10,832 26.4 11,051 26.9
Female 3,090 24.4 3,115 24.4 2,925 22.8 3,470 26.9 3,565 27.6
Transgender womanb 77 15.3 88 16.8 105 19.5 151 27.4 141 25.2
Transgender manb 4 22.7 2 11.2 3 16.0 6 31.9 2 10.6
Additional gender identityc 3 31.6 1 10.4 2 20.4 0 0.0 0 0.0
Age at death (yr)
13–24 89 0.2 10.8 77 0.2 10.5 72 0.1 11.2 74 0.1 13.2 48 0.1 9.4
25–34 710 1.6 14.2 722 1.6 14.5 714 1.6 14.5 755 1.7 15.7 787 1.7 16.7
35–44 1,403 3.4 15.3 1,341 3.3 15.1 1,296 3.1 14.8 1,487 3.5 17.4 1,502 3.5 17.8
45–54 3,615 8.6 19.6 3,371 8.1 19.2 2,892 7.1 17.5 3,034 7.4 19.7 2,923 7.2 20.3
≥55 7,012 7.6 35.1 7,143 7.6 32.9 7,510 7.8 32.1 9,109 9.3 36.3 9,499 9.6 35.8
Race/ethnicity
American Indian/Alaska Native 36 1.8 26.0 35 1.8 24.9 44 2.2 30.7 56 2.8 38.2 54 2.6 36.0
Asiand 67 0.4 10.7 64 0.4 9.8 76 0.5 11.3 77 0.5 11.1 104 0.6 14.6
Black/African American 5,641 16.9 26.2 5,451 16.2 25.1 5,365 15.8 24.5 6,277 18.2 28.5 6,273 18.1 28.4
Hispanic/Latinoe 2,242 5.0 18.0 2,307 5.0 18.2 2,227 4.7 17.4 2,740 5.7 21.1 2,771 5.6 21.2
Native Hawaiian/other Pacific Islander 8 1.7 21.4 9 1.9 23.4 12 2.4 30.3 10 2.0 25.2 11 2.1 26.3
White 3,940 2.3 25.6 3,881 2.3 25.2 3,860 2.3 25.1 4,223 2.5 27.5 4,375 2.5 28.6
Multiracial 895 19.7 27.5 907 19.3 27.9 899 18.5 27.7 1,076 21.2 33.3 1,171 22.4 36.6
Transmission categoryf
Male-to-male sexual contactg 5,432 20.0 5,241 19.0 5,404 19.3 6,175 21.9 6,398 22.4
Injection drug useh 2,844 36.6 2,775 36.3 2,643 35.1 3,037 41.0 2,937 40.5
   Male 1,752 37.4 1,724 37.5 1,632 36.1 1,882 42.6 1,814 42.0
   Female 1,092 35.5 1,051 34.5 1,012 33.5 1,154 38.7 1,123 38.3
Male-to-male sexual contactg and injection drug useh 1,145 31.3 1,227 33.8 1,130 31.5 1,328 37.4 1,292 37.0
Heterosexual contacti 3,255 23.2 3,266 23.0 3,167 22.1 3,734 25.9 3,963 27.4
   Male 1,318 27.5 1,251 25.9 1,305 26.7 1,489 30.5 1,596 32.6
   Female 1,937 21.0 2,015 21.6 1,861 19.7 2,245 23.6 2,367 24.7
Otherj 152 17.8 146 17.0 140 16.3 185 21.5 169 19.6
   Male 87 19.3 94 20.7 86 18.9 109 24.0 92 20.3
   Female 64 16.2 52 12.9 55 13.4 76 18.7 77 18.8
Region of residence
Northeast 2,881 6.0 21.7 2,750 5.7 20.8 2,849 6.0 21.6 3,484 7.1 26.7 3,318 6.8 25.7
Midwest 1,446 2.5 24.0 1,532 2.7 25.1 1,447 2.5 23.5 1,733 3.0 27.9 1,669 2.9 26.7
South 6,264 6.1 26.6 6,094 5.8 25.6 6,022 5.7 24.9 6,804 6.4 27.9 7,124 6.7 29.0
West 2,238 3.5 21.1 2,278 3.5 21.3 2,166 3.3 20.1 2,438 3.7 22.6 2,648 4.0 24.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 8,356 4.5 19.2 8,117 4.3 18.6 8,367 4.4 18.8 9,444 4.9 21.2 9,587 5.0 21.5
Metropolitan areas (pop. 50,000-499,999) 1,154 2.4 23.1 1,150 2.4 22.6 1,193 2.5 22.7 1,247 2.6 23.6 1,344 2.8 25.0
Nonmetropolitan areas (pop. <50,000) 758 2.0 25.4 670 1.7 22.3 734 1.9 23.9 806 2.1 26.0 856 2.2 27.4
Totalk 12,829 4.7 24.0 12,654 4.6 23.5 12,484 4.5 23.0 14,459 5.2 26.6 14,759 5.3 27.0

Abbreviations: pop, population; PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm.

a Denominator was calculated as (No. PWA at the end of [year X − 1]) + (No. new diagnoses during year X).
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Includes persons of unknown race/ethnicity.

Table 7e. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 pandemic) 2021
No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa
Gender
Male 9,861 24.1 9,645 23.4 9,641 23.2 11,024 26.5 11,233 26.9
Female 3,163 24.4 3,163 24.3 2,980 22.7 3,523 26.8 3,617 27.5
Transgender womanb 79 15.6 89 17.0 107 19.8 152 27.5 141 25.1
Transgender manb 4 22.6 2 11.1 3 15.9 6 31.7 2 10.5
Additional gender identityc 3 31.6 1 10.4 2 20.4 0 0.0 0 0.0
Age at death (yr)
13–24 91 0.2 10.9 81 0.2 10.9 73 0.1 11.3 74 0.1 13.1 49 0.1 9.6
25–34 724 1.6 14.4 735 1.6 14.7 723 1.6 14.5 760 1.6 15.6 792 1.7 16.7
35–44 1,438 3.5 15.5 1,374 3.3 15.2 1,325 3.1 15.0 1,520 3.5 17.6 1,526 3.5 17.8
45–54 3,701 8.7 19.7 3,430 8.2 19.2 2,974 7.2 17.7 3,089 7.4 19.7 2,971 7.2 20.3
≥55 7,156 7.6 35.1 7,280 7.6 32.9 7,638 7.8 32.0 9,262 9.4 36.2 9,655 9.7 35.6
Race/ethnicity
American Indian/Alaska Native 36 26.0 35 24.9 44 30.7 56 38.1 54 36.0
Asiand 67 10.6 64 9.8 76 11.2 78 11.2 104 14.5
Black/African American 5,644 26.2 5,451 25.1 5,365 24.4 6,279 28.5 6,273 28.4
Hispanic/Latinoe 2,520 18.9 2,549 18.8 2,470 18.0 2,982 21.6 3,005 21.5
Native Hawaiian/other Pacific Islander 8 20.5 11 27.2 14 33.7 10 24.2 11 25.2
White 3,940 25.6 3,882 25.2 3,861 25.1 4,224 27.5 4,375 28.6
Multiracial 895 27.5 908 27.9 902 27.8 1,076 33.3 1,171 36.6
Transmission categoryf
Male-to-male sexual contactg 5,483 20.0 5,292 19.0 5,460 19.4 6,232 21.9 6,439 22.4
Injection drug useh 2,954 36.7 2,879 36.3 2,746 35.2 3,127 40.8 3,022 40.3
   Male 1,841 37.6 1,805 37.5 1,714 36.3 1,957 42.3 1,888 41.8
   Female 1,113 35.4 1,073 34.5 1,032 33.5 1,169 38.5 1,134 37.9
Male-to-male sexual contactg and injection drug useh 1,164 31.3 1,244 33.8 1,146 31.5 1,349 37.5 1,307 36.9
Heterosexual contacti 3,355 23.4 3,332 23.0 3,238 22.1 3,811 25.8 4,055 27.4
   Male 1,366 27.7 1,293 26.0 1,342 26.8 1,528 30.4 1,647 32.7
   Female 1,989 21.1 2,039 21.4 1,895 19.7 2,283 23.5 2,408 24.6
Otherj 154 17.7 154 17.6 143 16.3 186 21.2 170 19.4
   Male 88 19.1 100 21.6 88 18.9 110 23.8 93 20.2
   Female 65 16.1 54 13.1 56 13.4 76 18.3 77 18.5
Region of residence
Northeast 2,881 6.0 21.7 2,750 5.7 20.8 2,849 6.0 21.6 3,484 7.1 26.7 3,318 6.8 25.7
Midwest 1,446 2.5 24.0 1,532 2.7 25.1 1,447 2.5 23.5 1,733 3.0 27.9 1,669 2.9 26.7
South 6,264 6.1 26.6 6,094 5.8 25.6 6,022 5.7 24.9 6,804 6.4 27.9 7,124 6.7 29.0
West 2,238 3.5 21.1 2,278 3.5 21.3 2,166 3.3 20.1 2,438 3.7 22.6 2,648 4.0 24.4
U.S. dependent areas 281 8.8 30.8 246 7.9 27.4 249 8.0 27.7 246 7.6 27.6 234 7.3 26.4
Totalk 13,110 4.8 24.1 12,900 4.7 23.6 12,733 4.6 23.1 14,705 5.2 26.6 14,993 5.3 27.0

Abbreviations: pop, population; PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm.

a Denominator was calculated as (No. PWA at the end of [year X − 1]) + (No. new diagnoses during year X).
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Includes persons of unknown race/ethnicity.

Table 7f. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2017–2021—United States and 6 dependent areas
2017 2018 2019
No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWAa Age-adjusted rate per 1,000 PWA No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWAa Age-adjusted rate per 1,000 PWA No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWAa Age-adjusted rate per 1,000 PWA
Alabama 199 4.9 4.8 33.6 28.4 169 4.1 3.9 27.9 24.6 171 4.1 4.0 27.6 21.9
Alaska 4 0.7 0.7 10.2 7.6 8 1.3 1.2 20.9 13.4 9 1.5 1.4 23.7 18.2
Arizona 195 3.3 3.1 25.3 26.0 200 3.3 3.2 25.4 22.9 170 2.8 2.7 21.1 15.9
Arkansas 79 3.2 3.1 30.5 25.6 62 2.5 2.5 23.8 20.7 79 3.1 3.0 29.2 31.7
California 1,433 4.4 4.2 20.2 17.3 1,412 4.3 4.0 19.9 17.3 1,383 4.2 3.9 19.4 19.7
Colorado 107 2.3 2.2 19.9 18.9 115 2.4 2.3 20.9 15.0 100 2.1 2.0 17.9 12.9
Connecticut 160 5.2 4.3 24.6 23.0 147 4.8 4.0 22.6 14.0 168 5.5 4.5 25.8 17.7
Delaware 58 7.1 6.0 28.3 18.0 54 6.6 5.6 26.6 18.1 64 7.7 7.4 30.9 27.7
District of Columbia 161 26.9 28.4 21.0 18.1 156 25.8 28.1 20.3 19.2 148 24.4 26.2 19.6 13.9
Florida 1,643 9.1 8.2 27.2 21.9 1,537 8.4 7.4 25.4 20.1 1,558 8.4 7.2 25.5 20.8
Georgia 655 7.6 7.3 23.9 21.6 662 7.6 7.3 23.6 20.1 642 7.3 6.9 22.5 19.2
Hawaii 31 2.6 2.5 22.0 36.3 31 2.6 2.2 22.7 15.5 39 3.3 2.7 28.6 22.2
Idaho 15 1.1 1.1 26.6 20.2 13 0.9 0.9 22.4 14.9 11 0.7 0.7 17.7 11.2
Illinois 381 3.6 3.3 21.4 19.2 429 4.0 3.7 23.9 20.2 413 3.9 3.5 23.2 19.1
Indiana 164 3.0 2.8 29.2 26.2 144 2.6 2.5 25.1 23.5 131 2.3 2.2 22.8 16.3
Iowa 30 1.1 1.2 19.9 13.9 37 1.4 1.3 24.1 16.2 45 1.7 1.5 29.3 20.9
Kansas 37 1.5 1.5 23.3 25.7 40 1.7 1.5 24.7 26.7 42 1.7 1.7 26.0 27.8
Kentucky 108 2.9 2.7 30.4 23.3 101 2.7 2.6 28.4 25.1 84 2.2 2.1 23.2 18.2
Louisiana 313 8.1 8.0 29.2 28.6 330 8.5 8.3 30.5 26.0 298 7.7 7.6 27.2 26.3
Maine 24 2.1 1.7 29.7 22.9 16 1.4 1.3 19.4 13.9 32 2.7 2.3 38.1 34.1
Maryland 476 9.4 8.6 26.7 19.7 502 9.9 8.8 28.0 21.9 459 9.0 8.0 25.8 19.8
Massachusetts 232 3.9 3.4 20.3 13.0 230 3.9 3.4 20.2 13.4 224 3.8 3.3 19.7 14.6
Michigan 225 2.7 2.5 27.4 23.3 242 2.9 2.5 29.2 24.8 217 2.6 2.2 25.8 22.3
Minnesota 70 1.5 1.4 18.0 14.7 66 1.4 1.3 16.7 12.1 58 1.2 1.2 14.5 14.2
Mississippib 173 7.0 7.0 36.8 31.8 187 7.5 7.6 39.3 34.5 135 5.4 5.4 28.1 21.6
Missouri 154 3.0 2.9 23.9 18.4 179 3.5 3.2 27.4 23.6 168 3.3 3.0 25.6 26.1
Montana 13 1.5 1.4 37.7 37.5 10 1.1 1.0 28.4 21.3 9 1.0 1.0 26.2 18.5
Nebraska 23 1.5 1.4 21.5 17.2 24 1.5 1.4 22.3 17.3 17 1.1 1.1 15.6 10.6
Nevada 138 5.6 5.2 29.4 29.6 135 5.3 4.9 27.7 24.7 119 4.6 4.4 23.6 21.0
New Hampshire 15 1.3 1.1 24.6 19.0 15 1.3 1.2 24.0 14.2 14 1.2 1.1 22.0 13.6
New Jersey 475 6.3 5.5 26.0 18.8 471 6.3 5.4 25.9 22.1 474 6.3 5.3 26.2 19.7
New Mexico 49 2.8 2.5 25.7 16.6 53 3.0 3.0 26.9 23.5 38 2.2 2.0 18.9 14.0
New York 1,468 8.8 7.8 19.9 15.0 1,409 8.5 7.4 19.2 13.3 1,448 8.7 7.5 20.0 14.4
North Carolina 392 4.5 4.2 27.7 23.7 363 4.1 3.8 25.0 19.3 355 4.0 3.7 23.8 19.2
North Dakota 3 0.5 0.4 15.2 14.3 6 1.0 0.9 28.8 24.4 5 0.8 0.8 22.1 17.9
Ohio 279 2.8 2.7 26.3 22.7 289 2.9 2.8 26.8 23.1 277 2.8 2.6 24.9 23.5
Oklahoma 82 2.5 2.6 27.5 25.2 86 2.6 2.5 28.2 32.7 120 3.7 3.5 38.6 31.5
Oregon 85 2.4 2.2 21.6 14.2 89 2.5 2.3 22.4 15.7 105 2.9 2.7 25.9 19.8
Pennsylvania 474 4.3 3.9 24.1 18.9 422 3.9 3.4 21.3 14.9 444 4.1 3.5 22.2 15.7
Rhode Island 28 3.1 2.6 19.4 14.3 32 3.5 3.1 22.0 13.7 35 3.8 3.0 24.0 15.5
South Carolina 263 6.2 5.6 28.9 23.3 240 5.6 5.3 26.0 19.7 232 5.3 4.8 24.8 18.4
South Dakota 3 0.4 0.5 11.2 8.0 11 1.5 1.6 37.8 32.8 8 1.1 1.2 26.1 16.6
Tennessee 259 4.6 4.4 30.4 27.2 275 4.8 4.6 31.4 27.1 246 4.3 4.1 27.9 21.4
Texas 1,147 5.0 5.0 25.0 23.5 1,108 4.8 4.8 23.7 22.7 1,143 4.8 4.8 24.0 21.1
Utah 19 0.8 0.8 13.5 9.5 35 1.4 1.6 23.8 37.8 31 1.2 1.3 20.8 15.6
Vermont 5 0.9 0.8 13.6 11.2 8 1.5 1.1 21.1 11.2 10 1.8 1.6 26.6 17.4
Virginia 231 3.2 2.9 21.3 18.0 225 3.1 2.9 20.3 17.9 255 3.5 3.2 22.5 18.9
Washington 145 2.3 2.2 20.3 14.7 170 2.7 2.5 23.4 16.7 148 2.3 2.1 20.2 18.7
West Virginiab 25 1.6 1.5 24.6 19.0 37 2.4 2.1 35.5 36.1 33 2.1 1.8 31.4 22.7
Wisconsin 77 1.6 1.5 25.2 18.0 65 1.3 1.2 21.2 17.4 66 1.3 1.2 21.0 15.1
Wyoming 4 0.8 0.7 22.3 51.7 7 1.5 1.4 38.7 25.6 4 0.8 0.6 22.0 12.5
Subtotal 12,829 4.7 4.4 24.0 20.1 12,654 4.6 4.3 23.5 19.4 12,484 4.5 4.1 23.0 19.0
U.S. dependent area
American Samoa 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 2 5.5 6.6 1,000 365.5
Guamb 0 0.0 0.0 0.0 0.0 3 2.4 3.0 66.7 84.1 4 3.1 3.2 88.9 53.5
Northern Mariana Islands 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Puerto Rico 277 9.6 8.9 31.5 28.9 241 8.6 7.8 27.9 32.1 243 8.6 8.0 28.2 24.7
Republic of Palau 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
U.S. Virgin Islandsb 4 4.5 4.0 13.8 10.4 2 2.3 1.5 6.8 3.7 0 0.0 0.0 0.0 0.0
Subtotal 281 8.8 8.2 30.8 28.2 246 7.9 7.2 27.4 31.4 249 8.0 7.4 27.7 24.1
Total 13,110 4.8 4.4 24.1 20.2 12,900 4.7 4.3 23.6 19.5 12,733 4.6 4.2 23.1 19.1
Table 7f. Deaths (any cause) of persons aged ≥13 years with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and area of residence, 2017–2021—United States and 6 dependent areas
2020 (COVID-19 pandemic) 2021
No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWAa Age-adjusted rate per 1,000 PWA No. Rate per 100,000 pop Age-adjusted rate per 100,000 pop Rate per 1,000 PWAa Age-adjusted rate per 1,000 PWA
Alabama 183 4.3 4.1 29.0 25.1 228 5.4 4.9 35.6 26.4
Alaska 11 1.8 1.8 28.9 22.3 16 2.7 2.6 41.7 32.6
Arizona 204 3.4 3.1 24.8 21.0 258 4.2 3.8 30.7 23.9
Arkansas 77 3.1 2.8 27.9 25.5 90 3.6 3.2 31.9 27.4
California 1,572 4.7 4.4 22.1 18.3 1,640 5.0 4.5 23.1 18.3
Colorado 120 2.5 2.4 21.2 19.4 145 2.9 2.7 25.6 21.7
Connecticut 166 5.4 4.5 25.7 16.5 156 5.0 4.0 24.4 22.0
Delaware 57 6.8 5.8 27.3 27.6 58 6.8 5.0 27.1 16.9
District of Columbia 197 33.4 35.3 26.5 17.7 199 34.8 36.5 26.8 17.7
Florida 1,767 9.5 8.2 28.9 22.9 1,866 9.9 8.3 30.3 24.0
Georgia 721 8.1 7.7 24.8 22.5 731 8.1 7.5 24.8 20.5
Hawaii 29 2.4 2.1 21.5 16.7 41 3.4 2.8 30.6 18.1
Idaho 12 0.8 0.7 19.0 11.7 12 0.8 0.7 18.9 11.3
Illinois 534 5.0 4.5 30.0 23.9 446 4.2 3.8 25.4 20.6
Indiana 152 2.7 2.5 26.0 19.0 164 2.9 2.7 27.2 28.9
Iowa 50 1.9 1.8 32.5 25.3 33 1.2 1.0 21.3 15.4
Kansas 46 1.9 1.7 27.2 18.5 44 1.8 1.6 25.1 17.8
Kentucky 118 3.1 3.1 31.6 29.6 100 2.6 2.5 26.3 19.8
Louisiana 338 8.7 8.5 30.8 26.6 360 9.3 9.0 32.7 26.8
Maine 18 1.5 1.1 21.5 11.8 30 2.5 1.9 34.3 20.5
Maryland 496 9.6 8.5 27.9 21.3 514 9.9 8.7 29.1 20.0
Massachusetts 234 3.9 3.3 20.7 13.5 240 4.0 3.4 21.3 13.8
Michigan 260 3.0 2.7 30.7 27.8 221 2.6 2.3 25.9 20.6
Minnesota 69 1.4 1.2 17.0 12.4 69 1.4 1.3 16.8 15.9
Mississippib 173 7.0 6.7 35.9 31.8 139 5.6 5.3 28.8 21.7
Missouri 189 3.7 3.3 28.8 26.3 212 4.1 3.6 32.2 29.4
Montana 4 0.4 0.4 11.3 6.0 8 0.9 0.8 21.3 13.5
Nebraska 23 1.4 1.4 20.1 15.8 30 1.9 1.7 25.7 21.9
Nevada 148 5.7 5.1 28.6 25.1 166 6.3 5.8 31.3 23.7
New Hampshire 14 1.2 0.8 21.8 14.9 15 1.2 1.1 22.6 13.8
New Jersey 527 6.7 5.7 29.3 22.3 541 6.9 5.8 30.3 21.8
New Mexico 62 3.5 3.2 30.3 19.5 56 3.1 2.9 27.1 22.6
New York 1,956 11.4 9.7 27.3 20.3 1,768 10.5 8.8 25.1 18.1
North Carolina 442 5.0 4.4 29.1 22.8 445 5.0 4.5 29.0 21.8
North Dakota 7 1.1 1.0 28.9 25.6 6 0.9 0.8 25.1 19.2
Ohio 322 3.2 2.9 28.6 25.4 369 3.7 3.4 32.4 26.7
Oklahoma 122 3.7 3.5 38.4 34.5 105 3.2 3.1 32.7 29.7
Oregon 101 2.8 2.4 25.4 21.4 114 3.1 2.7 28.7 19.0
Pennsylvania 519 4.7 4.0 26.1 18.3 532 4.8 4.1 26.7 17.6
Rhode Island 41 4.3 3.6 28.4 16.3 29 3.1 2.3 20.2 10.0
South Carolina 283 6.5 5.9 29.9 24.4 319 7.2 6.3 33.2 28.4
South Dakota 3 0.4 0.5 9.8 6.7 14 1.9 2.0 41.3 25.6
Tennessee 305 5.2 4.9 33.7 30.7 317 5.4 5.1 35.0 26.8
Texas 1,197 5.0 4.9 24.8 21.4 1,346 5.6 5.5 27.5 22.7
Utah 22 0.8 0.9 14.4 10.5 30 1.1 1.2 18.8 13.0
Vermont 9 1.6 1.4 23.7 23.9 7 1.2 1.0 18.2 9.4
Virginia 295 4.1 3.6 25.7 21.3 269 3.7 3.3 23.0 18.4
Washington 146 2.2 2.1 19.9 16.9 159 2.4 2.2 21.4 18.0
West Virginiab 33 2.1 2.0 31.0 27.6 38 2.5 2.1 34.9 24.5
Wisconsin 78 1.6 1.4 24.4 16.5 61 1.2 1.1 19.1 13.0
Wyoming 7 1.4 1.3 37.4 28.5 3 0.6 0.7 15.9 12.7
Subtotal 14,459 5.2 4.7 26.6 21.6 14,759 5.3 4.7 27.0 21.0
U.S. dependent area
American Samoa 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Guamb 1 0.8 0.8 23.8 13.8 0 0.0 0.0 0.0 0.0
Northern Mariana Islands 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Puerto Rico 240 8.3 7.3 28.1 21.0 233 8.0 6.8 27.4 24.5
Republic of Palau 1 5.5 6.0 166.7 87.5 0 0.0 0.0 0.0 0.0
U.S. Virgin Islandsb 4 4.6 4.7 13.6 15.1 1 1.1 0.7 3.4 1.6
Subtotal 246 7.6 6.8 27.6 20.7 234 7.3 6.2 26.4 23.5
Total 14,705 5.2 4.7 26.6 21.6 14,993 5.3 4.7 27.0 21.0

Abbreviations: PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); pop, population; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was unavailable, state at death (where a person’s death occurred) was used. When information on both residence at death and state at death (where a person’s death occurred) are not available, the most recent known address on or before the date of death is used. Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm.

a Denominator was calculated as (No. PWA at the end of [year X − 1]) + (No. new diagnoses during year X).
b Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Table 8a. Persons aged ≥13 years surviving >3 years after a diagnosis of HIV infection during 2013–2018, by year of diagnosis and selected characteristics—United States
Proportion survived >3 years
No. 2013 2014 2015 2016 2017 2018
Gender
Male 184,437 0.94 0.95 0.95 0.95 0.95 0.95
Female 43,828 0.92 0.94 0.94 0.94 0.94 0.94
Transgender womana 3,784 0.98 0.98 0.97 0.97 0.98 0.98
Transgender mana 182 * * * * * *
Additional gender identityb 95 * * * * * *
Age at diagnosis
13-24 51,459 0.99 0.99 0.99 0.99 0.99 0.99
25-34 77,163 0.97 0.97 0.98 0.98 0.97 0.97
35-44 44,967 0.94 0.95 0.95 0.95 0.95 0.95
45-54 36,084 0.90 0.91 0.92 0.91 0.91 0.91
≥55 22,653 0.80 0.82 0.82 0.83 0.84 0.85
Race/ethnicity
American Indian/Alaska Native 1,023 0.89 0.94 0.94 0.95 0.91 0.91
Asian 5,116 0.96 0.97 0.97 0.96 0.97 0.97
Black/African American 97,919 0.94 0.95 0.95 0.95 0.95 0.96
Hispanic/Latinoc 58,439 0.95 0.96 0.96 0.96 0.96 0.96
Native Hawaiian/other Pacific Islander 282 * * * * * *
White 58,877 0.93 0.94 0.94 0.93 0.93 0.93
Multiracial 10,670 0.95 0.96 0.95 0.95 0.96 0.95
Transmission categoryd
Male-to-male sexual contacte 152,545 0.95 0.96 0.96 0.96 0.96 0.96
Injection drug usef 14,010 0.86 0.87 0.89 0.88 0.88 0.88
   Male 7,643 0.85 0.86 0.88 0.87 0.87 0.88
   Female 6,368 0.88 0.89 0.91 0.89 0.90 0.88
Male-to-male sexual contacte and injection drug usef 9,331 0.94 0.96 0.95 0.95 0.95 0.94
Heterosexual contactg 55,984 0.92 0.93 0.93 0.94 0.93 0.94
   Male 18,596 0.89 0.91 0.91 0.91 0.91 0.91
   Female 37,389 0.93 0.95 0.95 0.95 0.94 0.95
Otherh 456 * * * * * *
   Male 196 * * * * * *
   Female 259 * * * * * *
Region of residence
Northeast 37,557 0.94 0.95 0.95 0.95 0.95 0.95
Midwest 30,634 0.94 0.95 0.95 0.95 0.95 0.95
South 118,795 0.94 0.94 0.95 0.95 0.95 0.95
West 45,340 0.94 0.95 0.95 0.95 0.95 0.96
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 190,785 0.94 0.95 0.95 0.95 0.95 0.95
Metropolitan areas (pop. 50,000-499,999) 26,305 0.92 0.93 0.94 0.94 0.94 0.94
Nonmetropolitan areas (pop. <50,000) 13,878 0.90 0.92 0.92 0.93 0.93 0.94
Total 232,326 0.94 0.95 0.95 0.95 0.95 0.95

Abbreviation: pop, population.

Note. Data are based on residence at time of diagnosis of HIV infection. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8b. Persons aged ≥13 years surviving >3 years after a diagnosis of HIV infection during 2013–2018, by year of diagnosis and selected characteristics—United States and 6 dependent areas
Proportion survived >3 years
No. 2013 2014 2015 2016 2017 2018
Gender
Male 187,086 0.94 0.95 0.95 0.95 0.95 0.95
Female 44,522 0.92 0.94 0.94 0.94 0.94 0.94
Transgender womana 3,803 0.98 0.98 0.97 0.97 0.98 0.98
Transgender mana 183 * * * * * *
Additional gender identityb 96 * * * * * *
Age at diagnosis
13-24 52,028 0.99 0.99 0.99 0.99 0.99 0.99
25-34 78,044 0.97 0.97 0.98 0.98 0.97 0.97
35-44 45,666 0.94 0.95 0.95 0.95 0.95 0.95
45-54 36,764 0.90 0.91 0.92 0.91 0.91 0.91
≥55 23,188 0.80 0.81 0.82 0.83 0.84 0.84
Race/ethnicity
American Indian/Alaska Native 1,023 0.89 0.94 0.94 0.95 0.91 0.91
Asian 5,130 0.96 0.97 0.97 0.96 0.97 0.97
Black/African American 97,984 0.94 0.95 0.95 0.95 0.95 0.96
Hispanic/Latinoc 61,678 0.94 0.95 0.96 0.96 0.96 0.96
Native Hawaiian/other Pacific Islander 296 * * * * * *
White 58,902 0.93 0.94 0.94 0.93 0.93 0.93
Multiracial 10,677 0.95 0.96 0.95 0.95 0.96 0.95
Transmission categoryd
Male-to-male sexual contacte 154,296 0.95 0.96 0.96 0.96 0.96 0.96
Injection drug usef 14,359 0.86 0.87 0.89 0.87 0.88 0.88
   Male 7,919 0.84 0.85 0.88 0.86 0.86 0.88
   Female 6,439 0.88 0.89 0.91 0.89 0.90 0.88
Male-to-male sexual contacte and injection drug usef 9,423 0.94 0.96 0.95 0.94 0.95 0.94
Heterosexual contactg 57,156 0.91 0.93 0.93 0.94 0.93 0.94
   Male 19,144 0.89 0.91 0.90 0.91 0.91 0.91
   Female 38,011 0.93 0.94 0.94 0.95 0.94 0.95
Otherh 457 * * * * * *
   Male 197 * * * * * *
   Female 260 * * * * * *
Region of residence
Northeast 37,557 0.94 0.95 0.95 0.95 0.95 0.95
Midwest 30,634 0.94 0.95 0.95 0.95 0.95 0.95
South 118,795 0.94 0.94 0.95 0.95 0.95 0.95
West 45,340 0.94 0.95 0.95 0.95 0.95 0.96
U.S. dependent areas 3,364 0.86 0.89 0.90 0.88 0.90 0.91
Total 235,690 0.94 0.95 0.95 0.95 0.95 0.95

Note. Data are based on residence at time of diagnosis of HIV infection. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8c. Persons aged ≥13 years surviving >3 years after a diagnosis of HIV infection during 2013–2018, by year of diagnosis and area of residence—United States and 6 dependent areas
Proportion survived >3 years
Area of residence No. 2013 2014 2015 2016 2017 2018
Alabama 3,850 0.93 0.92 0.94 0.95 0.95 0.93
Alaska 173 * * * * * *
Arizona 4,278 0.94 0.95 0.94 0.94 0.94 0.96
Arkansas 1,716 0.92 0.92 0.93 0.95 0.96 0.94
California 29,219 0.94 0.95 0.96 0.96 0.96 0.96
Colorado 2,310 0.97 0.95 0.95 0.95 0.97 0.97
Connecticut 1,669 0.94 0.96 0.99 0.98 0.92 0.97
Delaware 659 0.96 0.96 0.97 0.94 0.94 0.95
District of Columbia 2,188 0.96 0.96 0.96 0.96 0.96 0.94
Florida 26,801 0.93 0.94 0.94 0.95 0.95 0.95
Georgia 14,890 0.94 0.95 0.94 0.95 0.95 0.95
Hawaii 530 * * * * * *
Idaho 213 * * * * * *
Illinois 8,874 0.95 0.95 0.96 0.96 0.96 0.96
Indiana 3,080 0.93 0.94 0.94 0.95 0.94 0.94
Iowa 705 0.92 0.93 0.97 0.95 0.92 0.93
Kansas 850 0.90 0.96 0.94 0.95 0.97 0.96
Kentucky 2,112 0.92 0.92 0.95 0.93 0.93 0.95
Louisiana 6,423 0.94 0.94 0.94 0.95 0.95 0.94
Maine 256 * * * * * *
Maryland 6,752 0.94 0.96 0.96 0.96 0.94 0.95
Massachusetts 3,773 0.97 0.97 0.97 0.95 0.96 0.96
Michigan 4,479 0.93 0.95 0.95 0.95 0.95 0.95
Minnesota 1,766 0.93 0.95 0.97 0.98 0.97 0.96
Mississippia 2,768 0.92 0.93 0.93 0.92 0.94 0.93
Missouri 2,849 0.94 0.96 0.96 0.95 0.93 0.95
Montana 127 * * * * * *
Nebraska 484 * * * * * *
Nevada 2,833 0.94 0.95 0.95 0.94 0.94 0.97
New Hampshire 209 * * * * * *
New Jersey 6,847 0.91 0.94 0.95 0.95 0.94 0.94
New Mexico 840 0.94 0.93 0.91 0.99 0.94 0.93
New York 17,399 0.95 0.95 0.96 0.95 0.96 0.95
North Carolina 7,752 0.95 0.95 0.94 0.95 0.96 0.96
North Dakota 178 * * * * * *
Ohio 5,798 0.95 0.94 0.94 0.93 0.95 0.94
Oklahoma 1,816 0.92 0.94 0.94 0.95 0.92 0.93
Oregon 1,338 0.96 0.93 0.96 0.95 0.94 0.96
Pennsylvania 6,863 0.93 0.93 0.94 0.96 0.96 0.94
Rhode Island 457 * * * * * *
South Carolina 4,287 0.93 0.93 0.94 0.94 0.94 0.96
South Dakota 197 * * * * * *
Tennessee 4,418 0.92 0.93 0.93 0.95 0.94 0.95
Texas 26,476 0.94 0.95 0.95 0.95 0.95 0.95
Utah 717 0.94 0.98 0.97 0.94 0.97 0.96
Vermont 84 * * * * * *
Virginia 5,419 0.95 0.96 0.97 0.95 0.96 0.96
Washington 2,676 0.95 0.95 0.98 0.95 0.97 0.95
West Virginiaa 468 * * * * * *
Wisconsin 1,374 0.95 0.94 0.98 0.97 0.93 0.98
Wyoming 86 * * * * * *
Subtotal 232,326 0.94 0.95 0.95 0.95 0.95 0.95
U.S. dependent areas
American Samoa 0 * * * * * *
Guama 28 * * * * * *
Northern Mariana Islands 5 * * * * * *
Puerto Rico 3,223 0.86 0.89 0.90 0.88 0.89 0.91
Republic of Palau 3 * * * * * *
U.S. Virgin Islandsa 105 * * * * * *
Subtotal 3,364 0.86 0.89 0.90 0.88 0.90 0.91
Total 235,690 0.94 0.95 0.95 0.95 0.95 0.95

Abbreviation: pop, population.

Note. Data are based on residence at time of diagnosis of HIV infection. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Table 8d. Persons aged ≥13 years with HIV surviving >3 years after stage 3 (AIDS) classification during 2013–2018, by year of diagnosis and selected characteristics—United States
Proportion survived >3 years
No. 2013 2014 2015 2016 2017 2018
Gender
Male 85,480 0.86 0.85 0.86 0.86 0.86 0.86
Female 27,437 0.84 0.84 0.84 0.86 0.84 0.83
Transgender womana 1,498 0.93 0.92 0.91 0.92 0.93 0.90
Transgender mana 52 * * * * * *
Additional gender identityb 30 * * * * * *
Age at diagnosis
13-24 9,624 0.96 0.94 0.95 0.96 0.94 0.95
25-34 29,675 0.92 0.92 0.92 0.93 0.92 0.92
35-44 27,792 0.89 0.88 0.88 0.88 0.88 0.89
45-54 27,967 0.83 0.83 0.83 0.83 0.83 0.83
≥55 19,439 0.71 0.68 0.70 0.71 0.72 0.70
Race/ethnicity
American Indian/Alaska Native 434 * * * * * *
Asian 1,921 0.90 0.91 0.91 0.89 0.92 0.92
Black/African American 52,096 0.85 0.84 0.86 0.86 0.86 0.86
Hispanic/Latinoc 25,810 0.89 0.87 0.87 0.89 0.88 0.89
Native Hawaiian/other Pacific Islander 110 * * * * * *
White 27,493 0.84 0.83 0.82 0.82 0.82 0.81
Multiracial 6,633 0.89 0.88 0.87 0.86 0.85 0.85
Transmission categoryd
Male-to-male sexual contacte 62,520 0.88 0.87 0.87 0.88 0.88 0.88
Injection drug usef 11,040 0.77 0.76 0.76 0.76 0.76 0.76
   Male 6,042 0.75 0.74 0.74 0.73 0.75 0.76
   Female 4,998 0.79 0.77 0.78 0.79 0.77 0.77
Male-to-male sexual contacte and injection drug usef 5,466 0.84 0.85 0.85 0.84 0.85 0.82
Heterosexual contactg 34,351 0.84 0.84 0.85 0.86 0.85 0.84
   Male 12,449 0.82 0.82 0.83 0.83 0.83 0.83
   Female 21,903 0.85 0.85 0.86 0.87 0.86 0.85
Otherh 1,120 0.93 0.90 0.93 0.90 0.91 0.91
   Male 527 * * * * * *
   Female 592 * * * * * *
Region of residence
Northeast 19,994 0.87 0.87 0.87 0.87 0.87 0.87
Midwest 14,848 0.88 0.87 0.87 0.87 0.86 0.87
South 60,138 0.85 0.84 0.84 0.85 0.85 0.85
West 19,517 0.87 0.86 0.85 0.86 0.85 0.85
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 92,647 0.87 0.86 0.86 0.86 0.86 0.86
Metropolitan areas (pop. 50,000-499,999) 13,418 0.83 0.82 0.84 0.83 0.83 0.84
Nonmetropolitan areas (pop. <50,000) 7,889 0.82 0.81 0.81 0.84 0.82 0.84
Total 114,497 0.86 0.85 0.85 0.86 0.86 0.86

Abbreviation: pop, population.

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8e. Persons aged ≥13 years with HIV surviving >3 years after stage 3 (AIDS) classification during 2013–2018, by year of diagnosis and selected characteristics—United States and 6 dependent areas
Proportion survived >3 years
No. 2013 2014 2015 2016 2017 2018
Gender
Male 86,799 0.86 0.85 0.85 0.86 0.86 0.86
Female 27,922 0.84 0.84 0.84 0.86 0.84 0.83
Transgender womana 1,503 0.93 0.92 0.91 0.92 0.93 0.90
Transgender mana 52 * * * * * *
Additional gender identityb 30 * * * * * *
Age at diagnosis
13-24 9,730 0.96 0.94 0.95 0.95 0.94 0.95
25-34 29,975 0.92 0.92 0.92 0.93 0.92 0.92
35-44 28,248 0.89 0.87 0.88 0.88 0.88 0.89
45-54 28,512 0.83 0.83 0.82 0.83 0.83 0.83
≥55 19,841 0.71 0.68 0.70 0.71 0.72 0.70
Race/ethnicity
American Indian/Alaska Native 434 * * * * * *
Asian 1,927 0.90 0.91 0.91 0.89 0.92 0.92
Black/African American 52,133 0.85 0.84 0.86 0.86 0.86 0.86
Hispanic/Latinoc 27,553 0.88 0.86 0.86 0.88 0.87 0.88
Native Hawaiian/other Pacific Islander 122 * * * * * *
White 27,502 0.84 0.83 0.82 0.82 0.82 0.81
Multiracial 6,635 0.89 0.88 0.87 0.86 0.85 0.85
Transmission categoryd
Male-to-male sexual contacte 63,108 0.88 0.87 0.87 0.88 0.87 0.88
Injection drug usef 11,430 0.77 0.75 0.75 0.76 0.75 0.76
   Male 6,339 0.75 0.74 0.73 0.73 0.75 0.75
   Female 5,091 0.79 0.77 0.78 0.79 0.77 0.77
Male-to-male sexual contacte and injection drug usef 5,548 0.84 0.85 0.84 0.84 0.85 0.82
Heterosexual contactg 35,077 0.84 0.84 0.85 0.86 0.85 0.84
   Male 12,798 0.82 0.81 0.83 0.83 0.83 0.83
   Female 22,280 0.85 0.85 0.85 0.87 0.86 0.85
Otherh 1,143 0.93 0.90 0.92 0.91 0.91 0.90
   Male 535 * * * * * *
   Female 608 0.93 0.92 0.90 0.93 0.92 0.94
Region of residence
Northeast 19,994 0.87 0.87 0.87 0.87 0.87 0.87
Midwest 14,848 0.88 0.87 0.87 0.87 0.86 0.87
South 60,138 0.85 0.84 0.84 0.85 0.85 0.85
West 19,517 0.87 0.86 0.85 0.86 0.85 0.85
U.S. dependent areas 1,809 0.77 0.74 0.72 0.74 0.79 0.77
Total 116,306 0.86 0.85 0.85 0.86 0.85 0.85

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 8f. Persons aged ≥13 years with HIV surviving >3 years after stage 3 (AIDS) classification during 2013–2018, by year of diagnosis and area of residence—United States and 6 dependent areas
Proportion survived >3 years
Area of residence No. 2013 2014 2015 2016 2017 2018
Alabama 1,929 0.82 0.81 0.83 0.85 0.86 0.85
Alaska 91 * * * * * *
Arizona 1,825 0.84 0.85 0.81 0.83 0.83 0.86
Arkansas 783 0.87 0.77 0.84 0.89 0.88 0.82
California 12,209 0.87 0.85 0.86 0.86 0.85 0.84
Colorado 1,091 0.89 0.88 0.84 0.87 0.89 0.92
Connecticut 937 0.88 0.88 0.93 0.91 0.84 0.88
Delaware 413 * * * * * *
District of Columbia 1,221 0.88 0.82 0.85 0.90 0.83 0.88
Florida 13,834 0.82 0.81 0.83 0.84 0.84 0.84
Georgia 7,506 0.86 0.86 0.87 0.87 0.87 0.87
Hawaii 241 * * * * * *
Idaho 122 * * * * * *
Illinois 4,165 0.89 0.86 0.87 0.87 0.87 0.89
Indiana 1,475 0.85 0.86 0.84 0.84 0.82 0.86
Iowa 374 * * * * * *
Kansas 404 * * * * * *
Kentucky 980 0.81 0.84 0.81 0.86 0.85 0.83
Louisiana 3,236 0.84 0.81 0.84 0.86 0.86 0.86
Maine 132 * * * * * *
Maryland 3,786 0.87 0.88 0.87 0.85 0.86 0.87
Massachusetts 1,769 0.91 0.90 0.92 0.88 0.87 0.87
Michigan 2,201 0.85 0.88 0.83 0.87 0.83 0.86
Minnesota 906 0.90 0.90 0.91 0.96 0.95 0.91
Mississippia 1,741 0.84 0.81 0.83 0.82 0.83 0.84
Missouri 1,344 0.87 0.90 0.88 0.86 0.88 0.82
Montana 65 * * * * * *
Nebraska 263 * * * * * *
Nevada 1,296 0.87 0.83 0.83 0.82 0.83 0.84
New Hampshire 97 * * * * * *
New Jersey 3,584 0.84 0.86 0.85 0.85 0.87 0.85
New Mexico 365 * * * * * *
New York 9,606 0.88 0.86 0.86 0.88 0.87 0.87
North Carolina 3,944 0.87 0.84 0.83 0.83 0.86 0.86
North Dakota 76 * * * * * *
Ohio 2,901 0.89 0.85 0.89 0.85 0.87 0.85
Oklahoma 908 0.76 0.84 0.86 0.87 0.83 0.73
Oregon 694 0.88 0.86 0.89 0.86 0.82 0.86
Pennsylvania 3,585 0.85 0.86 0.86 0.88 0.86 0.87
Rhode Island 226 * * * * * *
South Carolina 2,349 0.84 0.82 0.85 0.84 0.83 0.88
South Dakota 104 * * * * * *
Tennessee 2,297 0.85 0.83 0.83 0.85 0.86 0.82
Texas 12,488 0.86 0.85 0.85 0.86 0.86 0.86
Utah 279 * * * * * *
Vermont 58 * * * * * *
Virginia 2,479 0.90 0.84 0.85 0.87 0.85 0.84
Washington 1,195 0.91 0.89 0.86 0.88 0.87 0.83
West Virginiaa 244 * * * * * *
Wisconsin 635 0.85 0.82 0.91 0.86 0.83 0.86
Wyoming 44 * * * * * *
Subtotal 114,497 0.86 0.85 0.85 0.86 0.86 0.86
U.S. dependent areas
American Samoa 0 * * * * * *
Guama 17 * * * * * *
Northern Mariana Islands 5 * * * * * *
Puerto Rico 1,729 0.76 0.73 0.72 0.74 0.79 0.76
Republic of Palau 1 * * * * * *
U.S. Virgin Islandsa 57 * * * * * *
Subtotal 1,809 0.77 0.74 0.72 0.74 0.79 0.77
Total 116,306 0.86 0.85 0.85 0.86 0.85 0.85

Note. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.

a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Table 9a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2021 among persons aged ≥16 years, by selected characteristics—United States
Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec (%)
Sex at birth
Male 337,697 989,200 34.1
Female 28,014 227,010 12.3
Age (yr)
16–24 48,552 246,290 19.7
25–34 145,758 434,680 33.5
35–44 88,516 238,470 37.1
45–54 46,224 173,420 26.7
≥55 36,740 123,350 29.8
Race/ethnicityd
Black/African American 51,878 468,540 11.1
Hispanic/Latinoe 64,018 312,820 20.5
Other 15,779 131,180 12.0
White 234,318 300,650 77.9
Total 365,994 1,216,210 30.1

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. PrEP coverage data are considered preliminary. Data for year 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

a Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; therefore, values may not sum to column total.
b Estimated by using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.
c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
d Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Race/ethnicity data were imputed, and the data source was based on a consumer database which might underrepresent certain populations. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted by applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.
e Hispanic/Latino persons can be of any race.

Table 9b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2021 among persons aged ≥16 years, by area of residence—United States and Puerto Rico
Area of residence Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec (%)
Alabama 2,764 11,020 25.1
Alaska 308 1,780 17.3
Arizona 6,571 25,780 25.5
Arkansas 1,275 5,130 24.9
California 50,239 165,030 30.4
Colorado 6,187 25,120 24.6
Connecticut 3,036 9,560 31.8
Delaware 645 4,400 14.7
District of Columbia 6,790 12,950 52.4
Florida 42,584 125,330 34.0
Georgia 12,173 39,030 31.2
Hawaii 1,134 4,360 26.0
Idaho 878 4,790 18.3
Illinois 18,417 55,860 33.0
Indiana 4,261 22,170 19.2
Iowa 1,951 4,760 41.0
Kansas 1,278 5,060 25.3
Kentucky 2,225 12,990 17.1
Louisiana 4,152 15,920 26.1
Maine 908 3,950 23.0
Maryland 5,793 27,300 21.2
Massachusetts 10,164 24,900 40.8
Michigan 5,900 29,570 20.0
Minnesota 5,251 21,720 24.2
Mississippi 1,592 4,530 35.1
Missouri 4,173 18,370 22.7
Montana 395 2,290 17.2
Nebraska 1,004 2,180 46.1
Nevada 4,877 11,390 42.8
New Hampshire 803 3,020 26.6
New Jersey 7,267 25,280 28.7
New Mexico 1,594 6,800 23.4
New York 39,082 72,640 53.8
North Carolina 7,964 32,490 24.5
North Dakota 246 1,520 16.2
Ohio 8,465 40,320 21.0
Oklahoma 2,321 11,030 21.0
Oregon 4,691 19,750 23.8
Pennsylvania 13,049 36,490 35.8
Puerto Rico 608 9,700 6.3
Rhode Island 1,512 3,880 39.0
South Carolina 2,934 10,390 28.2
South Dakota 214 910 23.5
Tennessee 7,227 22,460 32.2
Texas 34,728 123,790 28.1
Utah 3,262 6,840 47.7
Vermont 480 1,060 45.3
Virginia 6,280 31,430 20.0
Washington 11,377 40,050 28.4
West Virginia 707 5,250 13.5
Wisconsin 2,816 12,980 21.7
Wyoming 139 890 15.6

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.

Note. PrEP coverage data are considered preliminary. Data for year 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

a Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported.
b Estimated by using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.
c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 10a. Perinatally acquired HIV infection, by year of birth and mother’s race/ethnicity, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 pandemic) 2021
Race/ethnicitya No. Rate No. Rate No. Rate No. Rate No. Rate
Black/African American 29 5.2 22 4.0 17 3.1 24 4.5 16 3.1
Hispanic/Latinob 7 0.8 7 0.8 8 0.9 6 0.7 5 0.5
White 7 0.4 6 0.3 5 0.3 7 0.4 0 0.0
Otherc 8 2.2 7 1.9 3 0.8 1 0.3 1 0.3
Total 51 1.3 42 1.1 33 0.9 38 1.1 22 0.6

Note. Rates are per 100,000 live births. Because of delays in the reporting of births and diagnoses of HIV infection attributed to perinatal exposure, these numbers may be subject to change. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Please use caution when interpreting perinatally acquired HIV infection numbers.

a Live-birth data reflect race/ethnicity of the infant’s mother.
b Hispanic/Latino persons can be of any race.
c Includes American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and multiracial persons.

Table 10b. Perinatally acquired HIV infection among persons born in the United States, by year of birth and mother’s race/ethnicity, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 pandemic) 2021
Race/ethnicitya No. Rate No. Rate No. Rate No. Rate No. Rate
Black/African American 26 4.6 19 3.4 17 3.1 23 4.3 15 2.9
Hispanic/Latinob 5 0.6 7 0.8 8 0.9 6 0.7 5 0.5
White 6 0.3 6 0.3 5 0.3 6 0.3 0 0.0
Otherc 8 2.2 5 1.4 3 0.8 1 0.3 1 0.3
Total 45 1.2 37 1.0 33 0.9 36 1.0 21 0.6

Note. Rates are per 100,000 live births. Because of delays in the reporting of births and diagnoses of HIV infection attributed to perinatal exposure, these numbers may be subject to change. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Please use caution when interpreting perinatally acquired HIV infection numbers.

a Live-birth data reflect race/ethnicity of the infant’s mother.
b Hispanic/Latino persons can be of any race.
c Includes American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and multiracial persons.

Table 11. Status of CD4 and viral load reporting by HIV surveillance reporting area, as of December 2022—United States and 6 dependent areas
CD4 count (cells/µL) or CD4 percentage Viral load
Lab reporting requireda Reportable levelb Lab reporting requireda Reportable levelb
Alabama Yes All values Yes Any result
Alaska Yes All values Yes Any result
American Samoa No No
Arizona Yes All values Yes Any result
Arkansas Yes All values Yes Any result
California Yes All values Yes Any result
Colorado Yes All values Yes Any result
Connecticut Yes All values Yes Any result
Delaware Yes All values Yes Any result
District of Columbia Yes All values Yes Any result
Federated States of Micronesia No No
Florida Yes All values Yes Any result
Georgia Yes All values Yes Any result
Guam Yes All values Yes Any result
Hawaii Yes All values Yes Any result
Idaho Yes <200 or <14% Yes Detectable
Illinois Yes All values Yes Any result
Indiana Yes All values Yes Any result
Iowa Yes All values Yes Any result
Kansas Yes All values Yes Any result
Kentucky Yes All values Yes Any result
Louisiana Yes All values Yes Any result
Maine Yes All values Yes Any result
Marshall Islands No No
Maryland Yes All values Yes Any result
Massachusetts Yes All values Yes Any result
Michigan Yes All values Yes Any result
Minnesota Yes All values Yes Any result
Mississippi Yes All values Yes Any result
Missouri Yes All values Yes Any result
Montana Yes All values Yes Any result
Nebraska Yes All values Yes Any result
Nevada Yes All values Yes Any result
New Hampshire Yes All values Yes Any result
New Jersey Yes All values Yes Any result
New Mexico Yes All values Yes Any result
New York Yes All values Yes Any result
North Carolina Yes All values Yes Any result
North Dakota Yes All values Yes Any result
Northern Mariana Islands No No
Ohio Yes All values Yes Any result
Oklahoma Yes All values Yes Any result
Oregon Yes All values Yes Any result
Pennsylvania Yes All values Yes Any result
Puerto Rico Yes All values Yes Any result